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The clinical effectiveness and cost-effectiveness of
second-eye cataract surgery: a systematic review
and economic evaluation
Geoff Frampton,1* Petra Harris,1 Keith Cooper,1 Andrew Lotery2
and Jonathan Shepherd1
1Southampton Health Technology Assessments Centre (SHTAC), University of Southampton,
Southampton, UK
2Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton,
Southampton, UK
*Corresponding author
Background: Elective cataract surgery is the most commonly performed surgical procedure in the NHS.
In bilateral cataracts, the eye with greatest vision impairment from cataract is operated on first. First-eye
surgery can improve vision and quality of life. However, it is unclear whether or not cataract surgery on the
second eye provides enough incremental benefit to be considered clinically effective and cost-effective.
Objective: To conduct a systematic review of clinical effectiveness and analysis of cost-effectiveness of
second-eye cataract surgery in England and Wales, based on an economic model informed by systematic
reviews of cost-effectiveness and quality of life.
Data sources: Twelve electronic bibliographic databases, including MEDLINE, EMBASE, Web of Science,
The Cochrane Library and the Centre for Reviews and Dissemination databases were searched from
database inception to April 2013, with searches updated in July 2013. Reference lists of relevant
publications were also checked and experts consulted.
Review methods: Two reviewers independently screened references, extracted and checked data from
the included studies and appraised their risk of bias. Based on the review of cost-effectiveness, a de novo
economic model was developed to estimate the cost-effectiveness of second-eye surgery in bilateral
cataract patients. The model is based on changes in quality of life following second-eye surgery
and includes post-surgical complications.
Results: Three randomised controlled trials (RCTs) of clinical effectiveness, three studies of cost-effectiveness
and 10 studies of health-related quality of life (HRQoL) met the inclusion criteria for the systematic
reviews and, where possible, were used to inform the economic analysis. Heterogeneity of studies precluded
meta-analyses, and instead data were synthesised narratively. The RCTs assessed visual acuity, contrast
sensitivity, stereopsis and several measures of HRQoL. Improvements in binocular visual acuity and
contrast sensitivity were small and unlikely to be of clinical significance, but stereopsis was improved to a
clinically meaningful extent following second-eye surgery. Studies did not provide evidence that second-eye
surgery significantly affected HRQoL, apart from an improvement in the mental health component of
HRQoL in one RCT. In the model, second-eye surgery generated 0.68 incremental quality-adjusted life-years
with an incremental cost-effectiveness ratio of £1964. Model results were most sensitive to changes in the
utility gain associated with second-eye surgery, but otherwise robust to changes in parameter values.
The probability that second-eye surgery is cost-effective at willingness-to-pay thresholds of £10,000 and
£20,000 is 100%.
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Limitations: Clinical effectiveness studies were all conducted more than 9 years ago. Patients had
good vision pre surgery which may not represent all patients eligible for second-eye surgery. For some
vision-related patient-reported outcomes and HRQoL measures, thresholds for determining important
clinical effects are either unclear or have not been determined.
Conclusions: Second-eye cataract surgery is generally cost-effective based on the best available data
and under most assumptions. However, more up-to-date data are needed. A well-conducted RCT that
reflects current populations and enables the estimation of health state utility values would be appropriate.
Guidance is required on which vision-related, patient-reported outcomes are suitable for assessing effects
of cataract surgery in the NHS and how these measures should be interpreted clinically.
Study registration: This project is registered as PROSPERO CRD42013004211.
Funding: This project was funded by the National Institute for Health Research Health Technology
Assessment programme.
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Plain English summary
Cataract operations are the most frequent elective surgical procedure conducted in the NHS.In patients who have cataracts in both eyes, surgery to replace the lens in the worst-affected eye is a
cost-effective way to improve vision and may also improve quality of life. However, it is unclear whether
or not lens replacement surgery in the second eye provides enough further benefit to be considered
worthwhile by patients and cost-effective for the NHS. We conducted rigorous systematic reviews of
existing studies of the clinical effectiveness and cost-effectiveness of second-eye cataract surgery and its
impacts on patients’ quality of life, and developed an economic model to estimate the cost-effectiveness
of second-eye cataract surgery in the NHS. Three randomised controlled trials of clinical effectiveness,
three cost-effectiveness studies and 10 quality-of-life studies met our inclusion criteria. The clinical
effectiveness trials were all conducted before 2005 and included patients in their 70s who already had
good vision after one cataract operation. Clinically important improvement after second-eye surgery was
observed for stereopsis (depth perception) and, in one trial, in the mental health component of quality of
life. Studies did not provide evidence that second-eye surgery had a significant impact on other measures
of clinical vision, quality of life and vision-related functional ability, possibly because of limitations of the
outcome instruments employed. Our economic model shows that second-eye surgery would be considered
cost-effective under conventional willingness-to-pay thresholds used in the NHS, tested under a range of
scenarios and assumptions, using the best available evidence.
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Scientific summary
Background
Elective cataract surgery is the most commonly performed surgical procedure in the NHS. In bilateral
cataracts, the eye with greatest vision impairment as a result of a cataract is operated on first. Depending
on how severe the cataract is, cataract surgery in the first eye can substantially improve a person’s vision
and quality of life. However, it is unclear from existing studies whether or not second-eye surgery provides
enough incremental benefit to patients to be considered clinically effective and cost-effective, particularly
as the clinical criteria which have been used for determining eligibility of patients for cataract surgery
have become less stringent in recent years. Also, it is unclear at what degree of visual impairment
(or impairment of quality of life) it would be appropriate to recommend second-eye surgery.
Objectives
This health technology assessment aims to assess the clinical effectiveness and cost-effectiveness of
second-eye cataract surgery. Specific objectives were:
l to conduct a systematic review of studies assessing the clinical effectiveness of second-eye
cataract surgery
l to conduct an economic evaluation comprising:
¢ a systematic review of cost-effectiveness studies of second-eye cataract surgery
¢ a systematic review of studies of health-related quality of life (HRQoL) in people who have had
cataract surgery
¢ an economic model, developed de novo or adapted from an existing one, to estimate
cost-effectiveness of second-eye cataract surgery.
Methods
Systematic reviews of clinical effectiveness, cost-effectiveness and
health-related quality of life
Inclusion criteria for the systematic review of clinical effectiveness were:
l Population: adults aged 18 years and above who have had one cataract operation already and still
have or develop significant cataract-related visual impairment in the other eye.
l Interventions: cataract surgery for the second eye (any surgical technique).
l Comparators: cataract surgery in one eye only (with additional supportive care if this is usual practice,
such as prescription glasses).
l Outcomes: any measures of clinical vision (including measures of visual acuity, contrast sensitivity
and stereopsis); any patient-reported measures of visual disability and symptoms; patient satisfaction
with surgery and vision; HRQoL [e.g. European Quality of Life-5 Dimensions (EQ-5D) health survey];
adverse events.
l Types of studies: randomised controlled trials (RCTs). If necessary, non-RCT data were sought to inform
the cost-effectiveness analysis (e.g. on safety).
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The systematic reviews of cost-effectiveness and HRQoL employed the inclusion criteria listed above with
the following exceptions:
l Studies of any design were eligible for the cost-effectiveness review if they reported full economic
evaluations (e.g. cost-effectiveness, cost–utility).
l Studies of any design were eligible for the systematic review of HRQoL if they used generic
preference-based HRQoL measures or generic preference valuation methods, and reported health
utility values.
Twelve electronic bibliographic databases were searched in March–April 2013 using sensitive search
strategies developed and refined by an experienced information specialist. The databases included
MEDLINE, EMBASE, Web of Science, The Cochrane Library and the Centre for Reviews and Dissemination.
Relevant internet pages were also searched. Reference lists of included studies and of other relevant
publications were checked and experts contacted.
Retrieved references were screened for relevance against the inclusion criteria by two independent
reviewers using a standardised study selection worksheet. Studies that met all the inclusion criteria were
included in the systematic review. Data were extracted from the included studies by one reviewer using a
standard data extraction template and were checked by a second reviewer. The quality of the included
studies was assessed independently by two reviewers using the Cochrane Collaboration risk of bias criteria
for RCTs of clinical effectiveness and standardised checklists for studies of cost-effectiveness and HRQoL.
Data from the included studies were synthesised narratively.
Economic evaluation
An economic model was developed to estimate the cost-effectiveness of second-eye surgery in patients
with bilateral cataracts, compared with cataract surgery in one eye only (i.e. only first-eye surgery). In the
model, second-eye cataract surgery is associated with a change in visual acuity and a corresponding
change in HRQoL, assumed to last the patient’s lifetime. Patients undergoing surgery may or may not
experience post-surgical complications. Post-surgical complications and consequences are associated with
a health disutility and require additional treatment.
The model evaluates costs (in UK pounds using a 2012 price base) from the perspective of the NHS and
the impact of including Personal Social Services costs is explored. Outcomes in the model are expressed
as quality-adjusted life-years (QALYs), and cost-effectiveness is expressed in terms of incremental
cost-effectiveness ratios (ICERs). Uncertainty with regard to model input parameters was investigated
through deterministic and probabilistic sensitivity analyses, and scenario analyses. Both costs and outcomes
were discounted using a 3.5% annual discount rate, in line with current guidance.
Results
Systematic review of clinical effectiveness
In total, 993 potentially relevant references were identified, of which 12 full-text papers were retrieved
and three papers describing three RCTs, conducted between 1994 and 2004, met the inclusion criteria.
Two RCTs were conducted in the UK and one in Spain. Participants were elderly people (mean age
71.1–79.9 years) with bilateral cataracts. One RCT included only women, whereas the others also included
men. All were two-arm, parallel-group RCTs which compared patients expedited to receive second-eye
cataract surgery within a specified target period (intervention group) and patients who were scheduled
for second-eye surgery at the end of the study according to routine clinical practice (waiting list
comparator group). The target time for second-eye surgery in the intervention group was 4–6 weeks
after randomisation (two RCTs) or 2–4 months after first-eye surgery (one RCT). The number of
participants randomised ranged from 208 to 296.
SCIENTIFIC SUMMARY
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Owing to the type of surgical intervention under consideration, none of the RCTs were able to mask
participants to the allocation group. One RCT was additionally considered at high risk of detection bias as
outcome assessors were not masked, whereas another RCT was judged to be at high risk of reporting bias
as a result of evidence of selective reporting of outcomes. Judgements of low risk of bias could be made
with confidence only for selection bias (random sequence generation: one RCT; allocation concealment:
two RCTs); other domains of bias were judged to be unclear.
Outcomes were measured 4–12 months after the intervention group had received second-eye surgery.
The RCTs differed in their study characteristics, which precluded the pooling of any outcomes across the
RCTs in a meta-analysis.
All three RCTs reported measures of visual acuity, contrast sensitivity and stereopsis. Many participants
in all three RCTs already had good binocular visual acuity and contrast sensitivity before second-eye
cataract surgery. Binocular visual acuity and contrast sensitivity were statistically significantly better after
second-eye cataract surgery in three and two RCTs, respectively, but differences were small and appear to
be of limited clinical importance. In contrast, patients’ stereopsis at baseline varied among the RCTs, with
61–71% having no functional stereopsis in one RCT. Statistically and clinically significant improvements in
stereopsis occurred after second-eye surgery in all three RCTs, with the most substantial improvement
being in the RCT whose patients had the worst baseline stereopsis.
Patient-reported outcomes for HRQoL and psychological well-being were measured using generic health
status instruments in three RCTs [EQ-5D, short form questionnaire 12- and 36-item health survey
instruments (SF-12 and SF-36, respectively)], with instruments that assessed specific HRQoL domains in one
RCT (activities of daily living, anxiety, depression, falls efficacy and handicap), and with an instrument that
specifically assessed visual functional disability [Visual Function Index-14 (VF-14)] in two RCTs. Among
these measures, clinically meaningful improvements after second-eye cataract surgery were demonstrated
on only one outcome in one RCT (the mental health component score of the SF-12). This finding may
reflect limitations of some of the instruments employed.
Falls and fractures in elderly women were assessed as outcomes in one RCT. Compared with first-eye
cataract surgery, second-eye surgery did not reduce the number of falls or fractures significantly.
Only two RCTs provided information on surgical complications, but it is unclear how completely they were
reported, and some longer-term complications may have been missed by the relatively short follow-up
(6 or 12 months after surgery).
Systematic review of cost-effectiveness
A total of 190 potentially relevant references were identified by the cost-effectiveness searches. Of these,
the full texts of five papers were retrieved and four papers describing three studies published between
2003 and 2010 met the inclusion criteria. One of the studies was conducted in the UK, one in the USA
and the other in Finland. All three were cost–utility studies comparing second-eye cataract surgery with no
second-eye surgery. One study was a modelling study, one was a trial-based economic analysis and the
third was a prospective HRQoL study. Each of the studies based the effectiveness of the intervention
on a single trial or study, rather than a systematic review. Only one study modelled the costs of
treating complications.
There was variation between studies in the degree of pre-surgical visual impairment in the second eye.
In two studies the mean pre-surgical visual acuity was 0.24 (decimal, equivalent to around 6/24 metres),
whereas in the other study 86% of participants were described as having good vision in the eye to be
operated on (6/12 or better). Each study used a different HRQoL instrument [EQ-5D, time trade-off (TTO)
and 15D]. Post-surgical changes in HRQoL varied between the studies, with a utility gain of 0.109 in one
study and a utility loss of 0.01 in two studies.
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Cost-effectiveness results varied across the studies. One study reported an ICER of US$2495, and another
reported an ICER of £44,263. However, in the latter study the ICER reduced to £17,299 when a lifetime
horizon was used. The third study did not report an ICER as second-eye cataract surgery was associated
with negative QALYs.
In summary, there was variability across the three studies in terms of modelling approach, patient
characteristics and results, though second-eye cataract surgery would be considered cost-effective under
currently employed willingness-to-pay thresholds if a lifetime horizon is used. However, these economic
evaluations had various limitations, indicating a need to develop a de novo economic model to assess
cost-effectiveness of second-eye cataract surgery in the NHS.
Systematic review of health-related quality of life
Literature searching identified a total of 860 references, of which 10 studies, reported in a total
11 publications, were included in the review. The included studies were diverse in terms of aims,
comparisons made, study designs, patient characteristics and locations. In the majority of the studies in
which baseline clinical vision status was reported, the patients could be classed as having poor visual
acuity. A range of HRQoL instruments were used by the studies, the most common being the EQ-5D.
Other instruments used included the Health Utilities Index 3 (HUI-3) and TTO method. In four studies,
a comparison between first- and second-eye cataract surgery was possible. The utility changes observed
varied from negative to positive among the studies, but the more robust studies indicated net utility gains
after second-eye surgery.
Economic evaluation
In the base case analysis, second-eye cataract surgery generated 0.68 incremental QALYs at an additional
cost of £1341 compared with cataract surgery in one eye only. The ICER was £1964. In the probabilistic
analysis, the mean ICER was £1970 and the probability that second-eye cataract surgery would be
cost-effective at willingness-to-pay thresholds of £10,000 and £20,000, respectively, was 100%.
The base case results did not change significantly when input parameters and assumptions were varied
in deterministic sensitivity analyses and scenario analyses. Notable exceptions were the utility change
associated with second-eye surgery where ICERs ranged between −£2908 and £5734 per QALY in
scenario analyses that included utility estimates less favourable than the base case.
Discussion
This health technology assessment used standard rigorous methods for evidence synthesis and economic
decision modelling. Evidence for clinical effectiveness, cost-effectiveness and HRQoL improvement was
systematically sought and appraised and synthesised. The economic model was informed by previously
published models, and their limitations were taken into account where possible. Experts in ophthalmology
and patient care have been consulted for input throughout the review.
Limitations include the relatively small evidence base (three published RCTs and three published economic
evaluations), suboptimal reporting of studies and heterogeneity of study characteristics, precluding
quantitative meta-analysis. As is common in many economic evaluations, certain assumptions have been
made regarding resources, costs, surgical complications, patient characteristics and outcomes. These have
all been explicitly reported and tested in sensitivity and scenario analysis.
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Conclusions
Second-eye cataract surgery was associated with clinically meaningful improvement in stereopsis and,
in one RCT, in the mental health component of HRQoL. Most other measures of clinical vision, HRQoL
and vision-related functional ability did not change to a clinically important degree from before to after
second-eye surgery. However, changes in quality of life and vision-related functional ability were assessed
using instruments with known limitations and patients in the RCTs already had relatively good vision and
HRQoL after first-eye surgery. Based on economic modelling using the best available evidence, second-eye
surgery would be considered generally cost-effective under conventional willingness-to-pay thresholds used
in the NHS. The results were robust to a range of scenarios and assumptions but appear to be sensitive to
utility values chosen from published studies, meaning that second-eye surgery was not cost-effective in
at least one scenario analysis.
To overcome evidence limitations, there is a need to develop improved quality-of-life assessment tools
for patients with visual impairments that are capable of detecting clinically important effects of changes
in vision on quality of life and functional ability. To fully capture the effects of bilateral cataracts and
second-eye cataract surgery on patients’ clinical vision, HRQoL and visual disability, a ‘core’ set of outcome
measures may be appropriate, including tests of vision which may be more sensitive than binocular visual
acuity (e.g. including stereopsis and glare disability) as well as patient-reported functional disability
outcome(s). However, compared with the assessment of visual acuity, testing patients’ stereopsis would
likely incur additional costs associated with test equipment and staff training.
A well-designed RCT, using a representative UK patient population sample stratified by cataract severity
(or by another indicator of cataract-related visual function), and including a planned cost-effectiveness
evaluation based on methods for estimating utility changes (e.g. the TTO), would help to confirm the
clinical effectiveness and cost-effectiveness of second-eye cataract surgery under current NHS practice.
Study registration
This project is registered in the PROSPERO database, reference CRD42013004211.
Funding
This project was funded by the National Institute for Health Research Health Technology
Assessment programme.
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Chapter 1 Background
Description of the underlying health problem
Introduction
The transparent ocular lens is enclosed in a membranous capsule and consists of two layers: a central
ellipsoid, biconvex nucleus and a softer outer layer called the cortex. The lens contains epithelial cells that
give rise to lens fibres throughout life, meaning that it becomes thicker and more compact with age and
may lose optical clarity. Any loss of optical clarity in the lens is referred to as a cataract. Cataracts develop
most often as a result of biological ageing, although there are numerous risk factors and some types of
cataract are hereditary (see Cataract risk factors).
In the UK, one-quarter of the population will develop cataracts by the age of 75 years.1 Cataracts lead to
deterioration of vision, which may restrict daily activities and, in the elderly, independent living. Decreased
visual function is associated with diminished quality of life,2 as well as a decrease in physical and mental
health.3 Poor vision related to cataracts is also a risk factor for falls and traffic accidents, which may lead to
hospital admissions and limit independence.4,5 The only effective treatment available to restore or maintain
vision is the surgical removal of the cataract.1 Cataract surgery is the most frequently conducted elective
surgical procedure in the NHS, as well as in other Western countries.6
Cataract types and classification
Cataracts are classified in a number of ways, primarily according to the part of the lens that is affected,
and also according to their visual appearance and aetiology (e.g. some types of congenital cataract
have a characteristic appearance).7 The three most common types of age-related cataract are: nuclear
sclerotic cataract, located in the lens nucleus; cortical cataract, located in the cortex; and posterior
subcapsular cataract, located towards the back of the lens within the superficial posterior lens cortex.7–9
Nuclear cataract is the most common type of age-related cataract. Posterior subcapsular cataract is more
frequent among younger people.
Numerous clinical schemes have been developed for classifying the severity of the three main types of
age-related cataract. Most of these schemes are based on slit lamp assessment of the eye (in which a
narrow slit beam of light illuminates the eye) and comparison of the observations against standard
cataract diagrams or photographs to determine a score.10 The most popular classification schemes are the
Oxford Clinical Cataract Classification and Grading System11 and the Lens Opacities Classification System III
(LOCS III).12 Alternative, simpler, schemes for recording cataract severity based on the area of the lens
affected have also been used.10
Prevalence and incidence of the condition
Recent data on the prevalence and incidence of cataracts in England and Wales are lacking. According to
clinical experts, cataracts almost always develop bilaterally, i.e. patients with a cataract in one eye will
already have signs of, or will develop, a cataract in their second eye. Estimates of the prevalence of people
with cataracts in England have been made based on age- and sex-stratified regional population surveys,1
notably the North London Eye Study (1995–6), reported by Reidy and colleagues13 and Minassian and
colleagues,14 and a study based on the Somerset and Avon survey of health (SASH) (1996–7), reported by
Frost and colleagues,15 as well as other studies1 (described briefly below). These studies have produced
markedly different estimates of prevalence, reflecting differences in their methodology, including different
definitions of visual impairment and eligibility for cataract surgery.
The North London Eye Study randomly sampled people aged over 65 years from general practices in
north London (1547/1840 people responded) and provides prevalence data specifically for visually
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impairing cataracts [i.e. Snellen visual acuity less than 6/12 that is attributable to a lens opacity, but not
accounting for comorbidity or health-related quality of life (HRQoL)].13 The North London Eye Study found
a prevalence of cataracts causing visual impairment (visual acuity in one or both eyes poorer than 6/12,
attributable to lens opacity) of 30% [95% confidence interval (CI) 25.1% to 35.3%],13 and estimated the
incidence of new cataract cases per annum in England and Wales to be around 224,000.14 The prevalence
of cataracts increased steadily with age from 16% in the 65–69 years age group, to 71% in people aged
over 85 years.13
The SASH-based study by Frost and colleagues15 randomly sampled 2783 people aged ≥ 55 years from
19 general practice registers in south-west England, from which data on 1078 people were available for
analysis. Three definitions of eligibility for cataract were employed to reflect the likely range of eligibility
criteria used in practice, and these included ocular comorbidity as well as HRQoL.15 The estimated
prevalence of cataract (in one or both eyes) requiring extraction was much lower than that from the
North London Eye Study, ranging from 6 to 27 people per 1000 depending on the eligibility criteria.
When adjusted according to the population profile of England (based on the 1991 census), the prevalent
requirement for cataract surgery in England was estimated to range from 97,585 people (using the
strictest eligibility criterion) to 384,000 people (using the least restrictive eligibility criterion), and was
highest in patients aged over 74 years.15
Recent data collected by the Royal National Institute of Blind People (RNIB)16 indicate that 269,636 people
were treated for cataracts in England during 2012–13, which represents 0.48% of the population.
This number of operations exceeds some of the cataract prevalence estimates from Frost and colleagues
for England and Wales,15 indicating underestimation of the true prevalence if based on strict eligibility
criteria for surgery. However, direct comparisons are difficult to make since the studies by Frost and
colleagues15 and Reidy and colleagues13 were conducted over 15 years ago.
In a Medical Research Council (MRC) trial of assessment and management of older people in the
community (1994–2001), nurses tested visual acuity in 14,403 people aged 75 years and older from
49 general practices in the UK.17 Of 976 people with binocular visual impairment (binocular visual acuity
< 6/18) excluding refractive error, 25% were classified as cataracts being the main or contributory cause
of vision loss.
A study conducted in an urban population in England (the Newcastle 85+ cross-sectional study) based on
family practice records of 839 patients aged 85 years and older in 2006–7 found that 36% had a previous
history of cataract surgery in one or both eyes.18 Surveys conducted both in the UK and the USA indicate
that cataract prevalence is slightly higher in women,13,19 with 1.2 times as many women as men having
cataracts in the North London Eye Study.13 Prevalence also varies according to the type of cataract, with
nuclear cataract being more common than posterior subcapsular cataract.19
Assuming that it is reflective of the wider population case mix, the Cataract National Dataset, which
reflects 55,567 cataract operations conducted in 12 NHS trusts during November 2001 to July 2006,
would suggest that the ‘typical’ population in England presenting for cataract surgery in either eye would
be 62% female and of a mean age of 75.4 years.20 Pre-operative visual acuity was 6/12 or better in 55.3%
of those patients surveyed who were attending second-eye cataract surgery. However, it should be borne
in mind that visual acuity thresholds may have declined further since these data were collected.20
Cataract risk factors
Although cataracts are more common in older people, the risk of developing cataracts may be associated
with a wide range of factors. These include genetic factors,21 diet,22 metabolic and nutritional disorders
(e.g. diabetes mellitus, thyroid disorders), and treatment of ocular diseases (e.g. glaucoma) with steroids or
vitreoretinal surgery with heavy gases or oil in the eye. Extrinsic risk factors include infections, smoking,
alcohol and the use of systemic corticosteroids.23 Exposure to radiation also increases the risk of
developing cataracts, as the ocular lens is particularly sensitive to the effects of ionising radiation.
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Groups exposed to radiation that are at increased risk of developing cataracts include patients who have
received radiotherapy, clinicians who frequently use X-ray procedures and airline pilots exposed to
ultraviolet wavelengths.24,25 As the prevalence data referred to above suggest, women appear to have a
slightly higher risk of developing cataracts than men.13,17,19,23
Symptoms and diagnosis
Generally, age-related cataracts are progressive8 although during the early stages of cataract development
there may be minimal changes to an individual’s visual function. As cataracts develop further, they can
affect vision in a number of ways, including increasing myopia (nearsightedness) and astigmatism, inducing
monocular diplopia (double vision), reducing light transmission and/or changing colour perception.
Visual loss from cataracts is principally as a result of the decreased transmission of light through the lens.
Cataracts also increase scatter of intraocular light, which reduces the contrast of the retinal image, with
the visual decrement being greatest in glare or bright light conditions.10 During the later stages of opacity,
vision may be limited to light and dark distinction. Cataract symptoms include blurred or reduced vision,
and problems associated with glare or low-contrast conditions, ultimately leading to blindness if untreated,
but symptoms do depend on the location and size of the cataract, and whether cataracts are present in
one or both eyes. For example, glare may be a particular problem for people with posterior subcapsular
cataracts, although they may see well in dim illumination, whereas people with nuclear cataracts may
experience myopic refractive shift (improved near vision but worse distance vision), difficulty with night
driving and loss of colour discrimination ability.7
There is no single test to assess the effect of a cataract on a patient. Diagnosis usually involves examination
of the eye by an ophthalmologist or optometrist using a slit lamp and assessment of one or more
aspects of visual function, including visual acuity, contrast sensitivity and stereopsis (described in more
detail in Clinical vision outcome measures). Clinical decisions concerning the need for cataract surgery
also take into account the extent of symptoms and the impact of a cataract on the patient’s well-being
and quality of life (see Current service provision).
Measurement of the condition
Approaches for measuring the impact of cataracts on patients can be divided into those that assess impacts
on clinical vision and those that assess impacts on the way patients feel, for example how cataracts affect
patients’ symptoms and quality of life. The main clinical vision measures that have been used for assessing
effects of cataracts, both in clinical settings and as outcomes in clinical trials, are visual acuity, contrast
sensitivity and stereopsis (other vision outcomes such as glare disability may be important to patients, but
are less commonly reported in clinical trials of cataract surgery). A wide variety of validated patient-reported
outcomes relating to symptoms and quality of life have been used in clinical trials but, unlike measures of
clinical vision, they are not routinely employed in clinical decision-making practice for cataract surgery.
The three main clinical visual outcomes and some of the most frequently used patient-reported outcomes
that are used for assessing impacts of cataracts in clinical trials are described below.
Clinical vision outcome measures
For the outcome measures described below, assessments may be made with one eye covered (monocular
assessment) or with both eyes open (binocular assessment). In addition, assessments may be made under
specific conditions, for example to test for vision unaided or with spectacles, or to test for near or
distance vision.
Visual acuity
Visual acuity refers to a person’s sharpness of vision, commonly measured using a Snellen chart.26
Normal-distance visual acuity is defined as the ability of a person at a distance of 20 feet (or 6metres) from
the chart to separate lines that are one arc-minute apart (i.e. the ability to read the smallest line of letters
on the chart).27 Distance visual acuity is typically expressed as a ratio (comparing the closest distance that
the person would need to be from the chart in order to read the smallest line with the closest distance
a person with normal vision would need to be to read the same line). By definition, normal-distance visual
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acuity is 6/6 in metres or 20/20 in feet. Some studies report Snellen visual acuity as a decimal rather than a
ratio (Table 1). Visual acuity can also be expressed as the minimum angle of resolution (MAR) in minutes
of arc, usually converted to a logarithm (log-MAR), with larger values of log-MAR indicating worse visual
acuity.27,29 The clinical significance of changes in log-MAR visual acuity may be judged as those changes
which exceed the 95% range of test–retest reliability.30 However, published values vary according to the
study and type of chart used, and individual clinicians may draw on their own experience concerning
the repeatability of log-MAR test results when judging clinical importance of changes in vision. Published
95% ranges for log-MAR test–retest variance30 range from ± 0.07 to ± 0.19.
Visual acuity is enhanced by binocular compared with monocular vision.31 Binocular visual acuity reflects
what a patient actually sees when using both eyes, but may give a misleading indication of the impact of a
cataract, as the better-seeing eye can (depending on the extent of binocular summation or inhibition)
compensate for visual deficits in the fellow eye. Indeed, people with no vision in one eye may still achieve
normal or acceptable visual acuity with their functional eye. In many elderly patients, the monocular
visual acuity of the better-seeing eye provides a reasonable approximation of their binocular visual acuity.
However, in approximately one-fifth to one-third of elderly patients binocular vision is not well represented
by monocular vision measures.31
Visual acuity measures are often used to assess the need for cataract surgery, as well as for evaluating
the success of the operation. However, visual acuity may be relatively unaffected by cataracts until they
become severe, meaning that visual acuity may not be the most appropriate measurement tool.32
Contrast sensitivity
Optical contrast is the difference in luminance and/or colour of an object that makes it distinguishable
from the background and from other objects in the field of view. Contrast sensitivity refers to a person’s
ability to distinguish between an object and its background or, more specifically, the ability to discern
detail at low-contrast levels. People who can see details at very low contrast are said to have high-contrast
sensitivity. Numerous charts are available for assessing contrast sensitivity, of which the Pelli–Robson chart
is among the most widely used.33,34 The chart consists of lines of equally sized triplets of letters which
successively decrease in their contrast with the background and thus appear to gradually fade into it.33,34
Contrast sensitivity is usually reported as a logarithmic value (1/contrast), and is determined as the
logarithmic contrast sensitivity value of the last triplet for which at least two letters are correctly seen by
the viewer.33 The contrast sensitivity can also be expressed as a sensitivity on a dB scale (contrast sensitivity
in dB= –20 log10 contrast, i.e. 0.05 log-units= 1 dB, 0.5 log-units= 10 dB, 1.0 log-units= 20 dB). ‘Normal’
values for logarithmic contrast sensitivity are higher for binocular assessments than for monocular
TABLE 1 Commonly used indices of distance visual acuity
Typical
description
Snellen ratio for
assessment at
6m from chart
Snellen ratio for
assessment at
20 feet from chart
Snellen
decimal value
MAR
(minutes of arc) log-MAR
Varying degrees of
restricted visiona
6/60 20/200 0.1 10.0 1.0
6/30 20/100 0.2 5.0 0.7
6/15 20/50 0.4 2.5 0.4
Functional vision 6/12 20/40 0.5 2.0 0.3
Normal vision 6/6 20/20 1.0 1.0 0.0
Superlative vision 6/3 20/10 2.0 0.5 −0.3
a The UK Department for Work and Pensions classifies people with sight impairment (partial sightedness) as those who
have Snellen visual acuity from 3/60 to 6/60 with a full visual field; those with visual acuity up to 6/24 with a moderately
restricted visual field or opacities blocking vision in the eye itself; or those with visual acuity 6/18 or better with a gross
defect of visual fields or marked contraction of the visual field.28
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assessments and decrease with age,33,35 although, according to clinical experts consulted during this
project, age-adjusted reference values for contrast sensitivity are not used routinely in clinical practice.
Contrast sensitivity is enhanced by binocular compared with monocular vision.36 Lens opacification can
lead to a reduction in contrast sensitivity, with the reduction being greater as the extent of lens opacity
increases.37 When both eyes have equal contrast sensitivity, the binocular sensitivity is higher than the
monocular sensitivity (known as binocular summation). However, unequal monocular contrast sensitivities
can cause the binocular contrast sensitivity to decrease to a level below the monocular sensitivity of the
better eye (known as binocular inhibition). This is similar to visual acuity summation and inhibition.31
As a result, patients with a single cataract may complain of lower binocular contrast sensitivity compared
with using one eye only and may prefer to shut the cataractous eye.38 Binocular contrast sensitivity in
cataract patients has been shown to correlate strongly with perceived visual disability.35,39,40
Stereopsis
Stereopsis (also referred to as stereoacuity or depth perception) refers to a person’s ability to perceive the
three-dimensional structure of the environment based on the different two-dimensional images captured
by each eye. In normal vision, the brain is capable of measuring the disparity of vision between the
two eyes and ‘fusing’ these into a single image to produce the sensation of depth.41 If one eye is not
functioning properly, the brain may struggle to accurately combine the two images, affecting a person’s
ability to judge distances. Although some aspects of depth can be estimated using monocular cues, acute
depth perception requires binocular vision. Cataract in one or both eyes may therefore compromise a
person’s stereopsis. Suboptimal stereopsis has been shown to adversely affect motor skills,42 performance
with everyday tasks,35 driving ability40 and risk of falls in the elderly.43
Stereopsis is assessed by measuring the smallest lateral displacement (or ‘disparity’) of target images
presented to each eye that can be perceived by a patient in a ‘stereotest’.44,45 The results of a stereotest
are usually expressed as the smallest image displacement discernible by the viewer, either in seconds
of arc, or as logarithm units (e.g. 60 seconds of arc= 1.78 log-units). Unlike visual acuity and contrast
sensitivity, stereopsis tends to remain constant until people are in their mid-70s and then declines
rapidly.35,46 In older people, values < 150 seconds of arc may be considered good stereopsis. People who
cannot resolve images at high disparity are said to be ‘stereoblind’ (the threshold may vary but is often set
at ≥ 3000 seconds of arc).
Patient-reported outcome measures
A variety of instruments have been employed in research studies for assessing the impacts of cataract
surgery on patients’ symptoms, functional ability, well-being and HRQoL.1 These can be divided into generic
instruments which have been designed to apply across a range of different health conditions [e.g. the
European Quality of Life-5 Dimensions (EQ-5D) health survey and Short Form questionnaire-36 item health
survey instrument (SF-36)] and instruments that focus specifically on vision-related conditions
[e.g. the Visual Function Index (VF-14)]. Examples of vision-specific instruments are also provided
by Khadka and colleagues47 and McAlinden and colleagues.48
Impact on patients and the NHS
Without surgery, most types of cataract will progress with time, leading to loss of visual function, although
the rapidity and severity of visual decline depends on the type and severity of cataract present as well
as any ocular comorbidities (see Surgical and post-operative complications). Untreated cataracts may
ultimately lead to blindness. Benefits of cataract surgery include improved visual acuity, with 85–90% of
people having 6/12 best corrected vision as measured on a Snellen chart (i.e. meeting the driving
requirements in the UK); improved clarity of vision; and improved colour vision.9
Cataracts can affect patients directly by impairing their vision (e.g. visual acuity, contrast sensitivity and/or
stereopsis) and indirectly by the deterioration in functional abilities and quality of life that can result from
the visual impairment. In older people, deterioration of vision as a result of cataracts can have a range
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of consequences. People may have difficulty performing daily tasks, reading, using computers, or
participating in games or social activities. Elderly women with cataracts are at an increased risk of having
falls and fractures.4
An issue of particular concern among drivers is that cataracts can affect their ability to drive safely.16
Studies comparing populations of cataract patients who have or have not received cataract surgery suggest
that cataracts contribute to self-reported driving difficulty49 and increase the frequency of motor vehicle
collisions, as well as the financial costs associated with them.50 It has been suggested that providing
cataract surgery earlier, rather than after significant visual problems have become apparent, could reduce
traffic accidents among older drivers.5 Vision-related driving requirements are usually based only on visual
acuity,51 although drivers who pass a visual acuity test may have poor contrast sensitivity or other
visual defects which, although not tested, can impair their driving ability.52,53 In the UK, people are required
have a Snellen distance visual acuity of at least 6/12 (with spectacles if appropriate) in order to be allowed
to hold a driving licence.51 In addition, since 2001 the legal requirement for standards of vision for driving
has been based on being able to read a car number plate from 20 metres. This may overestimate the
driver’s functional vision in real-life motoring conditions, as many drivers with early cataracts experience
problems with night vision. According to clinical experts consulted during this project, in cases where
cataract surgery causes enough improvement in visual function for drivers to retain their eligibility to drive,
this may impact positively on their quality of life. However, there do not appear to be any data on how
many patients this would apply to, nor on the extent of the impact on quality of life.
Cataract surgery is the most common elective surgical procedure performed in the NHS,1 and cataracts
place a direct financial burden on the NHS in terms of the cost of treatment. However, performing
cataract surgery may lead to savings in health-care costs elsewhere, for example those associated with
falls and traffic accidents, although it is uncertain how important second-eye cataract surgery would be
compared with first-eye surgery in this respect.
According to a report by the RNIB published in 2013,16 there were 340,809 cataract operations in
England during 2012–13 (up to 28 February 2013). The most recent data available on the proportions of
first- and second-eye cataract surgery in England are from 2011–12 in the RNIB report,16 and indicate that
cases of second-eye cataract surgery that were conducted within 1 year of the first-eye surgery accounted
for 27% of all cataract operations. The National Schedule of Reference Costs54 puts the total cost of
cataract surgery for 2011–12 at £240M. Assuming that 27% of cataract operations are on the second
eye,16 an estimate of the cost per annum of second-eye surgery alone would be £64.8M. The burden
of cataracts to the NHS will increase as the population ages and larger numbers of older people seek
treatment. However, figures reported by the RNIB suggest that the frequency of second-eye cataract
operations has decreased in England from 96,336 in 2009–10 to 91,959 in 2011–12.16
Current service provision
Most cataract operations are performed on elderly patients, with 90% being on patients aged 60 years or
over.1 According to Cataract Surgery Guidelines published by the Royal College of Ophthalmologists in
2010,1 access to surgery is generally good, with NHS surgical waiting times under 3 months, although it
was acknowledged that there is geographical variation and overprovision may have occurred in some
areas.1,55 The RNIB report published in July 201316 indicates that the average time to treatment (from first
outpatient appointment to cataract surgery in either eye) during 2012–13 was 129 days (i.e. approximately
4 months), but with considerable regional variation among the Clinical Commissioning Groups (CCGs) in
England, with a range from 44 days to 222 days.16 In recent years, the clinical criteria which have been
used for determining eligibility of patients for cataract surgery have become less stringent, with a lowering
of the threshold of visual dysfunction.56 This has led to concerns about whether or not there may be
overprovision of cataract surgery55 and, if so, whether or not it would be cost-effective to treat cataract
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patients whose visual dysfunction is not so severe as to restrict their lifestyle.56 However, as mentioned
above, there has also been a decline in the frequency of second-eye operations,16 suggesting that access
to second-eye surgery may have been restricted.
The rates of second-eye cataract surgery per annum were investigated in the RNIB report.16 During the
reporting period, primary care trusts (PCTs) in England were replaced by CCGs. In order to present data
in a standard format, the RNIB report presents historical data under the name of the CCG that has
responsibility for each area. Rates of second-eye cataract surgery in England varied geographically among
the CCGs, ranging from 14.66 to 62.81 operations per 100,000 population during 2011 (the latest period
for which these data were reported). There is no agreed figure for what a good rate of second-eye
surgery should be, although data from 11 European countries suggests that 40% of patients who have a
first-eye cataract are likely to require second-eye surgery.16,57 Forty-four CCGs performed fewer than
30 second-eye cataract operations per 100,000 of population in 2011, while nine CCGs performed more
than 50 second-eye cataract operations per 100,000 of population. A limitation of these data is that it
is not possible to judge whether low surgery rates result from restrictive referral policies or from local
population profiles. An online survey conducted by the Royal College of Ophthalmologists among its
consultant ophthalmologist members in April 2011 (which did not distinguish between first- and
second-eye surgery) found that 44.4% of consultants felt that local commissioners had placed restrictions
on who could be listed for cataract surgery and 38.1% had encountered situations where they felt a
patient had been disadvantaged by restrictions on cataract surgery.58
Cataract management involves ophthalmologists, optometrists, nurses and technicians, with the ultimate
responsibility for diagnosis and management resting with the ophthalmologist. The surgery itself is
performed by an ophthalmic surgeon, although suitably trained non-medical members of the team may
undertake much of the assessment and follow-up examinations.1 People with cataracts may be referred to
a consultant ophthalmologist by their general practitioner (GP) based on a visual assessment report from
an optometrist, or may be referred directly by the optometrist. The actual surgery is usually undertaken
as a day case, taking up to half a day. After the procedure, suitably trained practitioners will process the
patient’s discharge and provide instructions for post-operative medication. Around 90% of cataract
operations are uncomplicated and the final post-operative assessment is often deferred until 4–6 weeks
after surgery.59
Currently, there is no set level of vision in the NHS for which an operation is considered essential.1,9,16,60
The survey conducted by the RNIB in February 2013 found wide variation in cataract commissioning
policies (i.e. referral criteria) across the CCGs in England. Forty-nine per cent of the commissioning policies
in England were found to have no arbitrary restrictions on vision or vision-related function; 33% had a
visual acuity restriction but allowed for exemptions (e.g. if patients experience glare or need to drive), and
18% had strict criteria for visual acuity thresholds and limited or no exemptions.16 Similar findings had
been obtained from previous RNIB surveys in June 201158 and May 2012,61 and a survey of CCGs in
England by academic researchers in May 2011.60 The academic researchers concluded that almost all
cataract surgery referral criteria employed in England (92%) were not evidence based, and some patients
who would benefit from cataract surgery were being restricted in their access to surgery.60 Two-thirds of
the referral policies in England made provision for second-eye surgery.60
The variation in service provision for second-eye surgery was not reported for all CCGs in England in the
July 2013 RNIB report,61 but is illustrated in the May 2012 RNIB report, which suggested that patients in
north-east England could have surgery as soon as they need it (i.e. they did not have to satisfy visual acuity
criteria), whereas some patients in the south-east of England would have to lose three lines of visual
acuity (Snellen 6/18) in order to be eligible to access second-eye surgery.61 According to clinical experts
consulted during this systematic review, most patients with bilateral cataracts prefer to have the second
eye operated on.
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Patients referred for second-eye cataract surgery are generally assessed for their second-eye surgery at the
time of their first-eye surgery post-operation check (e.g. 4–6 weeks post operation). They may then wait
up to a further 18 weeks for surgery unless there is an urgent reason to do it sooner, although, as noted
above, there is considerable geographical variation in waiting times. One reason for expedited second-eye
surgery would be where the difference in refraction between the two eyes is more than 2 dioptres
(anisometropia) as this can cause considerable visual discomfort and double vision (diplopia), making vision
with both eyes open worse than using the better eye alone in a small proportion of patients (around 5%
according to clinical experts consulted during this systematic review). In some cases cataract surgery is
justified on medical grounds (e.g. to prevent glaucoma, as large cataracts can increase intraocular pressure,
or to allow assessment of retinal disorders). It is very uncommon for cataract extraction to take place in
both eyes simultaneously because of the risk of associated complications, including bilateral infective
endophthalmitis (inflammation of the inside of the eye) which may lead to blindness in both eyes and
medico-legal concerns. Some cataract surgery referral policies in England allow simultaneous (same day)
bilateral cataract extraction.60 However, expert clinical opinion provided during this systematic review
suggests that 1% or fewer bilateral cataract extractions are undertaken sequentially on the same day.
Relevant national guidelines
Current guidance on referral criteria for cataract surgery is given in the Department of Health report
Action on Cataracts, which was published in 2000.62 The report led to a number of improvements in NHS
cataract care pathways during the 2000s, including enabling direct referral by optometrists, simplifying the
number of consultations required, increasing the throughput of patients and reducing waiting times,
and emphasising the need for care to be patient centred to prevent situations where people experience
a reduction in their quality of life owing to treatable cataracts.59,62 The most relevant current national
guidelines are the Royal College of Ophthalmologists Cataract Surgery Guidelines (2010) (next due for
review in 2015) which state that it is clinically and economically appropriate for second-eye surgery to be
offered to those patients who want it. A 1b recommendation is given (a recommendation based on at
least one randomised trial).1 Similarly, the Scottish Health Technologies Group issued a statement in
September 2012 advising that there is randomised controlled trial (RCT) evidence to support second-eye
surgery and evidence from cost–utility analysis to demonstrate lifetime cost-effectiveness.63 In England
and Wales, the National Institute for Health and Care Excellence (NICE) has not previously appraised
second-eye cataract surgery. It is thought that such an appraisal is unlikely to be conducted by NICE until
2018, although the RNIB and Royal College of Ophthalmologists have requested this to be prioritised.16
Description of the technology under assessment
An eye which retains its original crystalline lens is referred to as a phakic eye. The lens may or may not be
cataractous. An eye which has undergone a cataract operation with a lens implant is referred to as a
pseudophakic eye.
Routine cataract surgery consists of eight steps: (1) anaesthesia (with a local anaesthetic in around 96% of
cases); (2) surgical entry (typically a small incision through the cornea or sclera); (3) capsulorhexis – creation
of a small aperture in the lens capsule; (4) phacoemulsification – ultrasonic fragmentation of the
cataractous lens nucleus using a device called a phaco probe and removal by suction of the resulting lens
fragments; (5) removal by suction of the soft cortex which lies between the lens nucleus and the capsule;
(6) insertion of the lens implant, sometimes followed by intracameral injection of antibiotics; (7) suturing
of the eye if necessary; and (8) post-operative care, in which patients are given topical antibiotic and
anti-inflammatory drugs typically for 4–6 weeks post operation.
Check-ups following cataract surgery include measurement of visual acuity, a slit lamp examination,
measurement of intraocular pressure and ophthalmoscopy to evaluate the inside of the eye. The majority
of patients who receive cataract surgery (around 86%20) do not experience any complications and require
no further therapy or ongoing care after their post-surgery check-up.
BACKGROUND
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Surgical and post-operative complications
The most frequent adverse consequence of cataract surgery is a clouding of the back of the lens
capsule, known as posterior capsular opacification (PCO), which can lead to deterioration in vision months
or years after the initial surgery. For the purposes of this report, we refer to PCO as a complication
of cataract surgery, although strictly speaking PCO could be considered an expected consequence of
phacoemulsification in a proportion of patients since phacoemulsification leaves the lens capsule intact but
prone to opacification after cataract extraction. Clinical experts estimated that 20–30% of patients who
have cataract surgery will experience PCO. Except in rare cases, PCO is easily treated with a procedure
known as neodymium-doped yttrium–aluminium–garnet (Nd:YAG) laser lcapsulotomy in which a laser with
a Nd:YAG crystal is used to cut a hole in the opacity of the lens capsule to allow light to pass through.64
Laser capsulotomy is a painless outpatient surgical procedure that does not require anaesthesia.
A single laser capsulotomy can provide lifelong recovery of good vision, although complications may
occur in a minority of patients.64
Serious surgical complications associated with cataract surgery (which may be sight-threatening, or
increase the risk of sight-threatening sequelae) are posterior capsule rupture (PCR) during surgery65 and,
post operatively, endophthalmitis,66 retinal detachment,67,68 cystoid macular oedema69 and retained lens
fragments.70,71 These complications are relatively uncommon, affecting fewer than 2% of cataract
operations.1,20,68,72–74 However, the occurrence of PCR during surgery increases the risk of cystoid macular
oedema, endophthalmitis and retinal detachment.65
Other complications that may arise from cataract surgery9 but which are usually not serious, except in rare
cases, are uveitis, transient increase in intraocular pressure, bruising of the eye or eyelids after surgery
which usually resolves without problems, refractive surprise (an unexpected need for a particular glasses
prescription) and corneal decompensation (corneal oedema).
Identification of important subgroups
Important subgroups that may affect cataract surgery outcomes include patients’ age, pre-operative ocular
comorbidities and the experience of surgeons conducting the procedure. Data from the UK Cataract
National Dataset indicate that pre-operative risk factors for PCR and/or vitreous loss during cataract surgery
include (among others) increasing age, male gender, glaucoma, diabetic retinopathy and trainee surgeons
performing operations.75 Other pre- and peri-operative adverse risk factors for post-surgical monocular
vision loss are age-related macular degeneration, amblyopia, corneal pathology, previous vitrectomy and
posterior capsule rupture during surgery.76 The UK Cataract National Dataset found that, during 2001–6,
28.5% of people presenting for cataract surgery (one or both eyes) had one or more ocular comorbidities.
Post-operative visual acuity of 6/12 or better was achieved in 97% of patients who had no pre-operative
comorbidities and 79.9% of patients with one or more ocular comorbidities (51% and 30%, respectively,
achieved visual acuity 6/6 or better).20
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Chapter 2 Definition of the decision problem
Decision problem
Some patients with bilateral cataracts may have surgery on only one eye, but it is suggested that
surgery on the second eye may have additional benefit for patients in terms of improving vision and being
able to perform everyday activities (e.g. being able to drive). However, there is uncertainty about how
cost-effective second-eye surgery would be, with no systematic reviews hitherto having addressed this
question. The decision problem is relevant to current financial constraints faced by the NHS, with concerns
having been raised about possible overprovision of cataract surgery55,56 and the need to ensure adequate
patient access to cataract surgery.58,77
Overall aims and objectives of the assessment
The aim of this systematic review was to assess the clinical effectiveness and cost-effectiveness of
second-eye cataract surgery. The objectives were:
l to conduct a systematic review of studies assessing the clinical effectiveness of second-eye surgery
l to conduct an economic evaluation comprising:
¢ a systematic review of cost-effectiveness studies of second-eye surgery
¢ a systematic review of relevant quality-of-life studies
¢ an economic model, developed de novo or adapted from an existing one, to estimate
cost-effectiveness of second-eye cataract surgery.
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Chapter 3 Methods
The a priori methods for systematically reviewing the evidence of clinical effectiveness and cost-effectiveness are described in the research protocol (see Appendix 1). The protocol was sent to our
expert advisory group (AG) (see Acknowledgements) for comment and minor amendments were made as
appropriate. None of the comments received identified specific problems with the methods of the review.
Identification of studies
Sensitive search strategies were developed and refined by an experienced information specialist
(see Appendix 2).
Main searches for clinical effectiveness, cost-effectiveness and HRQoL literature were undertaken from
inception of databases to March/April 2013, with updated searches conducted in July 2013. Searches were
limited to the English language.
The strategies were applied to the following databases:
l Ovid MEDLINE (1946 to March 2013)
l Ovid MEDLINE Daily Update (12 March 2013)
l Ovid MEDLINE In-Process & Other Non-Indexed Citations (12 March 2013)
l Ovid EMBASE (1974–March 2013)
l Web of Science: Science Citation Index-Expanded (SCI-Expanded; 1970–March 2013); Conference
Proceedings Citation Index – Science (CPCI-S; 1990–March 2013); Conference Proceedings Citation
Index – Social Science and Humanities (CPCI-SSH)
l BIOSIS Previews (Web of Science platform; 1956–March 2013)
l The Cochrane Library: Cochrane Central Register of Controlled Trials; Cochrane Database of
Systematic Reviews
l Centre for Reviews and Dissemination (CRD): Database of Abstracts and Reviews of Effectiveness;
Health Technology Assessment (HTA) database.
In addition to the databases listed above, the searches of cost-effectiveness and HRQoL also included the
following databases:
l NHS Economic Evaluations Database (NHS EED) (cost-effectiveness searches)
l The King’s Fund database (HRQoL searches).
For each of the systematic reviews of clinical effectiveness, cost-effectiveness and HRQoL, internet pages of
the Cochrane Eyes and Vision Group, the Royal College of Ophthalmologists and NICE were searched.
The reference lists of included primary studies were checked for additional references. If any relevant
systematic reviews were identified, their reference lists were also checked for relevant references.
Experts on the review AG were also asked to identify additional published and unpublished references.
All search results were imported into a Reference Manager (Thomson ResearchSoft, San Francisco,
CA, USA) database.
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Study selection
Titles and abstracts of records identified by the bibliographic searches for clinical effectiveness literature
were assessed independently by two reviewers for potential eligibility, using a standardised eligibility
selection worksheet (see Appendix 3) containing the following pre-specified eligibility criteria:
l Population: adults (aged 18 years and over) who have had one cataract operation already and still have
or have developed a significant cataract causing visual impairment in the other eye.
l Intervention(s): cataract surgery for the second eye. Studies reporting any surgical technique
were included.
l Comparator(s): cataract surgery in one eye only (can include a ‘waiting list control’ group in which the
comparator population ultimately receives second-eye surgery, but not during the study period); and
patients may receive additional supportive care if this is usual practice, such as prescription glasses.
l Outcomes: any clinical visual measures (including measures of visual acuity; contrast sensitivity;
stereopsis); patient-reported visual disability and symptoms (e.g. VF-14); patient satisfaction with surgery
and vision; HRQoL (e.g. EQ-5D); and adverse events (including peri- and post-operative complications).
l Study design: RCTs. If relevant systematic reviews were identified, these were only used as a source of
references. Studies published as abstracts or conference presentations were only included if sufficient
details were presented to allow an appraisal of the methodology and the assessment of results to
be undertaken.
The systematic reviews of cost-effectiveness and HRQoL employed the inclusion criteria listed above, with
the following modifications (which were reflected in the study selection worksheets):
l Studies of any design were eligible for the cost-effectiveness review if they reported full economic
evaluations (e.g. cost-effectiveness, cost–utility).
l Studies of any design were eligible for the systematic review of HRQoL if they used generic
preference-based HRQoL measures or generic preference valuation methods, and reported
HRQoL outcomes. It was anticipated that there would be limited relevant literature on HRQoL in
patients receiving second-eye cataract surgery. Therefore, the criteria were broader and could also
include first-eye cataract surgery. While HRQoL data based on second-eye surgery were to be
prioritised for use in the economic evaluation, data from studies of first-eye surgery could be included
for context and to potentially inform sensitivity analysis.
Any disagreements between the reviewers regarding title and abstract screening using the above criteria
were resolved by discussion or, if necessary, consultation with a third reviewer. Full-text records were
then obtained for all titles and abstracts that met the inclusion criteria or remained unclear. The full-text
records were assessed independently by two reviewers using the same criteria as for titles and abstracts.
Any further disagreements between the reviewers were resolved through discussion and, if necessary,
recourse to a third independent reviewer.
For the systematic review of HRQoL, the inclusion criteria were slightly revised for screening full papers,
with the additional stipulation that to be included studies had to be primary research, and had to report
utility values (i.e. patient preferences for a health outcome, commonly measured on an interval scale
with 0 reflecting states of health equivalent to death and 1 reflecting perfect health) as opposed to,
for example, reporting only HRQoL scores (i.e. not related to patient preferences).
Only articles published in English were eligible for the systematic reviews. Conference abstracts were not
eligible for the systematic review of cost-effectiveness and HRQoL but were considered for the review of
clinical effectiveness, subject to reporting adequate detail to enable an appraisal of the methodology.
METHODS
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Data extraction and critical appraisal
Standardised forms were used to collect data from the studies that were included in the systematic reviews
(completed data extraction forms for the reviews of clinical effectiveness, cost-effectiveness and HRQoL are
shown, see Appendices 4, 7 and 9, respectively). In each systematic review, data were extracted by one
reviewer and then checked for accuracy by a second reviewer.
Randomised controlled trials included in the systematic review of clinical effectiveness were assessed in
terms of their risk of bias (selection bias, detection bias, performance bias, attrition bias and selective
reporting bias) using Cochrane Collaboration criteria.78,79 Risk of bias was assessed independently by two
reviewers who then met to compare their judgements. Disagreements were resolved through discussion
and, if necessary, consultation with a third reviewer. Tables summarising and explaining the risk of bias
judgements are included in the data extraction forms (see Appendix 4). Other aspects of study quality
relating to statistical procedures, outcome measurement and generalisability were also assessed and
recorded in the data extraction forms.
The methodological quality of studies included in the systematic review of cost-effectiveness was assessed
using accepted criteria for appraising economic evaluations.80,81 Owing to the diverse types of study design
eligible, the methodological quality of studies included in the systematic review of HRQoL was
not formally assessed.
Method of data synthesis
As specified in the protocol (see Appendix 1), studies were synthesised narratively following a structured
approach similar to one proposed by Rodgers and colleagues.82 Quantitative pooling of outcomes
across clinical effectiveness studies in a meta-analysis was not considered appropriate as the included
studies differed in their methodological characteristics (see Chapter 4, Clinical effectiveness outcomes).
Meta-analysis was also not possible for pooling outcomes in the systematic reviews of cost-effectiveness
or HRQoL because of the different types of study design included (see Chapter 5, Economic analysis).
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Chapter 4 Clinical effectiveness
Quantity and quality of research available
Searches identified a total of 993 references after de-duplication and full texts of 15 references were
retrieved after screening titles and abstracts. Reviewer agreement at title and abstract screening was good,
with both reviewers reaching the same decision in the study selection worksheet (see Appendix 3) for
99.2% of the titles and abstracts. The number of references excluded at each stage of the systematic
review is shown in Figure 1. Nine of the 15 potentially eligible references were excluded (see Appendix 6).
Three potentially relevant conference abstracts were identified but could not be appraised in detail because
of a lack of methodological information (see Appendix 5). The remaining three full-text references met the
inclusion criteria. These described three RCTs which we included in our systematic review. We did not
identify any relevant existing systematic reviews of the clinical effectiveness of second-eye cataract surgery
until after this report had been completed (see Relevant systematic reviews).
Characteristics of the included studies
Two of the studies were set in the UK83,84 and one in Spain85 (Table 2). The publication date was 2006 for
two of the studies83,85 and 1998 for the remaining study.84 However, trials started as early as 1994.84 Both
the UK studies used only one centre, a hospital ophthalmology department83 and an eye hospital.84 Castells
and colleagues85 conducted their study in two ophthalmology departments in public teaching hospitals.
Sample size ranged from 20884 to 296 randomised participants85 and the length of study follow-up was 485
to 12 months (see Table 2).83 All three studies received only academic (non-commercial) funding.
References for retrieval and screening
(n = 12)
Potential eligible references
(n = 15)
Total of titles and abstracts identified
(after de-duplication)
(n = 993)
Potentially relevant abstracts
(n = 3)a
Full papers excluded (n = 9)b
Reasons for exclusion:
• Design, n = 6
• Population, n = 5
• Intervention, n = 4
• Comparator, n = 4
• Outcomes, n = 1References included (n = 3),
describing three studies
Excluded
(n = 978)
FIGURE 1 Flow chart for the identification of studies. a, Listed in Appendix 5; and b, listed in Appendix 6.
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TABLE 2 Characteristics of the included studies
Parameter Laidlaw et al. (1998)84 Foss et al. (2006)83 Castells et al. (2006)85
Study design RCT RCT RCT
Country UK UK Spain
Study dates 1994–5 2000–4 1999–2000
Intervention Expedited second-eye
surgery target within
6 weeks
Expedited second-eye surgery
target within a month
Surgery in the first
eye 1–2 months after
enrolment, in the second
eye 2–4 months after
first-eye surgery
Comparator Routine second-eye surgery
(targeted 7–12 months)
Waiting list group, second-eye
surgery within 13 months
or the routine waiting time
when this became less than
13 months
First-eye surgery 1–2 months
after enrolling, second-eye
surgery offered at end
of study
Population: age (years) Intervention: mean 76
(range 52–97)
Comparator: mean 76
(range 41–93)
Intervention: median 79.2
(range 70–90)
Comparator: median 79.9
(range 70–92)
Intervention: mean 71.70
(SD 9.07)
Comparator: mean 72.03
(SD 8.87)
Population: sex, male, n (%) Intervention: 40 (38)
Comparator: 40 (39)
0 (100% female for both
groups)
Intervention: 57 (39)
Comparator: 55 (37)
Country (no of centres
and details)
UK (one centre – eye
hospital)
UK (one centre – hospital
ophthalmology department)
Spain (two centres –
ophthalmology departments
in public teaching hospitals)
Sample size (n randomised) 208 (intervention: n= 105;
comparator: n= 103)
239 (intervention: n= 120;
comparator: n= 119)
296 (intervention: n= 148;
comparator: n= 148)
Length of follow-up
after surgery
Approximately 6 months
(medians and interquartile
ranges reported for each
study group – see data
extraction form in
Appendix 4)
6 and 12 months (visual
and patient-reported outcomes
6 months; falls 12 months;
complications 6 or 12 months)
(assessments also at 3 and
9 months but results
not reported)
4–6 months after the last
surgery (first-eye surgery for
the comparator group and
after second-eye surgery for
the intervention group)
Losses to follow-up n/N (%) Intervention: 7/105 (7)
Comparator: 9/103 (9)
Intervention: 5/120 (4)
Comparator: 16/119 (13)
Intervention: 9/148 (6)
Comparator: 13/148 (9)
Key inclusion criteria Awaiting second-eye
surgery, a unilateral cataract
and uncomplicated
contralateral pseudophakia
with corrected Snellen VA
of at least 20/40 in the
pseudophakic eye
Women age > 70 years,
successful previous cataract
operation, second operable
cataract
Scheduled for first-eye
cataract surgery, bilateral
indication for cataract
surgery (VA worse than
0.3 log-MAR in both eyes)
Comorbidities NR Non-ocular comorbiditiesa
(intervention%, comparator%):
heart problems (33, 30); chest
problems (21, 19); arthritis
(76, 78); stroke (8, 6); previous
fracture (48, 48); postural
dizziness (35, 24); postural
hypotension (16; 12)
Ocular comorbidities
(unspecified), n/N (%):
intervention: 34/148 (23.0);
comparator: 36/148 (24.3)
Type of lens NR Folding silicone intraocular lens Foldable lens
CLINICAL EFFECTIVENESS
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Participants had an average age of between 7185 and 79 years,83 with an age range of 41–97 years
(see Table 2). Two studies had a higher percentage of female participants, ranging from 61%84 to 76%.85
Foss and colleagues83 limited their study to female participants. Only two studies reported comorbidities.
Foss and colleagues83 reported comorbidities relating to heart (31%), chest (20%) and arthritis (77%)
problems, while Castells and colleagues85 reported ocular comorbidities (24%), but provided no further
details. The key inclusion criteria for the Foss and colleagues83 study, apart from being female, was age
> 70 years, a successful previous cataract operation and a second operable cataract (see Table 2). The study
by Laidlaw and colleagues84 stipulated that participants had to be awaiting second-eye surgery, have a
unilateral cataract and uncomplicated contralateral pseudophakia, with corrected Snellen visual acuity of at
least 20/40 in the pseudophakic eye. Unlike the other two UK studies, the study by Castells and colleagues85
in Spain recruited participants who had not received any cataract surgery prior to enrolment, but were
scheduled for first-eye cataract surgery and had a bilateral indication for cataract surgery (visual acuity worse
than 0.3 log-MAR in both eyes). For this reason, the timing of baseline assessments differs between Castells
and colleagues85 and the other two RCTs, and this should be borne in mind when interpreting any changes
from baseline in the results of these studies. Castells and colleagues’85 baseline data were taken prior to
first-eye surgery, whereas in the other two RCTs the baseline data were taken prior to second-eye surgery.
Accordingly, changes from baseline in the RCTs by Laidlaw and colleagues84 and Foss and colleagues83
specifically refer to second-eye cataract surgery while changes from baseline in the RCT by Castells and
colleagues85 refer to the combination of both first- and second-eye surgery. Binocular corrected visual acuity
prior to second-eye surgery was good in each of the RCTs, ranging from 0.022 to 0.22 log-MAR (see Table 2),
i.e. better than Snellen 6/10.
All three RCTs reported exclusion criteria. Laidlaw and colleagues84 excluded patients with ocular
comorbidity or unsuccessful first-eye surgery. Foss and colleagues83 excluded participants with complex
cataracts, those with severe comorbid eye disease affecting visual acuity or with visual field defects, and
those with memory problems impacting on lengthy questionnaire completion or reliable recall of falls.
Castells and colleagues85 excluded participants with severe ocular comorbidity that would contraindicate
surgery in both eyes and those who were undergoing surgery combined with any other ophthalmological
procedure or experiencing complications of first-eye surgery that would contraindicate surgery in the
fellow eye. Overall, the participants in the three RCTs were similar in not having ocular comorbidities and
being aged in their 70s, although mean patient age was 7–8 years higher in the RCT by Foss and
colleagues83 than in the RCT by Castells and colleagues.85 The most notable difference in the included
populations was that Foss and colleagues83 included only women, in contrast to the other RCTs.
TABLE 2 Characteristics of the included studies (continued )
Parameter Laidlaw et al. (1998)84 Foss et al. (2006)83 Castells et al. (2006)85
Baseline visual acuity
before second-eye surgery
(log-MAR, mean)
0.022 (binocular, corrected) 0.09 (binocular, spectacles
corrected), 0.22
(binocular, unaided)
0.18 (binocular, corrected)b
Severity of cataract NR NR NR
Type of surgery NR Small-incision cataract surgery
(team A & C temporal clear
cornea, team B superior
clear cornea)
Ambulatory surgery using a
phacoemulsification
technique (3-mm corneal
incision without suture)
NR, not reported; SD, standard deviation; VA, visual acuity.
a Full data on the comorbidities reported by Foss and colleagues83 are given in the data extraction form for this study
(see Appendix 4).
b Visual acuity (VA) was not reported by Castells and colleagues85 prior to second-eye surgery in the intervention group;
data presented here are instead taken from the comparator group (i.e. waiting list control group) at 4–6 months
after first-eye surgery.
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In the study by Laidlaw and colleagues,84 the intervention group received expedited large-incision
second-eye cataract surgery, targeted to within 6 weeks, whereas the comparator group received
routine second-eye cataract surgery after 7–12 months (i.e. a waiting list control group). Surgical details
were not reported.
The study by Foss and colleagues83 employed small-incision phacoemulsification cataract surgery (temporal
clear or superior clear cornea) conducted by three teams inserting a folding silicone intraocular lens under
local anaesthetic. The intervention group received expedited second-eye surgery targeted to be within a
month, whereas the comparator waiting list group received second-eye surgery within 13 months, or the
routine waiting time when this became less than 13 months.
Castells and colleagues85 also used a phacoemulsification technique (3-mm corneal incision without suture),
inserting a foldable lens under topical anaesthesia. The comparator group had cataract surgery on the first
eye only between 1 and 2 months after enrolling, but were offered second-eye cataract surgery at the end
of the study. The intervention group received second-eye surgery 2–4 months after first-eye surgery.
Losses to follow-up ranged from 4% to 13% of the randomised population (see Table 2). None of the
RCTs fully described reasons for attrition. While the studies reported that analysis was performed on an
intention-to-treat (ITT) basis, this was unsupported by data presented and there were inconsistencies in
the reporting of the loss to follow-up of patients. In the RCTs of Laidlaw and colleagues84 and Castells
and colleagues,85 rates of attrition were similar for the first- and second-eye study groups. In Foss and
colleagues’ RCT, however,83 the rate of attrition was 9% higher in the waiting list comparator group.
Of 16 patients lost to follow-up in this group, seven dropped out in order to receive non-trial surgery.
Risk of bias
Risk of bias varied between the studies (Table 3). All three studies were judged at high risk of bias on at
least one domain. In four out of the six domains of bias, one or more of the studies provided insufficient
information to allow for a conclusion about the risk to be reached and were therefore judged unclear.
Explanations for risk of bias judgements are given in the data extraction forms (see Appendix 4).
The risk of selection bias relating to random sequence generation was low for the study by Castells and
colleagues85 and unclear for the remaining two studies.83,84
The risk of selection bias relating to allocation concealment was deemed low in two studies,83,84 but
unclear in the third study by Castells and colleagues.85
TABLE 3 Risk of bias
Domain of bias78
Laidlaw et al.
(1998)84
Foss et al.
(2006)83
Castells et al.
(2006)85
Selection bias: random sequence generation Unclear Unclear Low
Selection bias: allocation concealment Low Low Unclear
Detection bias: masking of outcome assessors Unclear High Unclear
Performance bias: masking of participants on
self-reported outcomes
High High High
Attrition bias: incomplete outcome data addressed Unclear Unclear Unclear
Reporting bias: free of selective reporting High Unclear Unclear
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The risk of detection bias as a result of not masking outcome assessors was unclear for two of the
studies,84,85 but considered high in the study by Castells and colleagues.85
It was not feasible for any of the RCTs to mask their participants to the surgical interventions, and all were
judged to be at high risk of performance bias through lack of masking of participants on self-reported
outcomes (note that a high risk of performance bias does not necessarily imply poor quality of study
design, given that masking may not be practically and/or ethically feasible79). Performance bias is less
relevant to objective outcomes such as measures of clinical vision than subjective measures such as
patient-reported questionnaires.
The risk of attrition bias was determined by considering whether or not the numbers of dropouts were
balanced across the study groups, whether or not the reasons for attrition were reported and, if so,
whether or not the reasons may have been influenced by the success or failure of the intervention.
The three RCTs were all judged to be at unclear risk of attrition bias for different reasons. Each RCT
reported that analysis was performed on an ITT basis but this was not supported by data presented as
none of the RCTs fully reported reasons for attrition. In the RCT by Castells and colleagues,85 and
Laidlaw and colleagues84 the rate of attrition was similar across the study groups. In the RCT by
Foss and colleagues84 more dropouts occurred in the routine surgery group (13%) than the expedited
surgery group (4%), with some of those leaving the routine surgery group switching to expedited surgery.
Dissatisfaction with waiting is a plausible reason for patients in the routine surgery group switching to
expedited surgery, which might mean that those remaining in the routine surgery group were those who
were least dissatisfied with waiting; however, the picture may be more complex (e.g. elderly patients may
feel dissatisfied with waiting, but may be reluctant to request a change). On balance, it is not possible to
say with any certainty whether or not the imbalance of attrition reported by Foss and colleagues83 would
have resulted in bias.
The risk of bias because of selective reporting (differences between reported and unreported findings)
was considered to be high in the study by Laidlaw and colleagues84 because data relating to secondary
outcomes were limited and because questions relating to vision in the right and left eye were recoded.
It was deemed to be unclear for various reasons in the remaining two studies.83,85
Overall, the assessment of study quality suggests that results of the three included RCTs should be
interpreted with caution as their outcomes may not be unbiased.
Clinical effectiveness outcomes
The RCTs differed in their designated primary outcomes. Laidlaw and colleagues84 specified four primary
outcomes: binocular distance visual acuity, near-reading visual acuity, stereopsis and selected questions
from a newly developed and piloted questionnaire assessing the patients’ perspective of treatment on the
second eye. Foss and colleagues83 specified one primary outcome: the number of patients experiencing
a fall. Castells and colleagues85 had four primary outcomes: binocular visual acuity, binocular contrast
sensitivity, stereopsis and patient-reported visual disability (assessed using the validated VF-14 instrument).
Secondary outcomes reported by Laidlaw and colleagues84 included reading speeds, general health status
and the remaining selected questions from their self-designed patient questionnaire. Foss and colleagues’83
secondary outcomes included binocular visual acuity, contrast sensitivity, stereopsis, health status, cognitive
function, activity, anxiety and depression, confidence, activities of daily living, visual disability, handicap
and HRQoL, as well as a subjective vision question. Secondary outcomes in the study by Castells and
colleagues85 were a cataract symptoms score, general health status, and two general questions about
trouble and satisfaction with vision.
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The three included RCTs had few outcomes in common, with only measures of visual acuity, contrast
sensitivity and stereopsis being reported in all the RCTs, although the studies differed in how they
measured and/or reported these outcomes (see Clinical vision outcomes). Only one other outcome,
patient-reported visual disability using the VF-14, was reported consistently in two RCTs, but baseline
VF-14 scores differed between these RCTs and the timing of the baseline assessments differed between
the RCTs (before first-eye surgery in the RCT of Castells and colleagues,85 and before second-eye surgery
in the RCT of Foss and colleagues;83 see Patient-reported outcomes).
As well as the heterogeneity of outcomes, the studies also had some notable differences in their
methodological characteristics (e.g. one study was conducted before phacoemulsification was introduced,84
one included only women83 and, as mentioned above, the RCTs differed in the timing of their baseline
assessments). Given this methodological heterogeneity and the relatively small number of studies included,
we considered it inappropriate to pool outcomes across the RCTs in a meta-analysis. Instead, the results
are synthesised narratively, as reported in the following sections.
Self-designed patient-reported outcomes which were reported by Laidlaw and colleagues84 and Castells
and colleagues85 are not included in the narrative synthesis as the validity and clinical interpretation of
these measures are unclear.
Clinical vision outcomes
None of the RCTs reported the severity, grade or type of cataract that their patients had. However,
Foss and colleagues83 stated that cataracts in their study were less severe than those in the earlier trial by
Laidaw and colleagues.84
Visual acuity
Foss and colleagues83 and Castells and colleagues85 reported that visual acuity was measured using
log-MAR-based Early Treatment of Diabetic Retinopathy Study (ETDRS) charts, whereas Laidlaw and
colleagues84 did not specify the chart type. At baseline, the mean binocular visual acuity in log-MAR units
for the intervention group ranged from 0.022 to 0.28 in the RCT by Laidlaw and colleagues84 and from
0.09 to 0.22 in the RCT by Foss and colleagues83 (see Table 4). These values indicate that the patients had
only minor impairment of visual acuity before second-eye cataract surgery (reference values of log-MAR are
given in Table 1). Foss and colleagues83 acknowledged that only 3% of patients in the routine surgery
group and 8% in the expedited surgery group had poor vision (Snellen acuity worse than 6/12), with the
median acuity at baseline being 6/7. The RCT by Castells and colleagues85 had baseline binocular visual
acuity of 0.54 log-MAR units, indicating a greater degree of visual acuity impairment (equivalent to a
Snellen acuity worse than 6/15 but better than 6/30). However, this was measured only prior to first-eye
surgery and may not be representative of binocular visual acuity with one pseudophakic eye.
All three studies reported measures of corrected binocular visual acuity after surgery (adjusted statistically
for baseline values in the RCTs of Laidlaw and colleagues84 and Foss and colleagues83), but they employed
different measures (see Table 4). Two of the RCTs, by Laidlaw and colleagues84 and Foss and colleagues,83
also reported changes in monocular visual acuity in the second-eye surgery group. When interpreting
log-MAR visual acuity, a common practice is to consider changes that exceed the 95% range of test–retest
variance as being ‘real’ differences, i.e. as being clinically important.30 Published 95% ranges for test–retest
reliability span the range from ± 0.07 to ± 0.19.30
Laidlaw and colleagues84 reported that 6 months after surgery, the differences in log-MAR binocular
mean distance visual acuity and binocular mean near-reading visual acuity between patients who had
received second-eye surgery and patients awaiting second-eye surgery was statistically significant, with
lower log-MAR point estimates for both measures in patients with second-eye surgery (see Table 4).
CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
22
TABLE 4 Visual acuity results
Study; outcome Intervention, mean (SD) Comparator, mean (SD)
Mean difference between
intervention and comparator
(95% CI); p-value
Laidlaw et al. (1998)84
Expedited surgery Routine surgery
At 6 monthsa
Baseline
(n= 105)
6 months
(n= 98)
Baseline
(n= 103)
6 months
(n= 94)
Binocular mean distance,
log-MAR
0.022 (0.101) −0.027 (NR) 0.063 (0.127) 0.052 (NR) 0.063 (0.035 to 0.090);
p< 0.0001
Binocular mean
near-reading, log-MAR
0.28 (0.13) 0.23 (NR) 0.29 (0.13) 0.27 (NR) 0.047 (0.017 to 0.077);
p< 0.0029
Monocular log-MAR for
the initially pseudophakic
(first) eye
NR NR NR NR 0.025 (−0.004 to 0.054)
Monocular log-MAR for
the initially cataractous
(second) eye
NR NR NR NR 0.756 (0.650 to 0.861)
Foss et al. (2006)83
Expedited surgery
(n= 120) Routine surgery (n= 119)
At 6 monthsbBaseline 6 months Baseline 6 months
Unaided visual acuity
(binocular), log-MAR
0.22 0.15 0.26 0.23 −0.04 (−0.01 to −0.08);
p= 0.001
Spectacles visual acuity
(binocular), log-MAR
0.09 0.04 0.11 0.09 −0.04 (−0.01 to −0.06);
p= 0.003
Pinhole visual acuity
(binocular), log-MAR
0.10 0.04 0.09 0.09 −0.06 (−0.03 to −0.09);
p<0.0005
Change in median visual
acuity in the operated eye
(i.e. monocular), log-MAR
0.44 −0.02 0.46c
Castells et al. (2006)85
mean (SD)
Both-eyes surgery
(n= 139)
One-eye-only surgery
(n=135)
At 4–6 monthsBaselined 4–6 months Baselined 4–6 months
Binocular visual acuity,
log-MAR
0.54 (0.17) 0.11 (0.10) 0.56 (0.19) 0.18 (0.17) 0.07 (0.03 to 0.12);
p< 0.001
Decimal scale 0.31 0.80 0.30 0.71 NR
> 0.3 log-MAR
(= 0.5 decimal), n (%)
NR 3 (2.2) NR 20 (14.8) NR; p< 0.001
> 0.1 to ≤ 0.3 log-MAR,
n (%)
NR 72 (51.8) NR 79 (58.5) NR
≤ 0.1 log-MAR
(= 0.8 decimal), n (%)
NR 64 (46.0) NR 36 (26.7) NR; p< 0.001
Change from baselined
(log-MAR)
−0.43 (0.18) −0.38 (0.23) 0.05 (−0.002 to 0.11)
NR, not reported; SD, standard deviation.
a From analysis of covariance adjusting for baseline (hence apparent discrepancies with observed differences between
the means).
b Mean differences adjusted for baseline values.
c Calculated by reviewer.
d All baseline measures were taken prior to first-eye surgery.
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However, the authors acknowledged that the small difference in mean binocular log-MAR visual acuity
would not be clinically significant (equivalent to half a Snellen line difference). This is in contrast to a
marked improvement in mean monocular visual acuity after surgery in the first eye (log-MAR= 0.756, on
average more than 4 Snellen line equivalents).84 Laidlaw and colleagues84 also acknowledged that many of
the visual acuity assessments were positively skewed, but suggested that numbers in the two treatment
arms were large enough to allow parametric analyses for outcome comparisons.
Foss and colleagues83 reported that log-MAR point estimates 6 months after surgery were lower for
binocular unaided visual acuity, spectacles visual acuity and pinhole visual acuity after expedited second-eye
surgery compared with routine surgery (see Table 4). Differences in point estimates after 6 months were
statistically significant for all three outcome measures. The median monocular visual acuity in the operated
(second) eye improved by 0.44 log-MAR units compared with deterioration of −0.02 log-MAR units in
the (second) eye awaiting routine surgery, but no statistical comparison was reported (see Table 4).
Castells and colleagues85 reported log-MAR for best corrected binocular visual acuity. Differences in point
estimates between patients with surgery in both eyes and patients with surgery in one eye only were
statistically significant 4–6 months after surgery and lower (better) in patients who had surgery in both
eyes (change from baseline was also reported, but baseline measurements were taken before first-eye
surgery so the change does not reflect effects of second-eye surgery alone). The binocular visual acuity
decimal value was higher for patients who had received surgery in both eyes compared with those
who had received surgery in one eye, but no statistical comparison was reported. The authors also
reported the number of patients in three log-MAR classes of the decimal scale (see Table 4). The best
(≤ 0.1 log-MAR) category contained significantly more patients who had received surgery in both eyes
(46%) compared with the number of patients who had received one-eye surgery (26.7%) (p< 0.001).
Conversely, the worst (> 0.3 log-MAR) category contained significantly fewer patients who had received
surgery in both eyes (2.2%) compared with the number of patients who had surgery in one eye (14.8%)
(p< 0.001). No statistical comparison for the middle category was reported. The change from baseline in
log-units was reported (see Table 4), although all baseline measures were taken prior to first-eye surgery
and, therefore, do not reflect effects of second-eye surgery alone.
Contrast sensitivity
Binocular contrast sensitivity assessed with a Pelli–Robson chart was reported after cataract surgery by all
three RCTs, although the measurement units differed or were unclear (Table 5) and colour contrast
sensitivity was not tested.
In Laidlaw and colleagues’ study,84 the mean difference in contrast sensitivity 6 months after surgery
(reported on an unspecified scale, presumably log-contrast sensitivity or dB) between the routine surgery
(1.54) and expedited surgery group (1.76) was statistically significant. However, the study authors stated
that the clinical importance of the significant difference in binocular acuity measures was only slight,
equivalent to four individual letters on the Pelli–Robson chart.
Foss and colleagues83 reported that at baseline contrast sensitivity was the best measurable (1.65 dB) in
44% of patients. Mean binocular contrast sensitivity on a dB scale increased more for those with expedited
second-eye surgery compared with those waiting for routine surgery. The mean difference between the
groups at 6 months was statistically significant. However, the difference was small, equivalent to less than
0.05 log-units. Experts consulted during the preparation of this report suggested that the interpretation
of such a small change in contrast sensitivity is not fully clear but the change is probably of limited
clinical importance.
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Castells and colleagues85 reported a difference in log-units for binocular contrast sensitivity 4–6 months
after surgery between those who had received surgery in both eyes (1.61 log-units) and those who had
received surgery in one eye (1.57 log-units); however, the difference was not statistically significant.
At follow-up, fewer patients who had surgery in both eyes (1.4%) were in the < 1.30 log-units category
of binocular contrast sensitivity than those who had received surgery in one eye (7.4%), with differences
between treatment groups less pronounced in the ≥ 1.30 to < 1.70 log-unit category (55.4 and 51.1
log-units, respectively) and the ≥ 1.70 log-unit category (43.2 and 41.5 log-units, respectively). However, no
statistical testing for the differences between the treatment groups in any of the three categories was
reported. The change from baseline in log-units was also reported (see Table 5), although baseline measures
were taken prior to first-eye surgery and, therefore, do not reflect effects of second-eye surgery alone.
TABLE 5 Contrast sensitivity results
Study; outcome Intervention Comparator
Mean difference between
intervention and comparator
(95% CI); p-value
Laidlaw et al. (1998)84
Expedited surgery Routine surgery
At 6 monthsa
Baseline
(n= 105)
6 months
(n= 98)
Baseline
(n= 103)
6 months
(n= 94)
Binocular mean contrast
sensitivity (scale unspecified),
mean (SD)
1.56 (0.15) 1.76 (NR) 1.53 (0.16) 1.54 (NR) −0.21 (−0.25 to −0.17);
p< 0.0001
Foss et al. (2006)83
Expedited surgery
(n= 120)
Routine surgery
(n= 119)
At 6 monthsbBaseline 6 months Baseline 6 months
Binocular contrast sensitivity
(dB), mean
1.45 1.60 1.42 1.50 0.09 (0.06 to 0.13);
p< 0.0005
Castells et al. (2006)85
Both-eyes surgery
(n= 139)
One-eye-only surgery
(n= 135)
At 4–6 monthsBaselinec 4–6 months Baselinec 4–6 months
Binocular contrast sensitivity,
mean log-units (SD)
1.14 (0.29) 1.61 (0.1) 1.13 (0.35) 1.57 (0.18) 0.04 (−0.002 to 0.09); stated
not significant
< 1.30, n (%) NR 2 (1.4) NR 10 (7.4) NR
≥ 1.30 to < 1.70, n (%) NR 77 (55.4) NR 69 (51.1) NR
≥ 1.70, n (%) NR 60 (43.2) NR 56 (41.5) NR
Change from baselinec
(log-units)
0.46 (0.32) 0.44 (0.36) 0.02 (−0.09 to 0.14)
NR, not reported; SD, standard deviation.
a From analysis of covariance adjusting for baseline (hence, apparent discrepancies with observed differences between
the means).
b Mean difference adjusted for baseline values.
c All baseline measures were taken prior to first-eye surgery.
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Stereopsis
All three RCTs reported measures for stereopsis, but the outcomes that were tested statistically were
different in each study (Table 6). All the RCTs assessed stereopsis using combinations of stereotests that
included the Wirt fly test44 to achieve a wide range of stereoscopic disparities (the tests employed in each
RCT are listed in the data extraction forms, see Appendix 4).
Baseline stereopsis was poor in the RCT by Laidlaw and colleagues,84 with 61–71% of patients having loss
of stereopsis (3000 seconds of arc or worse). In contrast, in the RCT by Foss and colleagues,83 65–76% of
TABLE 6 Stereopsis results
Study; outcome Intervention Comparator
Mean difference between
intervention and comparator
(95% CI); p-value
Laidlaw et al. (1998)84
Expedited surgery Routine surgery
At 6 monthsa
Baseline
(n= 105)
6 months
(n= 98)
Baseline
(n= 103)
6 months
(n= 94)
Stereoacuity, 3000 seconds
of arc or worse, n (%)b
64 (61) 12 (12) 73 (71) 66 (70) 58% (47% to 69%);
p< 0.0001
Foss et al. (2006)83
Expedited surgery Routine surgery
At 6 monthsc
Baseline
(n= 120)
6 months
(n= 115)
Baseline
(n= 119)
6 months
(n= 113)
Depth perception,
unspecified 5-point
ordinal scale
1.66 1.36 1.85 1.93 −0.45 (−0.22 to −0.69);
p< 0.0005
Stereopsis (seconds of arc), n (%)
150 76 (63) 100 (87) 65 (55) 67 (59) NR
300 22 (18) 9 (8) 27 (23) 23 (20) NR
600 11 (9) 4 (4) 11 (9) 10 (9) NR
> 600 Wirt abled 9 (8) 2 (2) 12 (10) 8 (7) NR
> 600 Wirt unabled 2 (2) 0 (0) 4 (3) 5 (4) NR
Castells et al. (2006)85
Both-eyes surgery
(n= 139)
One-eye-only surgery
(n= 135)
At 4–6 monthsBaselinee 4–6 months Baselinee 4–6 months
Stereopsis, mean
log-units (SD)
2.86 (0.66) 1.75 (0.24) 2.89 (0.70) 2.37 (0.69) 0.62 (0.45 to 0.79);
p< 0.001
≥ 3.48 (≥ 3000 seconds
of arc), n (%)
NR 0 NR 25 (18.5) p< 0.001
> 1.78 to < 3.48, n (%) NR 42 (30.4) NR 84 (62.2) NR
≤ 1.78 (≤ 60 seconds
of arc), n (%)
NR 96 (69.6) NR 26 (19.3) p< 0.001
Change from baselined
(log-units)
−1.11 (0.69) −0.51 (0.79) 0.60 (0.36 to 0.85);
p< 0.001
NR, not reported; SD, standard deviation.
a Analysis of covariance adjusted for baseline values.
b Includes those with undetectable stereoacuity and those able to see Wirt Fly only.
c Mean difference adjusted for baseline values.
d As reported by the authors without full explanation (the ‘Wirt-able’ subgroup would have better stereopsis than the
‘Wirt-unable’ subgroup).
e All baseline measures were taken prior to first-eye surgery.
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patients were in the best stereopsis class (150 seconds of arc) at baseline. Castells and colleagues’ baseline
data on stereopsis were collected before first-eye surgery, but data collected after first-eye surgery in the
one-eye-surgery group (as a proxy for baseline data in the second-eye surgery group) indicate moderate
stereopsis (2.37 log-units or approximately 230 seconds of arc) (see Table 6).85
In the study by Laidlaw and colleagues,84 the percentage of patients with stereopsis of 3000 seconds
arc or worse (indicating total loss of stereo vision) at 6 months in the expedited surgery group (12%)
was far lower compared with the routine surgery group (70%), indicating that second-eye surgery
substantially improved stereopsis. The difference was statistically significant (58%, 95% CI −47% to 69%;
p< 0.0001; see Table 6).
Foss and colleagues83 reported data for stereopsis in five classes ranging from 150 seconds of arc (best)
to > 600 seconds of arc and unable to see a ‘Wirt’ image (worst), but did not provide any statistical
comparisons (see Table 6). Six months after surgery, the best stereopsis class contained a higher proportion
of patients from the expedited surgery group (87%) than from the routine surgery group (59%). In
addition, Foss and colleagues83 recorded depth perception on an unspecified 5-point ordinal scale. Six
months after surgery, the scores were lower for expedited surgery patients (1.36) than for routine surgery
patients (1.93), with the difference being statistically significant (−0.45 ordinal scale units, 95% CI −0.22
to −0.69; p< 0.0005).
In the study by Castells and colleagues,85 the mean stereopsis in log-units 4–6 months after surgery was
significantly lower (i.e. better) in patients who had received surgery in both eyes (1.75 log-units) compared
with those who received surgery in one eye only (2.37 log-units) (mean difference 0.62 log-units, 95% CI
0.45 to 0.79 log-units; p< 0.001). Castells and colleagues85 also reported the proportions of patients in
each of the study groups that were in each of three classes of stereopsis (see Table 6). Significantly more
patients who had received surgery in both eyes (69.6%) than those who had received surgery in one
eye only (19.3%) were in the best stereopsis class (≤ 1.78 log-units, ≤ 60 seconds of arc; p< 0.001).
Conversely, significantly fewer patients who had received surgery in both eyes (0%) than those who had
received surgery in one eye only (18.5%) were in the worst stereopsis class (≥ 3.48 log-units, ≥ 3000
seconds of arc; p< 0.001). The change from baseline in log-units was also reported (see Table 6), although
baseline measures were taken prior to first-eye surgery and, therefore, do not reflect effects of second-eye
surgery alone.
Overall, the results from all three RCTs, although presented in different ways, show that improvements in
stereopsis occurred after second-eye surgery compared with single-eye surgery. Changes in the proportions
of patients in the worst and best stereopsis classes indicate that a proportion of patients would have
experienced a clinically meaningful change in stereopsis, i.e. they regained functional stereoscopic vision
following second-eye surgery. The improvement was most pronounced in the RCT by Laidlaw and
colleagues84 which had the lowest proportion of patients with functional stereopsis at baseline.
Patient-reported outcomes
There was a large variation in patient-reported outcomes between the studies, with few outcome
measures common to more than one RCT. Although general health status was reported by all three
studies, Laidlaw and colleagues84 utilised the SF-36, Foss and colleagues83 reported using the EQ-5D,
and Castells and colleagues85 the Short Form questionnaire-12 item health survey instrument (SF-12).
Both Foss and colleagues83 and Castells and colleagues85 assessed patient-reported visual disability as an
outcome using the VF-14 instrument.
Generic instruments assessing general health status
Laidlaw and colleagues84 administered the SF-36 6 months after surgery, but did not report any data for
the treatment groups, stating only that group differences were non-significant. The authors stated that
after Bonferroni corrections, Mann–Whitney U-tests found statistically significant differences in favour of
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the expedited surgery group in five out of seven of the quality-of-life questions, but provided no further
details. It is unclear whether or not the stated differences would be clinically significant.
Foss and colleagues83 employed the EQ-5D 6 months after surgery and found that the mean difference
between the treatment arms at 6 months (0.02) was not statistically significant (p= 0.36) (Table 7).
Castells and colleagues85 utilised the SF-12 4–6 months after surgery, reporting results for the physical
and mental component summary (see Table 7). Scores for the physical component summary were
marginally higher in patients who had been given surgery in both eyes compared with patients who
had been given surgery in one eye (mean difference 1.30, 95% CI 1.85 to 4.40), although statistical
significance was not reported. For the mental component summary, cataract surgery in both eyes resulted
in marginally higher scores (53.1) than cataract surgery in one eye (51.2). Although relatively small, the
point difference (1.90, 95% CI 0.03 to 3.79; p< 0.05) exceeds the threshold change of 0.03 units which is
considered to be clinically important for preference-based measures including the SF-12.86
Generic instruments assessing specific domains of quality of life or
psychological distress
Foss and colleagues83 reported the scores from the Barthel Index (assessing activities of daily living), the
Hospital Anxiety and Depression Scale (HADS), the Falls Efficacy Scale (confidence) and the London
Handicap Scale as outcome measures. The mean differences between treatment groups after 6 months on
three of these scales were mostly small and not statistically significant: 0.1 for the Barthel Index (p= 0.61),
0.2 for the HADS – Anxiety (p= 0.54), and 0.5 for the HADS – Depression (p= 0.47) (Table 8). The mean
differences between treatment groups after 6 months were statistically significant for confidence in
avoiding falls, measured by the Falls Efficacy Scale and perceived functional disability measured by the
London Handicap Scale. The mean difference between groups in the Falls Efficacy Scale was 3.6 points
(p= 0.008) and indicated, counterintuitively, that patients in the expedited surgery group had lower
TABLE 7 Patient-reported outcomes: general health status
Study; outcome Intervention, mean (SD) Comparator, mean (SD)
Mean difference between
intervention and comparator
(95% CI); p-value
Foss et al. (2006)83
Expedited surgery
(n= 120) Routine surgery (n= 119)
At 6 monthsaBaseline 6 months Baseline 6 months
EuroQoL – EQ-5D
Mean score
(0 to 1.0/worst–best)
0.74 0.73 0.72 0.69 0.02 (−0.03 to 0.08); p= 0.36
Castells et al. (2006)85
Both-eyes surgery
(n= 139)
One-eye-only surgery
(n= 135)
At 4–6 monthsBaselineb 4–6 months Baselineb 4–6 months
SF-12
Physical, Mean score
(0–100/worst–best)
45.57 (9.79) 47.5 (9.3) 44.82 (10.89) 46.2 (9.3) 1.30 (1.85 to 4.40)
Change from baselineb 1.76 (10.6) 1.40 (9.2) 0.36 (−3.04 to 3.56)
Mental, Mean score
(0–100/worst–best)
48.51 (9.36) 53.1 (4.9) 48.23 (10.38) 51.2 (6.6) 1.90 (0.03 to 3.79); p< 0.05
Change from baselineb 4.27 (10.2) 2.96 (10.5) 1.31 (−2.16 to 4.71)
SD, standard deviation.
a Mean difference adjusted for baseline values.
b All baseline measures were taken prior to first-eye surgery.
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confidence in avoiding falls, although both groups had relatively high scores overall, indicating a general
lack of confidence in avoiding falls among all the patients. The authors83 claimed that second-eye surgery
significantly improved confidence about falling, but this contradicts the published results, as higher scores
in this measure are associated with lower falls self-efficacy (see Table 8). The mean difference between
groups in the London Handicap Scale was 4.4 points (p< 0.0005) and indicated that patients in the
expedited surgery group had a lower degree of perceived functional disadvantage (see Table 8). As far as
we are aware, the minimal detectable change (MDC – the threshold for distinguishing actual change from
measurement error) and minimal clinically important difference (MCID – the minimum change in score
necessary for a patient to experience a clinically important improvement) have not been established for
these two patient-reported measures. Foss and colleagues83 did not specify whether or not they considered
these changes in falls efficacy and perceived handicap to be clinically meaningful.
Instruments assessing visual disability and symptoms
Patient-reported visual disability assessed using the VF-14 (rated from 0 to 100, where higher scores
indicate less functional impairment) was reported by two RCTs.83,85 Thresholds for the VF-14 for the MDC
and MCID have been proposed as 10.81 and 15.57 units, respectively, on the VF-14 scale.87
Both RCTs found less functional impairment was reported by those who had received second-eye
surgery (Table 9).
Foss and colleagues83 reported that the mean VF-14 score difference (7.5 points) between the expedited
surgery group and the routine surgery group at 6 months was statistically significant (see Table 9).
However, this difference in mean scores is smaller than both the MDC and MCID for the VF-14, suggesting
that a large proportion of the participants may not have experienced meaningful improvement in vision-
related function, which was already very good before second-eye surgery.
Castells and colleagues85 found that, 4–6 months after surgery patients who had received surgery in
both eyes reported less visual impairment than those who had received surgery in one eye (mean scores
97.7 vs. 89.5 points), with the mean difference in VF-14 score (8.24 points) being statistically significant.
However, being smaller than the MDC and MCID, this difference suggests that for the majority of
participants visual function may not have improved substantially after surgery in both eyes. In the best
(100 points) score category 74.1% of patients had received surgery in both eyes, compared with 43.0%
TABLE 8 Patient-reported outcomes: other generic instruments
Outcomes – all data are
from Foss et al. (2006)83
Expedited surgery
(n= 120)
Routine surgery
(n= 119)
Mean difference between
intervention and comparator
at 6 months (95% CI);
p-valueaBaseline 6 months Baseline 6 months
Barthel Index (activities of
daily living scale;
0–20/worst–best)
18.7 18.7 18.9 18.8 −0.1 (−0.2 to 0.3); p= 0.61
Confidence – Falls Efficacy
Scale (10–100/best–worst)b
85.5 86.1 84.4 81.7 3.6 (0.9 to 6.2); p= 0.008
London Handicap Scale
(0–100/worst–best)
82.3 85.2 82.2 80.8 4.4 (2.2 to 6.5); p< 0.0005
HADS (0–28/best–worst)
Anxiety 6.4 6.6 6.8 7.1 −0.2 (−1.0 to 0.5); p= 0.54
Depression 4.6 4.6 4.5 4.7 −0.5 (−0.7 to 0.3); p= 0.47
a Mean difference adjusted for baseline values.
b A total score of > 70 indicates that the person has a fear of falling.
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who had received surgery in one eye. In the worst (≤ 80 points) score category, only 3.6% had received
surgery in both eyes, compared with 19.3% who had one-eye surgery. Differences in point estimates were
statistically significant for both categories. No statistical comparison for the > 80 to < 100 points category
was reported (22.3% had surgery in both eyes; 37.8% had surgery in one eye) (see Table 9).
In both RCTs, VF-14 scores were already high after first-eye surgery. In the RCT of Foss and colleagues,83 50%
of scores were above 90% of the scale maximum, whereas in the RCT of Castells and colleagues85 the mean
score in the single-eye surgery was 89.5 points out of a possible maximum of 100 points. Vision-related
function was therefore already very good before second-eye surgery, with relatively limited improvement
possible on the assessment scale due to ceiling effects.
Falls and fractures
Only Foss and colleagues83 reported falling (in a female population) as an outcome (Table 10). A fall was
defined as unintentionally coming to rest on the ground or at a lower level with or without loss of
consciousness. The proportion of women experiencing falling during the 12-month follow-up period was
higher in the expedited surgery group (40%) than in the routine surgery group (34%). However, the
authors did not report a statistical comparison between the treatment groups. The hazard ratio for women
experiencing a first fall was 1.06 at 6 months follow-up, but not statistically significant, equating to a
non-significantly higher rate of first falls in those who had received second-eye surgery (22%) than in
women awaiting second-eye surgery (16%), whereas the number of women experiencing more than
one fall was the same in both groups (18%). The rate of falling per 1000 patient-days was also
non-significant. Fractures were experienced in 4% of women who had received second-eye surgery and
in 3% of women awaiting second-eye surgery.
TABLE 9 Patient-reported outcomes: visual disability (VF-14) results
Study; outcome Intervention Comparator
Mean difference between
intervention and
comparator (95% CI);
p-value
Foss et al. (2006)83
Expedited surgery (n= 120) Routine surgerya (n= 119)
At 6 monthsbBaseline 6 months Baseline 6 months
VF-14, mean score
(0 to 100/worst–best)
87.5 94.7 87.5 87.2 7.5 (5.1 to 9.9); p< 0.0005
Castells et al. (2006)85
Both-eyes surgery (n= 139) One-eye-only surgery (n= 135)
At 4–6 monthsBaselinec 4–6 months Baselinec 4–6 months
VF-14, mean score (SD)
(0 to 100/worst–best)
58.08 (20.59) 97.7 (7.1) 61.01 (22.28) 89.5 (15.9) 8.24 (4.35 to 12.36);
p< 0.001
Score ≤ 80, n (%) NR 5 (3.6) NR 26 (19.3) NR; p< 0.001
Score > 80 to < 100,
n (%)
NR 31 (22.3) NR 51 (37.8) NR
Score= 100, n (%) NR 103 (74.1) NR 58 (43.0) NR; p< 0.001
Change in score from
baseline, mean (SD)c
39.9 (20.7) 28.3 (20.4) 11.57 (4.79 to 18.12);
p< 0.001
NR, not reported; SD, standard deviation.
a Baseline values reported in table 2 and appendix 2 of the publication differed and data were extracted from table 2.83
b Mean difference adjusted for baseline values.
c All baseline measures were taken prior to first-eye surgery.
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Surgical complications
Two of the studies reported surgical complications.83,84 It should be noted that extracapsular cataract
extraction, which was the method employed by Laidlaw and colleagues,84 has historically been associated
with more problematic complications than the phacoemulsification approach to cataract surgery employed
in the more recent study by Foss and colleagues.83
Laidlaw and colleagues84 reported six types of surgical complication which were either sight-threatening or
necessitated further surgery. In total, 11 complications occurred in nine patients (9%) in the expedited
surgery group (Table 11). The most common complications were cystoid macular oedema (three events)
and iris prolapse (three events).
TABLE 10 Falls and fractures from Foss and colleagues83
Outcomes measured during
12 months after surgery
Expedited surgery
(n= 120)
Routine surgery
(n= 119) Hazard or risk ratio (95% CI); p-value
Total no. of patients
experiencing falling, n (%)
48 (40) 41 (34) NR
Number of patients
experiencing first fall
26 (22)a 19 (16)a Hazard ratio 1.06 (95% CI 0.69 to 1.61);
log-rank test 0.06, 1df, p= 0.80
Number of patients
experiencing > 1 fall
22 (18) 22 (18) Hazard ratio 0.85 (95% CI 0.49 to 1.56);
log-rank test 0.26, 1df, p= 0.61
Rate of falling per
1000 patient-days (range)
2.9 (0 to 31) 4.3 (0 to 120) Rate ratio 0.68 (95% CI 0.39 to 1.19);
p= 0.18b
Fractures 5 (4%) 3 (3%) Risk ratio 2.5 (95% CI 0.5 to 12.5);
Fisher’s exact test, p= 0.45
NR, not reported.
a Calculated by reviewer.
b Hazard or risk ratio; p= unintentionally coming to rest on the ground or at a lower level with or without loss of
consciousness.28 Stated that statistically adjusting the relative risk of falling for prognostic factors (history of falls,
history of stroke, poor visual acuity, reported postural dizziness, and baseline visual disability and confidence) had no
effect on the results.
TABLE 11 Surgical complications
Study name, outcomes Expedited surgery
Laidlaw et al. (1998)84 n = 9/98 (9%), total of 11 complications
Vitreous loss 2
Retinal detachment 1
Cystoid macular oedema 3
Iris prolapse 3
Corneal oedema 1
Implant failure with subsequent secondary lens implantation 1
Foss et al. (2006)83 n/N (%)
Iris damage 1/115 (0.9)
Endophthalmitis 0/115 (0)
Anterior vitrectomy performed 4/115 (3)
Posterior capsular opacification noted at 6 months 12/115 (10)
YAG capsulotomy performed during study period 10/115 (9)
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Foss and colleagues,83 reported seven types of surgical complications, although two (section stitched and iris
hooks) are surgical procedures rather than complications and we have not extracted these. The most frequent
complication in the expedited surgery group was PCO at 6 months (10%), with Nd:YAG laser capsulotomy
(to treat PCO) being performed at any time during the study period in 9% of the patients (see Table 11).
A limitation of these data is that it is not clear how complete the reporting of complications was, since
follow-up differed between the RCTs and different complications were listed in each RCT. Foss and
colleagues83 had a 12-month follow-up for most clinical outcomes but, as noted above, assessed only
incidence of PCO 6 months after surgery, whereas Laidlaw and colleagues84 had a 6-month follow-up.
The frequencies of complications such as PCO and retinal detachment, which may occur more than a year
after cataract surgery, might therefore have been underestimated in both RCTs. It is unclear whether
Laidlaw and colleagues84 had no cases of PCO up to 6 months after surgery or whether they did not
record this complication. The RCT of Laidlaw and colleagues84 was conducted before phacoemulsification
was introduced, and the complications they reported with extracapsular cataract surgery might not be
reflective of current practice, as the safety of cataract surgery has improved since the introduction of
phacoemulsification.88 Among the complications reported in these RCTs, the most serious are retinal
detachment and those involving vitreous loss or vitrectomy.
Castells and colleagues85 reported the number of post-randomisation exclusions that were due to
complications of first-eye surgery. There were two exclusions from the second-eye surgery group and one
from the single-eye surgery group.
Adverse events
Other than surgical complications, the only other adverse event that was reported in the RCTs was
mortality. A patient flow chart presented by Laidlaw and colleagues84 suggests that no mortality occurred
during their RCT. Foss and colleagues83 reported that three patients died during their RCT: one in the
expedited surgery group and two in the routine practice group. Castells and colleagues85 also reported
that three patients died during their RCT, of whom one was in the single-eye surgery group and two of
whom were in the second-eye surgery group. Causes of mortality were not reported in any of the studies.
Ongoing studies
No ongoing studies were identified up to 10 July 2013.
Relevant systematic reviews
No relevant systematic reviews were identified in the study protocol (see Appendix 1) or during bibliographic
searches conducted up to July 2013. However, after data synthesis had been completed, we identified a
systematic review, published in October 2013, of the benefits of second-eye cataract surgery in the elderly.89
Ishikawa and colleagues’89 inclusion criteria did not limit studies to RCTs, although their searches were limited to
English-language publications. They included 10 primary studies, of which three were the RCTs that we report
above,83–85 five were cohort studies, and two were before-and-after studies (no other RCTs were identified).
One of the cohort studies they included, by Räsänen and colleagues,90 also investigated cost-effectiveness and
HRQoL and is included in our systematic reviews of cost-effectiveness and HRQoL (see Systematic review of
cost-effectiveness evidence and Systematic review of health related quality-of-life studies).
Ishikawa and colleagues89 concluded that second-eye surgery led to improvement in visual acuity, contrast
sensitivity, stereopsis, and self-reported visual functioning, supported by moderate-quality evidence. They also
concluded that there was improvement in HRQoL based on mixed-quality evidence, but no improvement in
falls reduction, based on limited-quality evidence. Interpretation of these findings is not straightforward,
however, since the assessment of evidence quality was based on ‘best evidence synthesis guidelines’ which
assessed only whether or not an improvement in outcomes occurred and did not consider the magnitude and
variance of any observed improvements. Moreover, no quantitative results were presented and it was not
specified whether the reported improvements in outcomes were based on clinical importance, statistical
significance or other criteria.89
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Summary of clinical effectiveness
Study characteristics
Three parallel-group RCTs conducted from 1994 to 2006, each randomising 208–296 elderly participants
(mean age 71.1–79.9 years), met the selection criteria and were included in the systematic review
of clinical effectiveness.83–85 The RCTs varied in quality, with all three being deemed at high risk of
performance bias (patients could not be masked to the treatment group).
One RCT was conducted before phacoemulsification was introduced in the UK84 and one RCT included
only women;83 the RCTs also differed in the timing of their baseline assessments. Owing to this
methodological heterogeneity, quantitative pooling of outcomes in a meta-analysis was deemed
inappropriate. Instead we synthesised outcomes narratively.
Effects on vision
All three RCTs reported measures of visual acuity, contrast sensitivity and stereopsis, but they did not
report any other measures of clinical vision (e.g. glare disability). The three RCTs all indicated statistically
significant slight improvements in binocular visual acuity (ranging from 0.04 to 0.063 log-MAR) after
second-eye surgery compared with surgery in one eye alone. However, these differences (less than
1 Snellen line equivalent) would not be considered clinically important. Changes in monocular visual acuity
in the second eye after surgery were reported in two RCTs and were relatively large (0.46 log-MAR83 and
0.75 log-MAR84), although neither RCT stated whether or not the changes were statistically significant.
Binocular contrast sensitivity was higher after second-eye surgery in all three RCTs, with the difference
statistically significant in two RCTs.83,84 However, the differences were clinically small, equivalent to 0.09 dB
(less than 0.05 log-units)83 or no more than four letters on a Pelli–Robson chart.84
Baseline stereopsis differed among the RCTs, being notably poor in the RCT by Laidlaw and colleagues,84
with 61–71% of patients having no functional stereopsis (3000 seconds of arc or worse). In contrast, in
the RCT by Foss and colleagues83 65–76% of patients were in the best stereopsis class (150 seconds of
arc) at baseline. Castells and colleagues85 did not collect baseline data immediately before second-eye
surgery, but their data collected after first-eye surgery (a proxy for baseline data in the second-eye surgery
group) indicate moderate stereopsis (mean approximately 230 seconds of arc). Stereopsis significantly
improved after second-eye surgery in all three RCTs, although different ways of presenting and analysing
these data were used in each RCT. These improvements would be of clinical benefit to patients’ vision and
were largest in the RCT by Laidlaw and colleagues84 whose patients had the worst baseline stereopsis.
Effects on patient-reported outcomes
Three RCTs measured patient-reported outcomes for general HRQoL, but each used a different
preference-based instrument (SF-12, SF-36 or EQ-5D).83–85 Of these, the mental health component
summary of the SF-12 indicated a statistically significant and clinically relevant improvement after
second-eye surgery.85 However, differences in the other measures between first- and second-eye surgery
were not statistically significant (EQ-5D, SF-36)83,84 or the statistical significance was not reported
(physical health component summary of the SF-12).85 One RCT, which focused specifically on elderly
women,83 employed generic instruments to assess specific domains of HRQoL and psychological distress.
No statistically significant differences were found between first- and second-eye cataract surgery for
activities of daily living, anxiety or depression. Statistically significant differences between the study groups
were found for falls efficacy and handicap, although the differences in scores (3.6 on the Falls Efficacy
Scale and 4.4 on the London Handicap Scale) were modest in comparison with already high baseline
scores. The clinical importance of these findings is unclear, as the MCID has not been established for these
patient-reported outcome measures and the authors of the RCT did not discuss clinical interpretation.83
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The only validated vision-specific instrument used was the VF-14, which assesses the impact on
14 vision-dependent activities. Two RCTs that employed this instrument recorded significantly higher
(better) scores in the group who had received second-eye surgery, with mean differences of 7.5 points83
and 8.24 points.85 However, these differences are smaller than the proposed MCD and MCID for the
VF-14,87 suggesting that they did not reach clinical significance.
In summary, the majority of patient-reported outcome measures employed by the three RCTs did not
demonstrate convincing effects of second-eye cataract surgery on patients’ HRQoL. This might
reflect relatively good visual acuity and HRQoL that many patients had before second-eye surgery
(i.e. ceiling effects of these outcomes) and/or limitations of the assessment instruments that were
employed (see Chapter 7).
Effects on falls and fractures
Falls and fractures were assessed only in one RCT.83 Compared with first-eye cataract surgery, second-eye
surgery did not reduce the number of falls or fractures significantly.
Surgical complications
Two RCTs reported surgical complications, although one84 was conducted before phacoemulsification
was introduced in the UK. In the more recent RCT, more relevant to current practice,83 the reported
complications were typical of those associated with phacoemulsification, the most frequent being PCO
(10% at 6 months).
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Chapter 5 Economic analysis
Systematic review of cost-effectiveness evidence
A systematic review of the literature was conducted to identify economic evaluations of second-eye
cataract surgery, following the methods reported in Chapter 3. The purpose was to assess the current
evidence base for cost-effectiveness evaluations and whether or not there is a need for further economic
modelling, since any further modelling required would be informed by the methods used in previous
cost-effectiveness studies.
A total of 190 potentially relevant references were found in the cost-effectiveness searches. Of these,
the full texts of five papers were retrieved and four papers met all of the a priori inclusion criteria.90–93
A summary of the selection process and the reasons for exclusion is presented in Figure 2. One study was
excluded as a result of having a non-relevant intervention94 (see Appendix 8 for the list of excluded
studies). Of the four papers included, two were linked.92,93 For the purposes of this report, we refer to the
main publication by Busbee and colleagues.92 Characteristics of the included studies are shown in Table 12
and discussed in more detail subsequently. The full data extraction forms for all included studies are
provided (see Appendix 7).
Critical appraisal of the studies
The cost-effectiveness studies were assessed against a critical appraisal checklist (Table 13). This checklist
assessed the quality of the studies and their generalisability to the UK and was adapted by the review
authors from checklists by Philips and colleagues,80 Drummond and colleagues81 and the NICE reference
case requirements.95
Two of the cost-effectiveness studies by Räsänen and colleagues90 and Sach and colleagues,91 were also
included in our systematic review of HRQoL (see Systematic review of health-related quality-of-life studies
for a more detailed consideration of their HRQoL results).
References for retrieval and
screening
(n = 5)
Total references identified from
searching (after de-duplication)
(n = 190)
Excluded
(n = 185)
Excluded
(intervention, n = 1) 
References included in our systematic review
(n = 3; described in four papers)
Potential eligible references
(n = 5)
FIGURE 2 Flow chart of identification of studies for inclusion in the review of cost-effectiveness.
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All studies clearly defined the study question and explained the competing alternative. Two studies used a
relevant comparator,91,92 whereas the other used a comparator that would be unlikely to be used in the UK
(a hypothetical no-treatment group).90 Each study clearly stated the patient group of interest and the study
perspective. One of the studies was conducted in the UK,91 and the other studies were conducted in the
USA92 and Finland,90 and it is unclear how generalisable these studies are to the UK NHS. The study type
and methodology are appropriate for the decision problem in this report (see Chapter 2).
TABLE 12 Characteristics of economic evaluations
Author Busbee et al. (2003)92 Räsänen et al. (2006)90 Sach et al. (2010)91
Country USA Finland UK
Funding source Retina Research and
Development Fund, the
Principals Initiative Research
Award, Premier’s Award for
Research Excellence
Research grants from the
Helsinki and Uusimaa
Hospital Group
Trent Regional NHS Research
and Development Scheme
and the PPP Foundation
(now the Health Foundation)
Study type Decision tree model
(cost–utility analysis)
Prospective HRQoL study
(cost–utility analysis)
Within-trial cost–utility analysis
Perspective Third-party insurer Secondary health-care
provider
UK NHS and PSS (and carers)
Study population Patients from the US National
Cataract Patient Outcomes
Research Team (PORT) study
(722 individuals), who were
undergoing a cataract
extraction (median age
73 years)
Patients scheduled for
routine cataract operation
(386 individuals, of whom
219 were available for final
analysis). Mean age varied
from 69 to 75 years across
three subgroups
Women over 70 years of
age, without other visual
comorbidities, who previously
had a successful first-eye
cataract surgery and had a
second operable cataract
Baseline
visual acuity
Mean VA Snellen
0.24 (decimal)
Mean best corrected VA in
surgical eye Snellen 0.24
(decimal), (0.76 log-MAR)
Mean VA 0.09 log-MAR
(spectacles corrected),
binocular vision
Intervention(s) Second-eye cataract surgery Second-eye cataract surgery
(group C); only one eye was
operated (group A); both eyes
were operated (group B)
Second-eye cataract surgery
Comparator Unilateral pseudophakia No treatment Waiting list controls
Intervention effect:
visual acuity
Mean VA Snellen 0.74 NR Mean VA 0.04 log-MAR
binocular vision 6 months
after surgery
Intervention effect:
quality of life
Mean change in QoL
before-and-after second-eye
surgery of 0.109, using
TTO valuation
Mean change in QoL between
6 months post surgery and
baseline was −0.01, using 15D
Mean change in QoL
before-and-after second-eye
surgery of −0.01, using EQ-5D
Currency base,
price year
US$, 2001 Euro, 2002–3 UK £, 2004
Time horizon Lifetime Lifetime 1 year/lifetime
Base case results Second-eye cataract surgery
had cost–utility of US$2495
per QALY gained
Mean hospital costs at
6 months, €1323, mean
QALYs gained −0.0219;
ICERs not reported
The ICER for surgery in the
1-year base casewas £44,263.
The long-term ICERwas £17,299
ICER, incremental cost-effectiveness ratio; NR, not reported; PPP, public – private partnerships; PSS, Personal Social Services;
QALY, quality-adjusted life-year; QoL, quality of life; TTO, time trade-off; VA, visual acuity.
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Reported descriptions of the parameters and assumptions varied between studies. Räsänen and
colleagues90 provided limited information on assumptions and costs in their analysis, whereas the other
two studies91,92 provided more complete information on their inputs and assumptions.
Busbee and colleagues92 based the effectiveness of the intervention on a single study, rather than a
systematic review. They also included HRQoL, using standardised and generic instruments and reported the
health benefits in terms of QALYs. Two studies91,92 discounted costs and benefits. The other study90 only
discounted costs, as all costs were incurred in the first 6 months. All three studies assessed uncertainty
through sensitivity analyses. Busbee and colleagues92 did not give any details of whether or not their
model was validated.
Overall, the studies were found to vary in methodology quality. The studies by Busbee and colleagues92
and Sach and colleagues91 were of reasonable methodological quality, whereas Räsänen and
colleagues’ study90 had limitations in its reporting and assumptions. The study by Sach and colleagues
was of most relevance to the UK NHS91 (see Table 13).
TABLE 13 Critical appraisal checklist of economic evaluation
Item
Busbee et al.
(2003)92
Räsänen et al.
(2006)90
Sach et al.
(2010)91
1 Is there a clear statement of the decision problem? Yes Yes Yes
2 Is the comparator routinely used in UK NHS? Yes No Yes
3 Is the patient group in the study similar to those of interest
in UK NHS?
Yes Yes Yes
4 Is the health-care system comparable to UK? ? ? Yes
5 Is the setting comparable to the UK? ? Yes Yes
6 Is the perspective of the analysis clearly stated? Yes Yes Yes
7 Is the study type appropriate? Yes Yes Yes
8 Is the economic evaluation methodology appropriate? Yes Yes Yes
9 Is the structure of the analysis described and does it reflect the
disease process?
Yes Yes Yes
10 Are assumptions of the analysis listed and justified? Yes ? Yes
11 Are the data inputs for the analysis described and justified? Yes ? Yes
12 Is the effectiveness of the intervention established based on a
systematic review?
No N/Aa N/Aa
13 Are health benefits measured in QALYs? Yes Yes Yes
14 Are health benefits measured using a standardised and validated
generic instrument?
Yes Yes Yes
15 Are the resource costs described and justified? Yes ? Yes
16 Have the costs and outcomes been discounted? Yes Nob Yes
17 Has uncertainty been assessed? Yes Yes Yes
18 Has model validation been reported? No N/Aa N/Aa
?, unclear; N/A, not applicable.
a These items are not relevant to the study types of Sach et al.91 and Räsänen et al.90 as they are economic evaluations
based on single studies.
b Costs were not discounted, but outcomes were discounted for Räsänen et al.90
DOI: 10.3310/hta18680 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 68
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Frampton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
37
Busbee and colleagues
Study approach
Busbee and colleagues92 developed a decision tree model in TreeAge software (TreeAge Software Inc.,
Williamstown, MA, USA). The model incorporated costs and consequences associated with second-eye
cataract surgery compared with unilateral pseudophakia, including complications associated with
cataract surgery. The model was based on one developed by the same authors for initial (first-eye) cataract
surgery.96 Costs and benefits were discounted at 3% per annum. Costs were in US dollars and the price
year was 2001. In a linked study by Brown and colleagues,93 the price year was 2003. The model had a
lifetime horizon.
The theoretical patient in the model presented with visual acuity in the pseudophakic eye equal to the
mean post-operative visual acuity reported from the US National Cataract Patient Outcomes Research
Team (PORT)97 (which included patients with mean age 73 years), and the post-operative visual acuity for
the second-eye surgery was equal to that of the first-eye surgery (20/27). Complication rates associated
with cataract extraction were taken from a previous study for first-eye cataract surgery96. Complications
included in the model were PCO, endophthalmitis, cystoid macular oedema, lost lens fragments,
intraocular lens dislocation, pseudophakic bullous keratopathy and PCO with subsequent
retinal detachment.
Estimation of quality-adjusted life-years
Utility values were based on data from a large study of patients with ophthalmic disease98 and derived
from patient preferences by using a time trade-off (TTO) model. Utility values associated with subsequent
good visual acuity in both eyes after uneventful cataract extraction were based on a study that compared
the utility change from unilateral good vision (i.e. 20/25 or better in one eye) compared with bilateral
good vision (i.e. 20/25 or better vision in both eyes).99 The utility value corresponding to unilateral
pseudophakia was 0.858 and the reference case utility value for an ocular health state after second-eye
cataract surgery was 0.967. These visual outcomes for each complication after treatment, with the
exception of PCO, were assigned a utility value of 0.858. For PCO without retinal detachment, it was
assumed that visual acuity returned to 20/27 in the operated eye, and had a utility value of 0.97.
Estimation of costs
The model included costs for cataract surgery, ambulatory and surgical procedures and retinal procedures.
It also included drug expenditure costs associated with cataract surgery for medical and post-operative
management. The cost of cataract surgery and management of endophthalmitis, intraocular lens
dislocation, cystoid macular oedema and lost lens fragments was assumed to occur close to the initiation
of cataract management. Other complications incurred costs at the mean time of treatment after surgery,
i.e. 2 years for PCO, and 1 year for retinal detachment and pseudophakic bullous keratopathy.
Cost-effectiveness results
Second-eye cataract surgery resulted in 1.308 quality-adjusted life-years (QALYs) gained. Discounting the
QALYs gained by an annual 3% rate resulted in 0.92 QALYs gained over 12 years. Second-eye cataract
surgery resulted in a total discounted health-care cost of US$2509. No costs were presented for unilateral
pseudophakia. The cost–utility of second-eye cataract surgery was US$2727 per QALY gained. In the
linked study by Brown and colleagues,99 the cost–utility of second-eye cataract surgery was US$2495
per QALY.
Räsänen and colleagues
Study approach
Räsänen and colleagues90 conducted a prospective HRQoL study to evaluate the cost–utility of routine
cataract surgery in a real-world setting. They compared three groups: group A, in which only one eye was
operated on; group B, in which both eyes were operated on during the follow-up; and group C, in which
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the first eye had been operated on earlier and the second eye was to be operated on. Group C is the
group of most relevance to this review and is referred to as the intervention group. All groups were
compared with a hypothetical situation of no treatment using age- and sex-matched controls from the
general population based on data from a nationwide survey. The analysis included the costs of cataract
surgery only, and the time horizon was lifetime, with health benefits discounted at 5% per annum.
The analysis used data from 386 patients scheduled for routine cataract operation (219 were available for
final analysis) in the Helsinki University Eye Hospital (group A, n= 87; group B, n= 73; group C, n= 59).
The mean age varied from 69 to 75 years across the three subgroups. The best decimal corrected
visual acuity in the operated eye prior to cataract surgery was 0.19, 0.17, 0.24 in groups A, B and C,
respectively, and in the non-operated eye was 0.58, 0.28 and 0.63, respectively. The visual acuity after
surgery was not reported.
Estimation of quality-adjusted life-years
The 15D generic HRQoL instrument was used to estimate HRQoL.100 The 15D HRQoL questionnaire is a
15-dimension standardised and self-administered instrument (covering moving, seeing, hearing, breathing,
sleeping, eating, speech, excretion, usual activities, mental function, discomfort and symptoms, depression,
distress, vitality and sexual activity). Patients completed the 15D at baseline and then again approximately
6 months after the cataract operation. The HRQoL gain was assumed to last until the end of the remaining
statistical life expectancy of each patient based on life tables from 2002 from Statistics Finland. The utility
gain from cataract surgery was negative for group C (−0.01) and small for the other two groups (group A,
0.0; group B, 0.03).
Estimation of costs
Direct health-care costs were obtained from the Ecomed® clinical patient administration system
(Datawell Ltd, Espoo, Finland). Costing covered all relevant specialty-related costs including pre- and
post-operative outpatient visits to the eye hospital. However, the costs of the visits to the referring
ophthalmologists who were usually also responsible for the post-operative re-examination of the patients
and prescription of eyeglasses, was not included in the analysis. Indirect costs, such as period of disability,
were not included.
Cost-effectiveness results
The mean hospital costs at 6 months for groups A, B and C were €1318, €2289 and €1323,
respectively. The QALY gain was 0.1605, 0.4464 and −0.0219 for groups A, B and C respectively. The
mean cost per QALY gained was €8212 in group A and €5128 in group B. The study did not estimate
the cost-effectiveness for group C (i.e. second-eye surgery), as there was a negative utility change.
Sach and colleagues
Study approach
Sach and colleagues91 developed a cost–utility analysis alongside a RCT of second-eye cataract surgery
in secondary care ophthalmology clinics in UK. [The RCT, by Foss and colleagues,83 is included in our
systematic review of clinical effectiveness (see Chapter 4, Clinical effectiveness)]. The costs and health
benefits were measured for the operated group and a waiting list control group. These costs and benefits
were extrapolated from the trial period to the lifetime of the patients. Costs were in UK pounds and the
price year was 2004. Costs and benefits were discounted at 3.5% per annum.
Eligible women either received immediate second-eye surgery or were allocated to a waiting list control
group (12-month wait). The trial consisted of 229 women, with 116 in the intervention group (mean age
79 years) and 113 in the control group (mean age 80 years). More details of the patient characteristics
are shown in Table 2. Patients were followed up for 1 year. The trial provided data for HRQoL for the
economic evaluation. The authors describe the patients as having minimal visual dysfunction in the eye to
be operated on (86% had Snellen binocular visual acuity of 6/12 or better).
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Estimation of quality-adjusted life-years
Patients’ HRQoL was estimated using the EuroQoL EQ-5D administered at baseline and at 6 months from
the Foss and colleagues’ trial.83 Area under the curve analysis was performed to take account of the
baseline in estimating the number of QALYs for a 1-year period. In the base case, it was assumed that
patient utility values at 1 month after surgery would be the same as the 6-month utility value. It was
assumed that utility remained constant over the remaining lifetime for both groups.
The authors discuss the potential limitations of using the EQ-5D to assess cataract surgery, including
possible lack of precision and responsiveness making it hard to detect small changes (the EQ-5D does
not incorporate sensory function in its descriptive system). The authors also suggest their results are
conservative because of their assumption that the difference in HRQoL between intervention and control
groups is constant over the patients’ lifetime, whereas one would expect some deterioration in the
control group in utility over time (mean utility declined from 0.72 to 0.69 in the 6-month period used to
measure utility in the study).
Estimation of costs
Costs were derived from Foss and colleagues’ RCT.83 Patient diaries were used to collect individual
patient-level data on all contacts with health and social services, including care home admissions, informal
care, and equipment and home modifications. No costs were included for treating adverse events from
the cataract surgery. Data were collected at 3 and 9 months through telephone interviews and at 6 and
12 months through face-to-face interviews.
Patient life expectancy was estimated using UK government life tables. Annual costs for the control group
were assumed to remain constant in subsequent years, assuming that future costs were similar to those
seen during the trial period. For the intervention group, costs in the final three-quarters of the year were
rescaled to better reflect costs over a full year. As with the control group, these costs were assumed to
remain constant over the remaining lifespan.
Cost-effectiveness results
Over 1 year, the mean difference per patient in the base case was 0.015 QALYs. For the lifetime analysis,
the mean difference was 0.074 QALYs. The mean total cost per patient (excluding carer time cost) in the
operated group was £2139, compared with £1492 in the control group. The mean total cost per patient
for the lifetime analysis was £12,171 and £10,887 in the operated and the control group, respectively.
The incremental cost-effectiveness ratio (ICER) for surgery in the base case was £44,263 per QALY
gained. The lifetime ICER was £17,299 per QALY gained.
Comparison of studies
Cost-effectiveness results varied across the studies. Busbee and colleagues92 reported an ICER of US$2495
per QALY,92 and Sach and colleagues91 reported an ICER of £44,263. However, in the latter study the ICER
was reduced to £17,299 per QALY when a lifetime horizon was used. Räsänen and colleagues90 did not
report an ICER, as second-eye cataract surgery was associated with negative QALYs.
The cost-effectiveness results were driven by the changes in utility in the studies. Each study used a
different HRQoL instrument (EQ-5D, TTO or 15D). Post-surgical changes in HRQoL varied between the
studies, with a utility gain of 0.109 in one study92 and a utility loss of 0.01 in two studies.90,91 Räsänen and
colleagues90 suggested that the reason for the lack of impact on HRQoL could be that two-thirds of the
patients reported only minimal pre-operative subjective seeing problems despite objective evidence of poor
visual acuity in the surgical eye, and one-third of patients had a secondary ophthalmic diagnosis which
might have reduced the benefit of cataract surgery.
There was variation between the studies in the degree of pre-surgical visual impairment in the
second eye. For Busbee and colleagues92 and group C of Räsänen and colleagues (second-eye patients),90
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the mean pre-surgical visual acuity was 0.24 decimal (equivalent to around 6/24 metres), whereas in the
Sach and colleagues’ study91 pre-surgical visual acuity was 0.09 decimal (or 6/7 metres).
The studies differed in their approaches to measuring the costs of second-eye surgery. Busbee and
colleagues’92 report was the only study to assess the costs associated with treating post-operative
complications, although the other studies collected hospital costs after surgery. Sach and colleagues91
conducted the only study to include the post-surgery costs associated with social services, such as
residential care costs. Two of the studies extrapolated the short-term costs to a lifetime horizon by
assuming future costs to be similar to those seen during the trial period, whereas Räsänen and
colleagues90 used only the costs of the cataract procedure and hospitalisation and did not consider
further costs.
In summary, there was variability across the three studies in terms of modelling approaches, patient
characteristics, assumptions and parameter values, and this led to substantial differences in the estimated
cost-effectiveness of the second-eye surgery. Therefore, no existing model was considered appropriate for
this HTA and a de novo model was developed (see Methods for economic analysis).
Systematic review of health-related quality-of-life studies
A systematic review of studies reporting HRQoL in patients undergoing cataract surgery was conducted
following the methods previously reported (see Chapter 3). The aim of this review was to identify HRQoL
utility estimates that potentially could be included in our economic evaluation of second-eye cataract
surgery (see Methods for economic analysis). The intention was to identify studies evaluating changes in
HRQoL from cataract surgery which used generic preference-based HRQoL measures to value health utility
[e.g. standard gamble (SG) or TTO]. These measures are favoured by NICE and other health-care
organisations as they permit comparison of cost-effectiveness (e.g. in terms of QALYs) with other
health-care interventions to inform decisions about recommended treatments.95 Figure 3 presents the
flow of studies through the inclusion/exclusion process in a flow chart.
References for retrieval and screening
(n = 32)
Total of titles and abstracts identified
and screened (after de-duplication)
(n = 860)
Full papers excluded (n = 21)
Reasons for exclusion:
• no utility values reported, n = 17
• irrelevant study design, n = 4
Studies included
(n = 10; reported in 11 publications)
Excluded
(n = 828)
FIGURE 3 Flow chart for the systematic review of HRQoL studies.
DOI: 10.3310/hta18680 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 68
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Frampton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
A literature search identified a total of 860 references, the majority of which (96%) were excluded
based on titles and abstracts. Of the full papers retrieved for further screening, 21 were excluded.
The main reason for exclusion was the absence of reported utility values.
A total of 10 studies, reported in a total of 11 publications, were included in the review.40,86,90,91,94,101–106
The included studies were diverse in terms of their aims, comparisons made, study designs, patient
characteristics and locations. The full data extraction forms for all included studies are provided
(see Appendix 9).
Characteristics of the included studies
Half of the studies (Table 14) were conducted in Europe,40,90,91,101,106 of which two were from the UK.40,91
One of the UK studies, by Sach and colleagues,91 was a cost-effectiveness study conducted alongside
a RCT and was included in our systematic review of cost-effectiveness (see Systematic review of
cost-effectiveness evidence), with the RCT itself (Foss and colleagues83) included in our systematic review
of clinical effectiveness (see Chapter 4). Of the remaining studies, two were from the USA,102,104 one from
Japan94,103 and one from Australia.105
Study designs included RCTs with economic evaluations,91,101,104 and RCTs with HRQoL evaluations,40 with
the remainder of the studies being observational. The observational designs comprised single cohorts of
patients;86,103,106 single cohorts of patients with subgroups based on whether patients received first-eye,
second-eye or bilateral surgery;90,94 and a case–control study.105
Mean ages, in years, in the studies were generally in the early 70s, but ranged from 69 to 81 years.
The majority of the patient populations studied were mixed sex, with the exception of two studies in
which all patients were female.40,91 In the majority of the studies in which baseline clinical vision status was
reported, the patients could be classed as having poor visual acuity. The mean visual acuity (generally in
the eye to be operated on) was most often below Snellen 6/12, indicating visually impairing cataracts.107
One study was an exception,91 with patients described as having minimal visual dysfunction in the eye to
be operated on (86% had a baseline visual acuity of 6/12 or better).
A range of HRQoL instruments were used by the studies, the most common being the EQ-5D (seven
studies).40,86,91,94,101,105,106 Four studies used the TTO method with patients to elicit utility values,94,101,103,105
three studies used the Health Utilities Index 3 (HUI-3)86,94,103 and two studies asked patients to rate their
HRQoL using a visual analogue scale (VAS) [in one case the EuroQol-visual analogue scales (EQ-VAS);106
in the other study101 the VAS instrument was not specified].
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The studies were classified into three groups based on the comparisons it is possible to make (Table 15):
studies in which a comparison between first- and second-eye cataract surgery is possible;90,91,94,101
non-second-eye cataract surgery comparisons (including, but not restricted to, studies assessing only
first-eye surgery);40,86,103,104 and studies assessing the impact of cataract surgery complications on HRQoL.105,106
The following instruments were used in one study each: HUI-286, Short Form questionnaire-6 Dimensions
(SF-6D),86 the Quality of Well-Being – Self-Administered (QWB-SA) questionnaire86 and the 15D.90
It was common for studies to use more than one instrument, for purposes of comparison. For example,
Feeny and colleagues86 compared agreement among five generic preference-based measures of HRQoL
in a cohort of patients undergoing cataract surgery. Some of the studies used other instruments to
assess patient symptoms and HRQoL but data are not presented for them here (in line with our
inclusion criteria) as they were vision-specific rather than generic health instruments and/or they were
generic health instruments that did not yield health utilities. These included the VF-14,40 the Visual
Function Questionnaire-25 item (VFQ-25),105 the Activities of Daily Vision Scale,104 the SF-12,104
Charlson Comorbidity Index104 and the London Handicap Scale40 (see Table 15).
Results of the included studies
This section focuses on the results of the four studies which provided second-eye cataract surgery
comparisons, as these are most relevant to the decision problem of this report. The results of these and
the other six studies are summarised in Table 15.
Dolders and colleagues101 reported a cost–utility analysis comparing monofocal and multifocal intraocular
lenses (IOLs) in cataract surgery in the Netherlands. Patients were randomised to receive surgery with either
a monofocal or a multifocal IOL (n= 143 analysed). The patients were interviewed to assess HRQoL and all
other outcomes at three time points: T1 (1–2 weeks before first-eye surgery), T2 (3 months after first-eye
surgery) and T3 (3 months post operatively after second-eye surgery). Although not an intention of the
authors, it is possible to examine changes in utility values from T2 to T3 in both randomised arms,
analogous to assessing the effect of second-eye surgery. Utility values were elicited through use of VAS,
TTO and SG (the EQ-5D was used, but utility values were not reported in the study publication). Although
there was a general increase in utility from baseline (T1) to post-first-eye surgery (T2), utility values declined
(in both trial arms) between first- (T2) and second-eye surgery (T3). This decline was common to all three
utility instruments used.
Hiratsuka and colleagues94 assessed HRQoL using the TTO, the EQ-5D and the HUI-3 prior to, and
3 months after, cataract surgery. Patients were recruited from Japanese hospital ophthalmological clinics
and private surgical clinics, with the aim of reflecting a real-world setting. Patients were classified using
three subgroups: first-eye surgery (n= 157), second-eye surgery (n= 60) and bilateral eye surgery (n= 312).
For second-eye surgery patients, increases in utility values ranged from 0.08 (HUI-3) to 0.24 (TTO) and
were statistically significant for all instruments. Generally, utility gains were slightly higher for second-eye
cataract surgery patients compared with first-eye patients (except on the HUI-3), and utility gains for
bilateral eye surgery were slightly higher compared with first- and second-eye cataract surgery (except on
the EQ-5D) (see Table 15). However, differences between these subgroups were not tested statistically. The
authors suggest that the TTO method, when used to measure ophthalmic treatment, is more sensitive to
small changes in utility than generic survey questionnaires such as the EQ-5D and HUI-3. However, they
note that even the relatively smaller utility gains for EQ-5D and HUI-3 were statistically significant.
The study by Räsänen and colleagues90 was similar in design to that of Hiratsuka and colleagues,94 comprising
three subgroups of Finnish patients: first-eye surgery (group A, n= 87); bilateral eye surgery (group B, n= 73),
and second-eye surgery (group C, n= 59). HRQoL was measured using the 15D instrument, at baseline and
at the 6-month follow-up. There was no change in utility for first-eye surgery patients, a slight increase of
0.03 for bilateral eye surgery patients, and a reduction of 0.01 for second-eye surgery patients. The only
statistically significant result was for the bilateral surgery group. The authors propose a number of
explanations for lack of improvement in HRQoL, including the fact that two-thirds of patients reported only
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minimal pre-operative subjective seeing problems, despite objective evidence of poor visual acuity in the
surgical eye (though at baseline there was poor correlation between 15D score and visual acuity in
the surgical eye); the real-world setting of a university clinic and its mixed sample; that one-third of patients
had a secondary ophthalmic diagnosis (which might reduce the benefit of surgery); and potential insensitivity
of the 15D to measure changes in HRQoL (it includes only one question relating to sight).
Sach and colleagues,91 as reported earlier, conducted a cost-effectiveness study alongside a RCT in the UK
comparing expedited second-eye surgery (n= 116, target within 1 month) with a waiting list control group
(n= 113, described as routine surgery, target within 13 months). All patients were female and described
as having minimal visual dysfunction in the eye to be operated on (approximately 86% of participants
had baseline visual acuity of 6/12). There was a reduction in utility in both arms following surgery: −0.01
and −0.03 for expedited second-eye and unoperated second-eye surgery patients, respectively
(representing a 0.02 gain for second-eye cataract surgery patients). The difference between arms was
reported to be not statistically significant. The authors discuss the potential limitations of using EQ-5D to
assess the benefits of cataract surgery, noting that it does not incorporate sensory function in its
descriptive system and, therefore, may lack precision and responsiveness to changes in HRQoL.
Discussion
There was variation in the utility estimates across the studies included in the review. Räsänen and
colleagues90 reported a decrease in utility of 0.01 following second-eye surgery compared with no change
for patients undergoing first-eye surgery. Sach and colleagues91 also reported a decrease of 0.01 for
second-eye surgery compared with a slightly bigger decrease of 0.03 for patients not undergoing
second-eye surgery, representing a net 0.02 utility gain. Dolders and colleagues101 reported decreases in
utility of 0.01 to 0.08 from completion of first-eye surgery to completion of second-eye surgery, with
estimates varying according to which HRQoL instrument was used. In their study, for first-eye cataract
surgery there was an increase in utility for some instruments, no change for other instruments and for
some instruments there was a slight decrease.
Hiratsuka and colleagues94 reported statistically significant increases in utility following second-eye surgery,
with the magnitude of the increase varying according to which instrument was used. The EQ-5D and the
HUI-3 both yielded gains of 0.09, whereas the TTO yielded a larger value of 0.24. The TTO estimates were
derived directly from preferences valued by cataract surgery patients themselves, while the EQ-5D and
HUI-3, though completed by patients, use preferences valued by samples of the general public. The EQ-5D
does not include a sensory function and may not always be sensitive to improvements in clinical vision
following cataract surgery.90,91,108 However, the HUI-3 does contain a visual utility subscale and may be
more responsive to change. For example, the study by Feeny and colleagues86 (presumed to include
first-eye cataract surgery patients, though not explicitly stated) compared a number of generic HRQoL
instruments and found that the largest increases in utility were for the HUI-3 and for subscales for
sensation (HUI-2 sensation) and vision (HUI-3 vision) (see Table 14). Feeny and colleagues86 suggest that a
change of 0.03 or more in the utility score for preference-based measures is interpreted as a clinically
important change for cataract surgery. They also propose that for the single-attribute utility scores for
HUI-2 sensation (which includes vision) and HUI-3 vision, the guideline for a clinically important difference
is 0.05. The utility estimates reported by Hiratsuka and colleagues94 therefore exceed these thresholds for
clinically important differences and may be suitable for inclusion in cost-effectiveness analysis.
Of the four studies, those by Sach and colleagues91 and Hiratsuka and colleagues94 are considered to be
the most appropriate for informing the assessment of cost-effectiveness of second-eye cataract surgery in
this HTA, based on methodological quality. Each study has advantages and disadvantages. To summarise,
Sach and colleagues91 benefited from a RCT design directly comparing patients receiving second-eye
surgery with patients on a waiting list. The study was conducted in the UK and the utility estimates could
therefore be considered more relevant to the NHS. However, the patient population was exclusively
female, and had mild visual impairment, so in this respect is less typical than the UK patient population
where visual impairment is greater.20 Furthermore, the authors report patients’ binocular rather than
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monocular visual acuity at baseline, prohibiting an assessment of the degree of visual impairment in the
eye to be operated on (the second eye). The study also assessed HRQoL using the EQ-5D which, as
discussed above, does not include a sensory function. Similarly, Hiratsuka and colleagues94 employed the
EQ-5D but also used the TTO method and the HUI-3, which has a visual utility subscale and is therefore
potentially more sensitive to improvements in vision following cataract surgery. Hiratsuka and colleagues94
also reported baseline monocular visual acuity for both eyes, allowing an assessment of the degree of
visual impairment in the eye to be operated on. However, the study was observational in design, and
patients undergoing second-eye cataract surgery were a relatively small subgroup of a wider group
of patients having first-eye or bilateral cataract surgery. Therefore, reported visual acuity is not specific to
second-eye cataract surgery patients. Furthermore, this was a Japanese study and applicability to the UK
patient population is questionable. Given that expert clinical advice sought in the production of this
report suggests that use of a HRQoL instrument that is sensitive to changes in clinical vision is a key
consideration, on balance Hiratsuka and colleagues94 would be the most appropriate study for informing
the assessment of cost-effectiveness in this report, as will be described in the next section.
The remaining two studies which reported changes in HRQoL following first- and second-eye surgery
(see Table 14) were not considered appropriate for informing the base case of our cost-effectiveness
analysis. Räsänen and colleagues90 used a HRQoL utility measure, 15D, not commonly used outside
Scandinavia. The utility loss for second-eye surgery was small and there was no statistical difference
between the utility at baseline and at 6 months. Furthermore, it is unclear whether or not this utility loss
was due to other factors such as general health utility decline for an old population, as the study was for a
single cohort. Dolders and colleagues101 employed several preference-based instruments (see Table 14)
which provide relevant utility estimates but it is unclear whether the study could reliably detect changes in
utilities since no statistical tests of differences in relation to first- and second-eye surgery were reported. This
may reflect that the aim of the study was to compare two different types of IOL, not to compare first- and
second-eye surgery. Nevertheless, the study by Dolders and colleagues101 does provide information on utility
changes in relation to first- and second-eye surgery within each of the IOL comparison groups (albeit of
uncertain reliability) and the results suggest that second-eye surgery was consistently associated with a
decline in utility values compared with first-eye surgery. For this reason we have explored the impact of this
study on the economic analysis results in a scenario analysis (see Results of the economic analysis).
Methods for economic analysis
Overview
As no existing published cost-effectiveness model was considered appropriate owing to methodological
limitations and non-relevance to the NHS, we developed an economic model to estimate the
cost-effectiveness of second-eye cataract surgery in patients with bilateral cataracts, compared with
patients with bilateral cataracts who receive only first-eye cataract surgery. The modelling was conducted
following accepted standards for economic evaluation.80,81,95
The model was structured to include outcomes proposed in the research protocol (see Appendix 1).
Model data input parameters were identified from our systematic reviews of clinical effectiveness,
cost-effectiveness and HRQoL, and from the wider literature where necessary. Second-eye cataract surgery
is associated with a change in visual acuity and a corresponding change in HRQoL, assumed to last the
patient’s lifetime. Patients undergoing surgery either experience post-surgical complications or do not.
Complications are associated with a health disutility and require additional treatment and/or monitoring.
The model evaluates costs (in UK pounds using a 2012 price base) from the perspective of the NHS and
Personal Social Services (PSS). Outcomes in the model are expressed as QALYs and cost-effectiveness is
expressed in terms of ICERs. Uncertainty with regard to model input parameters is investigated through
deterministic and probabilistic sensitivity analyses, and scenario analyses. Both costs and outcomes are
discounted using a 3.5% annual discount rate in line with current guidance.95,109
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Description of the model
The conceptualisation and design of the model was informed by the assessment of the models included in
our systematic review of cost-effectiveness (see Systematic review of cost-effectiveness evidence). The
modelling structure was similar to that developed by Busbee and colleagues,92 with some modifications to
allow patients to experience long-term complications in any subsequent year.
The UK Cataract National Dataset20 has been used to supply some of the assumptions and input
parameters for the economic model, as it provides a large set of routinely collected data (55,567 cataract
operations from 12 NHS trusts between 2001 and 2006), with an unselected case mix of patients
considered representative of routine practice in the NHS. It reports characteristics of surgical procedures,
patient demographic information and comorbidities, pre- and post-operative data on visual acuity for both
first and second eyes, and intraoperative and post-operative complications. Although there are data
limitations, such as the percentage of various post-operative complications being available for only 30% of
all operations, the study nonetheless provides the most comprehensive published data available which is
relevant to the UK and is regarded to be ‘fit for purpose’.20
Figure 4 shows a schematic of the model. A hypothetical cohort of patients that receives second-eye
cataract surgery is compared with a cohort which receives no second-eye surgery (not shown). Patients
receiving surgery may experience short-term post-operative complications (endophthalmitis, cystoid macular
oedema and retained lens fragments). They may also experience longer-term post-surgical complications
and consequences (PCO or retinal detachment). These post-surgical complications and consequences are
associated with additional outpatient visits and additional remedial procedures. Patients remain in the
short- or long-term complications health states (including PCO or retinal detachment) for one cycle and then
are assumed to be successfully treated. Patients may die in any model cycle (based on general population
mortality rates). The model has a lifetime (25-year) horizon, with a cycle length of 1 year.
The patient cohort starting age is 75 years based on the mean age at surgery of patients in the UK
Cataract National Dataset.20 Pre-operative visual acuity in the surgical (second) eye in the cohort was
assumed to be 6/12 or better, and this was based on the UK Cataract National Dataset which reported
that 55% of patients undergoing second-eye cataract surgery had a mean visual acuity of 6/12 or better in
the operated eye.20
Mean life expectancy for all patients in the model was calculated to be 9.7 years, based on UK
mortality tables.110
No long-term
complications
Post-operative 
complicationa
No
complication
Death
Long-term 
complicationb
Second-eye
surgery
FIGURE 4 Schematic representation of the economic model. a, post-operative complication: endophthalmitis,
cystoid macular oedema, retained lens fragments; and b, long-term complications: PCO, retinal detachment.
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The model included the following assumptions:
l Utility values for the second-eye cataract surgery are assumed to remain constant over patient lifetimes,
unless patients have complications from the surgery. Utility values for the no second-eye surgery group
are assumed to decline over time owing to unoperated cataract progression and age-related visual
acuity decline.
l Post-surgical complications are assumed to incur a disutility for 1 year.
l The model does not consider intraoperative complications as these are assumed to manifest as
post-operative complications.
l It was assumed that the incidence of post-surgical complications would not differ between first- or
second-eye cataract surgery and, hence, the rates used were not specific to studies of second-eye
surgical patients.
l With the exception of costs for long-term post-surgical complications, the costs for outpatient visits and
further procedures were assumed to be the same after the first year for the second-eye cataract surgery
and no-surgery groups.
Evaluation of uncertainty
The evaluation of the cost-effectiveness of second-eye cataract surgery is subject to uncertainties about
variables such as clinical effectiveness, HRQoL and resource use. This is the result of data limitations in
current published studies. Uncertainty was assessed using deterministic and probabilistic sensitivity
analyses (PSA). One-way deterministic sensitivity analyses were conducted to evaluate the influence of
individual parameters on the model results and test the robustness of the cost-effectiveness results to
variations in the structural assumptions and parameter inputs (see Results of the economic analysis).
Multiparameter uncertainty in the model was addressed using PSA.111 In the PSA, probability distributions
were assigned to the point estimates used in the base case analysis. The model was run for 1000
iterations, with a different set of parameter values for each iteration, by sampling parameter values at
random from their probability distributions. The uncertainty surrounding the cost-effectiveness of the
treatment is represented on a cost-effectiveness acceptability curve (CEAC) according to the probability
that the intervention will be cost-effective at a particular willingness-to-pay threshold.
Model validation
The model was validated by checking the model structure, calculations and data inputs for technical
correctness. The structure was reviewed by clinical experts from our AG to establish that it was appropriate
for the disease and its treatment. The robustness of the model to changes in input values was tested using
sensitivity analyses to ensure that any changes to the input values produced changes to the results of the
expected direction and magnitude. To establish its external consistency, the model results were compared
with outcomes reported in clinical trials and other economic evaluations.
Data sources
Post-surgical complications and consequences
Of the three economic evaluations in our systematic review of cost-effectiveness, only the study by
Busbee and colleagues92 included surgical complications and consequences (see Systematic review of
cost-effectiveness evidence). However, it is important that complications are included in economic evaluations
of cataract surgery as many require treatment which will incur additional costs. Furthermore, some
complications affect vision and have a consequent adverse effect on HRQoL.
In our model, we have included a range of post-surgical complications and consequences, but have not
directly included intraoperative complications. Many post-surgical complications are associated with
intraoperative complications (e.g. retinal detachment may be caused by PCR during surgery) and we
have therefore assumed that the occurrence of intraoperative complications is reflected by rates of
post-operative complications. Post-operative complications included in the model are classified as
short-term (endophthalmitis, cystoid macula oedema, retained lens fragments) or longer-term expected
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consequences (PCO, retinal detachment). The complications were included following expert clinical advice
and all were also included in the economic evaluation reported by Busbee and colleagues.92 Other
potential complications were considered to be rare or to have minimal costs or adverse effects on patients’
utility. We assumed that the incidence of post-surgical complications would not differ between first- or
second-eye cataract surgery and, hence, the rates used were not specific to studies of second-eye
surgical patients.
It was assumed that short-term post-surgical complications occurred within the first year of surgery and,
hence, in the first model cycle. The UK National Cataract Survey73 reported a 0.1% rate of endophthalmitis
in its sample of 18,454 patients (77% of whom had surgery performed by phacoemulsification) 3 months
post surgery. Similarly, the British Ophthalmological Surveillance Unit72 reported a rate of 0.14% in its
sample of 211 patients, 92% of whom had phacoemulsification. The incidence rate chosen for our model
was therefore 0.1% (Table 16). This compares with a rate of acute endophthalmitis of 0.128% from a
systematic review of 215 international studies.74 The incidence of cystoid macular oedema (CMO) used
in the model was 1.62%, taken from the UK Cataract National Dataset.20 Estimates of the occurrence
of lost lens fragments vary from 0.1% to 1.6% in the international literature.70 The rate of lost lens
fragments reported by the UK Cataract National Dataset20 was 0.45%, and this value was included in our
model (see Table 16).
Longer-term post-surgical complications and consequences were assumed to occur in only the first three
successive model cycles for PCO and in any model cycle for retinal detachment. Incidence of PCO and
retinal detachment were likely to be underestimated in the UK Cataract National Dataset20 (which had
short-term follow-up) and were instead based on estimates from a meta-analysis of Japanese clinical
studies, as reported in an economic evaluation by the Eye Care Comparative Effectiveness Research Team
(ECCERT).114 Probabilities of PCO in surgical patients were: 3.49%, 9.49% and 5.06% for years 1, 2 and
3, respectively. The probability of retinal detachment was 0.26% in year 1, and 0.14% in year 2 and all
following years (see Table 16).67
We did not model secondary complications arising from the treatment of primary post-surgical
complications. We modelled only the risk of complications arising from the second-eye cataract surgery
itself, as these secondary complications will probably have a negligible effect on the model results.
Costs
Costs for cataract surgery (phacoemulsification) were taken from 2011–12 NHS reference costs.54 The vast
majority of operations (98.7%) are day-case procedures, at a cost of £851 each.54 The remaining 1.3%
were inpatient operations, at a cost of £1748 each. A weighted average for the cost of surgery was
estimated as £862.66. A mean of 6.94 outpatient visits for cataract surgery patients and 2.81 visits for
non-surgery patients was assumed based on the number reported in the UK economic evaluation by
Sach and colleagues.91 A mean of 4.4 GP visits for cataract surgery patients and four visits for non-surgery
patients was assumed.91 Ophthalmic outpatient visits were costed at £85 per visit54 and GP visits
at £43 per consultation.112
The costs of procedures for treating post-surgical complications and consequences were estimated using
2011–12 NHS reference costs.54 We did not include the cost of any prescribed pharmaceutical treatments
as these are not thought to significantly impact on costs. For treatment of all post-surgical complications
we assumed an additional two ophthalmic outpatient appointments would be required. Longer-term
complication costs for PCO are incurred within the first three years, and retinal detachment may occur
in any year.
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TABLE 16 Input parameters used in the economic model
Parameter
Base
case
Upper
estimate
Lower
estimate Source
Costs
Cataract surgery (weighted average day
case and inpatient)
£862.66 £1121.46 £603.86 NHS reference costs 2011–12
(HRG code BZ02Z)54
Ophthalmology outpatient visit £85.12 £110.66 £59.58 NHS reference costs 2011–12
(service code 130)54
GP visits £43.00 £55.90 £30.10 PSSRU 2012112
PCO (YAG laser posterior
capsulotomy)
£506.42 £658.35 £354.49 NHS reference costs 2011–12
(HRG code BZ04Z lens capsulotomy)54
Retinal detachment (vitrectomy) £1615.65 £2100.35 £1130.96 NHS reference costs 2011–12
(HRG code BZ21Z major vitreous
retinal procedures)54
Endophthalmitis
(vitreous tap; vitrectomy)
£760.11 £988.14 £532.08 NHS reference costs 2011–12
(HRG codes BZ21Z and BZ23Z)54
CMO (fluorescein angiography
and OCT)
£313.30a £407.29 £219.31 Colquitt et al. (2008)113
Lost lens fragments (vitrectomy) £451.69 £587.20 £316.18 NHS reference costs 2011–12
(HRG code BZ23Z minor vitreous
retinal procedures)54
Resources
Outpatient visits surgery 6.94 7.98 5.90 Sach et al. (2010)91
Outpatient visits no surgery 2.81 Sach et al. (2010)91
GP visits surgery 4.40 5.21 3.59 Sach et al. (2010)91
GP visits no surgery 4.00 Sach et al. (2010)91
Incidence of complications
PCO year 1 3.49% 5.24% 1.75% ECCERT114
PCO year 2 9.49% 14.24% 4.75% ECCERT114
PCO year 3 5.06% 7.59% 2.53% ECCERT114
Retinal detachment year 1 0.26% 0.39% 0.13% Erie et al. (2006)67
Retinal detachment year 2+ 0.14% 0.21% 0.07% Erie et al. (2006)67
Endophthalmitis 0.10% 0.15% 0.05% UK National Cataract Survey73
CMO 1.62% 2.43% 0.81% UK Cataract National Dataset20
Lost lens fragments 0.45% 0.68% 0.23% UK Cataract National Dataset20
Utilities
Utility no surgery 0.70 Hiratsuka et al. (2011)94
Utility gain for surgical group 0.08 0.14 0.017 Hiratsuka et al. (2011)94
Reduction in utility for non-second-eye
surgery group, per year
0.002 0.004 0.0001 ECCERT114
Other parameters
VA decimal (pre-second-eye surgery) 0.50 UK Cataract National Dataset20
VA decimal (post-second-eye surgery) 0.80 1.20 0.67 UK Cataract National Dataset20
Discount rate, benefits/costs 3.50% 6.00% 1.5% NICE reference case95
HRG, Health Resource Group; OCT, optical coherence tomography; PSSRU, Personal Social Services Research Unit;
VA, visual acuity.
a Costs for fluorescein angiography and OCT inflated to current prices.
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We assumed that 80% of patients with endophthalmitis would receive a vitreous tap (biopsy).54 Patients
with severe cases may require vitrectomy. The British Ophthalmological Surveillance Unit72 reported that
18% of patients with endophthalmitis in its study required a vitrectomy, and this percentage was used
in our economic model.54
Lost lens fragments in the post-operative period may need to be removed by vitrectomy, but a small
number of fragments may dissolve spontaneously. Patients may be prescribed topical anti-inflammatory
drops and intraocular pressure, CMO and retinal detachment monitored. We assumed that the majority
of cases will require a day-case vitrectomy and chose an arbitrary rate of 70%, at a mean total cost of
£451.69 per case.54 No surgical treatment was assumed to be necessary for CMO; however, patients
would undergo fluorescein angiography and optical coherence tomography, at a cost of £84.79 and
£58.27, respectively [costs were taken from a previous HTA on the treatment for macular degeneration113
and inflated to current prices using the Personal Social Services Research Unit (PSSRU)112 inflation indices].
PCO is most commonly treated using Nd:YAG laser capsulotomy,1 costing a total of £506.42 per case,
assumed to be a day-case operation.54 Retinal detachment was assumed to be treated via day-case
vitrectomy, at a total cost of £1615.65 per case (see Table 16).54
It is unclear whether there are differences in PSS costs for patients who have second-eye cataract surgery
and those who do not. The study by Sach and colleagues91 found a reduction in PSS costs of £339 per
person for patients with second-eye surgery compared with the no-surgery group. However, this difference
was not statistically significant and contrasted with their earlier study of first-eye surgery, which found an
increase in PSS costs of £560 per person for those who had surgery.115 In the base case, we have assumed
there is no difference in PSS costs for patients who have second-eye surgery and those who do not, and
have tested this assumption in a scenario analysis (see Scenario analyses with unadjusted utility gain).
Health-related quality of life
Health-related quality of life utility estimates were taken from the Japanese economic evaluation by
Hiratsuka and colleagues94 which was included in our systematic review of HRQoL (see Systematic review
of health-related quality-of-life studies). As discussed earlier (see Systematic review of health-related
quality-of-life studies), the rationale for using this study was because it estimated health utility using a
generic preference-based HRQoL instrument (HUI-3) that included a visual utility subscale. The gain in
utility (0.08) was assumed to last the patient’s lifetime, as assumed by other economic evaluations,92 and is
in accord with clinical consensus of a permanent improvement in clinical vision from cataract surgery.
As noted earlier (see Systematic review of health-related quality-of-life studies), Hiratsuka and colleagues94
found a bigger utility increase of 0.24 using the TTO approach. The estimate chosen for our model, based
on HUI-3, may therefore be regarded as conservative. To account for a potentially bigger improvement in
HRQoL, the 0.24 estimate was included in a scenario analysis (see Scenario analyses with unadjusted
utility gain).
In the base case, we assumed that the utility gain from the Hiratsuka and colleagues study94 was generalisable
to our UK NHS cohort, although there are likely to be differences in the population characteristics.
Hiratsuka and colleagues’ study94 was chosen in preference to the economic evaluation by Sach and
colleagues,91 which estimated utility using the EQ-5D. As noted, the EQ-5D does not include any
sensory-related dimensions and may not be sensitive to improvements in vision following cataract
surgery. However, in recognition of some of the merits of the Sach and colleagues91 study (e.g. it was
based on a RCT conducted in UK patients) we have included its utility estimates in a scenario analysis
(see Scenario analyses with unadjusted utility gain).
In the base case, we have assumed that visual acuity declines with unoperated cataract progression and
age for the non-second-eye surgery group. The decline was estimated using data from the Japanese
ECCERT study,114 which estimated that, for those with visual acuity between 0.5 and 0.9 (decimal), there is
a 2.27% probability of a decline in visual acuity to between 0.1 and 0.4 (decimal) in each successive year.
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We calculated that this would be equivalent to an annual mean visual acuity decline per patient of 0.01
and, thus, a mean utility decline of 0.002.
We assumed that second-eye cataract surgery patients experiencing post-surgical complications and
consequences retain their baseline HRQoL for the duration of the complication, and once successfully
treated they would experience the same gain in utility as patients with uncomplicated surgery. These
complications are known to impair visual acuity and therefore are likely to reduce HRQoL. The study by
Clark and colleagues,105 included in our systematic review of HRQoL studies (see Systematic review of
health-related quality-of-life studies), assessed HRQoL at 12 months post surgery to ensure that results
reflected the long-term impact of endophthalmitis rather than just its acute effect. We therefore assumed
that the disutility associated with endophthalmitis, and also with CMO and retained lens fragments,
lasted for one model cycle, i.e. 1 year. As these are short-term complications, this may be considered a
conservative assumption, and we have therefore explored the effect of shorter periods of disutility in
scenario analysis (see Scenario analyses with unadjusted utility gain). Similarly, the duration of the disutility
associated with PCO and retinal detachment is assumed to be for 1 year.
A summary of all the parameter values included in the economic model is given in Table 16.
Results of the economic analysis
This section reports the cost-effectiveness results for second-eye cataract surgery compared with no
second-eye cataract surgery. Results in terms of costs and QALYs are presented for each group, with
costs and benefits discounted at 3.5%.95 The summary results are shown in Table 17 for one average
hypothetical patient. In the base case analysis, patients receiving second-eye cataract surgery had an
additional cost of £1341, an additional 0.68 QALY, and an ICER of £1964 per QALY gained compared
with no second-eye cataract surgery. The results indicate that second-eye cataract surgery is likely to be
cost-effective at conventional willingness-to-pay thresholds.95
Sensitivity analysis
A one-way deterministic sensitivity analysis (DSA) was performed, by varying one parameter at a time from
its base case value and leaving all other variables unchanged. All parameters were varied between the high
and low estimates in Table 16. The estimates used for the sensitivity analysis were based on the uncertainty
of these data, and where data were available these were based on the 95% CI ranges for these parameters
(e.g. resources). Where these data were not available, an alternative suitable range was chosen, based
on ranges commonly used in other economic evaluations, as follows: cataract surgery costs (± 30%),
post-surgical complication incidence rates (± 50%), costs for treating post-surgical complications
(± 30%) and the discount rate for costs (2–5%).
TABLE 17 Summary of the discounted cost-effectiveness results
Parameter QALYs Costs ICER (cost/QALY)
No second-eye cataract surgery 5.29 £411
Second-eye cataract surgery 5.97 £1752
Incremental 0.68 £1341 £1964
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Table 18 shows the results of the DSA for the model parameters. The cost-effectiveness results are robust
to changes in these parameters. The model results are most sensitive to the utility gain, where the ICER
varies between £1185 and £6342 per QALY. This reflects the uncertainty around the utility gain estimate
from the Hiratsuka and colleagues94 study which had a 95% CI between 0.017 and 0.14. The model
results are also sensitive to the cost of the cataract operation. The model results are insensitive to changes
in the parameter values for the complications associated with cataract surgery.
Probabilistic sensitivity analysis
In the PSA, all parameters were sampled probabilistically from an appropriate distribution using similar
ranges as used in the DSA. The parameters included in the PSA, the form of distribution used for sampling
each parameter, and the upper and lower limits assumed for each variable are provided (see Appendix 10).
One thousand simulations were run. The PSA results are presented in Table 19 and are similar to the
results of the deterministic analysis, with an ICER of £1970. The scatterplot for cost and QALYs for
the PSA is shown in Figure 5. The CEAC is shown in Figure 6 and indicates that, at the £20,000
TABLE 18 Deterministic sensitivity analysis for second-eye cataract surgery
Parameter
Baseline
value
Higher
Estimate
Lower
estimate
ICER (cost/QALY)
Higher
estimate
Lower
estimate Range
Utility gain second-eye surgery 0.08 0.14 0.017 £1185 £6342 £5157
Cataract operation cost £862.66 £1121.46 £603.86 £2343 £1585 £758
Discount rate benefits 3.5% 6.0% 1.5% £2310 £1702 £608
Non-operated eye utility decline 0.002 0.004 0.0001 £1748 £2225 £476
Cataract outpatient appointment cost £85.12 £110.66 £59.58 £2118 £1809 £309
Mean number of outpatient
appointments, surgery group
6.94 7.98 5.9 £2094 £1834 £259
Mean number of GP visits,
surgery group
4.4 5.21 3.6 £2015 £1914 £101
PCO incidence year 2 9.49% 14.24% 4.75% £2005 £1923 £82
PCO cost £506.42 £658.35 £354.49 £2000 £1928 £71
PCO incidence year 3 5.06% 7.59% 2.53% £1984 £1944 £40
PCO incidence year 1 3.49% 5.24% 1.75% £1980 £1948 £33
Retinal detachment incidence year 2+ 0.14% 0.21% 0.07% £1977 £1950 £27
Discount rate costs 3.5% 6.0% 1.5% £1954 £1973 £19
Retinal detachment cost £1615.65 £2100.35 £1130.96 £1973 £1955 £18
GP visit cost £43.00 £55.90 £30.10 £1971 £1956 £15
CMO incidence 1.62% 2.43% 0.81% £1969 £1958 £11
Retinal detachment incidence year 1 0.26% 0.39% 0.13% £1967 £1961 £7
Lost lens fragments incidence 0.45% 0.68% 0.23% £1966 £1962 £4
CMO cost £313.30 £407.29 £219.31 £1966 £1962 £4
Lost lens fragments cost £451.69 £587.20 £316.18 £1965 £1963 £2
Endophthalmitis incidence 0.10% 0.15% 0.05% £1965 £1963 £1
Endophthalmitis cost £760.11 £988.14 £532.08 £1964 £1964 £1
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TABLE 19 Base case probabilistic cost-effectiveness results
Parameter QALYs Costs ICER (Cost/QALY)
No second-eye cataract surgery 5.29 £412
Second-eye cataract surgery 5.97 £1747
Incremental 0.68 £1335 £1970
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FIGURE 5 Scatterplot of the additional costs and QALYs for second-eye surgery compared with no surgery.
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willingness-to-pay threshold, second-eye surgery has the highest probability of being cost-effective of
100%. The cost-effectiveness estimate was less than £10,000 per QALY in 100% of the simulations.
Scenario analyses with unadjusted utility gain
In addition to the sensitivity analyses, six scenario analyses were undertaken to investigate the uncertainty
around structural model assumptions and input parameter values (scenarios A to F) (Table 20). A further
three scenario analyses to explore the effect of adjusting utility values (scenarios G and H) and the
impact of varying pre-operative visual acuity (scenario I) are described below (see Scenario analyses with
adjusted utility gain).
Scenario A: health-related quality-of-life measures
Scenario A investigates the impact of different utility gains from second-eye cataract surgery. For our base
case we have used the utility gain from the HUI-3 HRQoL measure (0.08) from the Hiratsuka and colleagues94
study. The rationale for choosing this study is discussed (see Methods for economic analysis). In this scenario,
we investigated the impact of using other more and less favourable HRQoL estimates. The utility difference
(the difference between second-eye surgery and unoperated second-eye patients) from the study by Sach
and colleagues91 was 0.02 (based on the EQ-5D). For this scenario, the results gave a less favourable ICER of
£5734. Using the TTO utility gain (0.24) from the Hiratsuka and colleagues94 study gave a more favourable
ICER of £713 per QALY gained. Using the TTO utility loss (0.08) from second-eye surgery (multifocal IOL
group) from the Dolders and colleagues study101 results in a reduction in QALYs for second-eye surgery, and
so it is dominated by (i.e. more costly and less effective than) not having second-eye surgery.
Scenario B: frequency of surgical complications
Scenario B investigates the effect of varying the frequency of post-surgical complications, as there was
uncertainty around some of these parameter estimates. We took extreme values and varied the frequency
of complications from zero to double that used in the base case analysis. The frequency of complications
only had a small impact on the model results, with the ICER varying from £1763 per QALY to £2174 per
QALY, respectively.
TABLE 20 Cost-effectiveness results for scenario analyses A–F
Scenario
Incremental
QALYs
Incremental
costs
ICERs
(cost/QALY)
Base case 0.68 £1341 £1964
A Using EQ-5D utility gain (0.02) from Sach et al. (2010)91 0.23 £1341 £5734
Using TTO utility (0.24) gain from Hiratsuka et al. (2011)94 1.88 £1341 £713
Using TTO utility loss (−0.08) from Dolders et al. (2004)101 −0.51 £1341 −£2607a
B No post-surgical complications included 0.70 £1231 £1763
Double frequency of post-surgical complications 0.67 £1451 £2174
C Duration of disutility for post-surgical complications,
6 months
0.69 £1341 £1942
Duration of disutility for post-surgical complications, 2 years 0.66 £1341 £2022
D Time horizon 5 years 0.31 £1332 £4271
Time horizon 10 years 0.53 £1337 £2544
E PSS costs 0.68 £1002 £1467
F Utility loss from Dolders et al. (2004)101 and double
frequency of post-surgical complications
0.5 £1451 −£2908a
a Second-eye surgery is dominated by (i.e. more costly and less effective than) first-eye surgery alone.
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Scenario C: duration of disutility for post-surgical complications
and consequences
In the base case, patients with complications are assumed to retain the pre-surgery utility values for 1 year
following surgery. However, some complications may last less than a year, whereas others may last longer.
We tested the sensitivity of this assumption by varying the duration of disutility between 6 months and
2 years. This scenario also had minimal impact on the model results, with the ICER varying between £1942
per QALY and £2022 per QALY.
Scenario D: time horizon
The time horizon used in the model for the base case was 25 years. Each of the three economic
evaluations in our systematic review of cost-effectiveness employed a lifetime horizon, though one of
them91 also included a 1-year horizon. We investigated the effect of choosing shorter, more conservative,
time horizons on the model results. Scenario D used time horizons of 5 and 10 years, with increases in
ICERs of £4271 per QALY and £2544 per QALY, respectively.
Scenario E: Personal Social Services costs
As discussed earlier, it is unclear how PSS costs for patients who have second-eye cataract surgery differ
from those who do not. In the base case, we have assumed that there is no difference in PSS costs for
patients who have second-eye surgery and those who do not. In scenario E, this assumption was tested
using the differences in PSS costs from the study by Sach and colleagues.91 In that study there was a
reduction in PSS costs for patients with second-eye surgery (£411) compared with the no second-eye
surgery group (£750). Using these costs for the first year gave a more favourable ICER of £1467 per QALY.
Scenario F: worst-case scenario
We investigated the effect of a worst-case scenario on the model results. Scenario F presents the
combination of scenarios A and B, i.e. using the lower utility gain from the Dolders and colleagues study101
and double the frequency of post-surgical complications than in the base case. In this scenario, not
performing second-eye surgery is the preferred option with an ICER of −£2908 per QALY.
In general, the model results were robust to changes in assumptions and model structure, and the results
are within conventional cost-effectiveness ranges, varying between £713 and £5734 per QALY, except for
the analyses using the utility loss from the Dolders and colleagues study,101 in which second-eye cataract
surgery was dominated (i.e. was less effective and more costly) (scenarios A and F).
Scenario analyses with adjusted utility gain
In the base case analysis we assumed that the utility gain estimated by Hiratsuka and colleagues94 was
generalisable to the UK patient population. However, the baseline visual acuity of the patient population in
Hiratsuka and colleagues’ study94 may not reflect that of UK patients. Therefore, we conducted further
scenario analyses in which we adjusted the utility gain to account for this disparity in visual acuity.
We assumed that the utility gain from second-eye surgery is proportional to the improvement in visual
acuity, and therefore developed a method to link visual acuity gain to utility gain. Using this method we
were able to calculate the estimated utility gain according to the baseline and post-operative visual acuity.
The visual acuity of the study populations in Hiratsuka and colleagues’ study94 and in the UK Cataract
National Dataset20 are shown in Table 21. Hiratsuka and colleagues94 reported their results using the
log-MAR scale, whereas the UK Cataract National Dataset20 has used the Snellen scale. For the purposes
of the model, we have converted the values from these studies to the decimal scale. All values shown
are the visual acuity for monocular vision.
There was some uncertainty around the visual acuity gain for the second-eye cataract surgery in the
Hiratsuka and colleagues study.94 The values given in Table 21 for pre- and post-operative visual acuity
are for the whole study sample, which also included patients undergoing first-eye cataract surgery and
ECONOMIC ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62
patients receiving bilateral cataract surgery. It is unclear what the post-surgical visual acuity would be if it
was restricted to the subgroup of patients undergoing second-eye cataract surgery. Furthermore, we
assume, for the subgroup of patients in the study undergoing second-eye surgery, that the ‘better eye’ is
the eye to be operated on. This was because the study also included patients receiving first-eye surgery
and we assumed that the first-eye surgery would be on the ‘worse eye’.
The mean baseline visual acuity of patients in the study by Hiratsuka and colleagues94 was log-MAR
0.16 (decimal 0.7) in the better eye. For the better eye, utility values from Hiratsuka and colleagues94
are associated with a post-surgery mean visual acuity of −0.05 log-MAR (approximate to decimal visual
acuity 1.1). There was therefore an estimated visual acuity gain of 0.4 on the decimal scale.
We then calculated the expected utility gain for our modelled cohort, which represents a hypothetical cohort
treated in the UK. The median baseline visual acuity of patients in the UK Cataract National Dataset20
(UKNCD) was 6/12 (decimal 0.5) and the median post-operative visual acuity for this group was 6/7.5
(decimal 0.8) and, therefore, the estimated visual acuity gain is 0.3 on the decimal scale.
The adjusted utility gain was as follows:
Adjusted utility gain ¼ Original utility gain VA gainUKNCD
VA gainHiratsuka
(1)
and the adjusted utility gain is 0.08 × 0.3/0.4= 0.06.
Scenario G: adjusted utility gain
Scenario G shows the results using the adjusted utility gain of 0.06 for second-eye surgery. In this scenario,
the results are slightly less favourable with an ICER of £2515 per QALY (Table 22).
Scenario H: assumption on adjusted utility gain
As described earlier, we assumed that the subgroup of second-eye cataract surgery patients from
Hiratsuka and colleagues94 underwent surgery on what the authors refer to as the better eye, as the study
population predominantly comprised patients undergoing first-eye cataract surgery. However, it may be
that patients from this study underwent second-eye surgery on what the authors refer to as the worse eye.
The worse-eye pre- and post-operative visual acuity was 0.51 and 0.03 log-MAR, respectively, equivalent to
a visual acuity gain of log-MAR 0.48 (decimal 0.7) (see Table 21). Thus, the visual acuity gain would be
almost double the gain from surgery on the better eye. Using this assumption, the utility gain, adjusted for
our modelled cohort based on the UK National Cataract Dataset using the formula above,20 would
TABLE 21 Visual acuity from selected studies
Study Log-MAR Snellen Decimal Change
Hiratsuka et al. (2011)94
Better-eye pre-operative VA 0.16 0.7
Better-eye post-operative VA −0.05 1.1 0.4
Worse-eye pre-operative VA 0.51 0.3
Worse-eye post-operative VA 0.03 1 0.7
UK Cataract National Dataset20
Median pre-operative VA 6/12 0.5
Median post-operative VA 6/7.5 0.8 0.3
a VA, visual acuity.
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therefore be 0.034 (compared with 0.06 in the base case). For this scenario, the ICER increases to £3935
per QALY and would still be considered cost-effective at conventional willingness-to-pay thresholds.
Scenario I – baseline visual acuity
Scenario I investigates the effect of different baseline visual acuity estimates in the operated eye, for the
ranges 6/18 to 6/7.5 (the base case assumed 6/12 or better). The purpose was to explore changes in
cost-effectiveness given that second-eye cataract surgery has been suggested to be more beneficial to
patients when the degree of visual impairment in the operated eye is greater.107 The mean post-operative
visual acuity gain for each group was calculated from the UK Cataract National Dataset.20 (The calculated
mean post-operative visual acuity is shown as a decimal, and does not always correspond exactly to whole
number ratios on the Snellen scale reported in the publication.)20 The scenario analysis indicates that the
mean visual acuity gain would be higher in patients with lower baseline visual acuity. For example,
the visual acuity gain for the group with baseline visual acuity of 6/15 would be 0.46, compared with
0.24 for the group with baseline visual acuity of 6/9. The ICERs for patients with poorer baseline visual
acuity of 6/15 and 6/18 are £1964 per QALY and £1714 per QALY and for better baseline visual acuity
of 6/9 and 6/7.5 are £2866 per QALY and £4344 per QALY, respectively.
Summary of cost-effectiveness
A systematic search of the literature found three economic evaluations of second-eye cataract surgery and
one additional linked publication. One of the studies was conducted in the UK91 and the other studies
were conducted in the USA92 and Finland.90 The cost-effectiveness estimates varied widely between the
studies, depending on the assumed improvement of HRQoL associated with the procedure. All three
economic evaluations had methodological limitations, such as not reporting all modelling assumptions,
and none was wholly relevant to the NHS.
A systematic review of HRQoL studies for patients with second-eye cataract surgery identified a total of
10 studies, reported in a total of 11 publications.40,86,90,91,94,101–106 Half of the studies were conducted in
Europe,40,90,91,101,106 of which two were from the UK.40,91 One of the UK studies, by Sach and colleagues,91
was also in our systematic review of cost-effectiveness evidence (see Systematic review of cost-effectiveness
evidence) and the RCT on which it was based was included in our systematic review of clinical effectiveness
(see Chapter 4). Four studies allowed comparisons to be made between second-eye cataract surgery and no
second-eye cataract surgery.90,91,94,101 There was variation between these studies in utility change, with some
reporting utility loss following second-eye cataract surgery, and some reporting gain. One study showed
variations in the magnitude of the increase according to which assessment instrument was used.94
TABLE 22 Cost-effectiveness results for scenario analyses with adjusted utility gain G–I
Scenario
Incremental
QALYs
Incremental
costs
ICERs
(cost/QALY)
Base case 0.68 £1341 £1964
G Adjusted utility gain of 0.06 0.53 £1341 £2515
H Worse eye VA from Hiratsuka et al. (2011)94 study,
utility gain of 0.034
0.34 £1341 £3935
I Pre-surgical VA 6/15, post-surgical VA 6/7.5 (0.8) 0.68 £1341 £1964
Pre-surgical VA 6/18, post-surgical VA 6/7.5 (0.8) 0.78 £1341 £1714
Pre-surgical VA 6/9, post-surgical VA 6/6.5 (0.9) 0.47 £1341 £2866
Pre-surgical VA 6/7.5, post-surgical VA ≈ 6/6 (0.95) 0.31 £1341 £4344
a VA, visual acuity.
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The HUI-3 yielded a utility gain of 0.08, whereas the TTO yielded a larger utility gain of 0.24, giving large
variation in the estimates from this study.
We developed a de novo economic model, designed to overcome the limitations of the existing published
models. The decision analytical model included short- and long-term complications associated with
second-eye cataract surgery. Patients who had surgery showed improvement in HRQoL proportionate
to their gain in visual acuity. Costs included in the model were for the surgery and associated hospital
visits, and the costs associated with treating complications from surgery. The model base case results
for second-eye surgery showed increased QALYs at an increased cost compared with no surgery.
The incremental cost-effectiveness estimate was £1964 per QALY gained. The effect of varying the
parameter values in the economic model was assessed in sensitivity and scenario analyses. The model
results were most sensitive to changes in the utility gain associated with second-eye surgery, but otherwise
were robust to changes in the parameter values. The PSA estimated the probability that surgery would be
cost-effective at the £20,000 and £10,000 willingness-to-pay thresholds as 100%.
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Chapter 6 Assessment of factors relevant to
the NHS and other parties
Increased provision of second-eye cataract surgery will have health service budget implications, althoughit is uncertain exactly how many additional operations will be required. As mentioned in Chapter 1,
there were 340,809 cataract operations in England during 2012–13. The total cost of cataract surgery for
2011–12 was estimated to be £240M.54 Based on estimates that 27% of cataract operations are in the
second eye,16 the cost per annum of second-eye surgery would be around £64.8M. Therefore, if provision
of second-eye surgery is to increase, costs will exceed this figure.
We assume that little investment would be required in new infrastructure, equipment or training as this
would be an extension of an existing service, rather than scaling-up of a new service (an exception would
be if additional patient assessments such as for stereopsis are to be performed, which would require
additional staff training and equipment costs). However, provision of additional cataract surgery may
place further demands on operating theatres/clinics and ophthalmologist time. On the other hand,
it may potentially fill any spare capacity and lead to efficiencies, though this is unlikely to be widespread.
Our systematic review of clinical effectiveness found only limited evidence that second-eye cataract
surgery improved patients’ quality of life. It was not clear whether or not patients experienced meaningful
improvement in visual acuity which was already very good before second-eye surgery, although
stereopsis was consistently improved in all the RCTs. A possible explanation for the lack of evidence
that second-eye surgery affected HRQoL could be that the patient-reported measures of HRQoL
administered do not specifically assess visual function.91 It is possible that for some patients, particularly
those with greater cataract-related visual impairment, second-eye surgery may provide a marked
improvement in their activities of daily living and general HRQoL. Consequently, they may become less
dependent on family and carers to assist them in activities such as reading, shopping, cooking and transport.
They may be less at risk of falls and accidents, and may be able to participate more in recreation and
physical activity, with consequent improvements in physical health and psychological health and well-being.
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Chapter 7 Discussion
Statement of principal findings
Clinical effectiveness
Our systematic review demonstrates that the evidence base for the clinical effectiveness of second-eye
cataract surgery is limited, with only three RCTs having met the inclusion criteria.83–85 These RCTs appear
relevant to a rather specific population group, namely elderly people in their 70s who had bilateral
cataracts and had good binocular visual acuity after their first cataract operation. Although this population
is relevant to the NHS, it is unclear whether it would also be representative of population groups such as
those younger or older than their 70s who are eligible for second-eye cataract surgery or those with
poorer visual acuity after first-eye surgery. The included RCTs are also now relatively old, having been
conducted between 9 and 19 years prior to our systematic review, and it may be questioned whether or
not they remain fully relevant to current clinical practice. The oldest of the RCTs was conducted by
Laidlaw and colleagues84 during 1994–5, before the introduction of phacoemulsification in the UK.
Compared with extracapsular cataract surgery, which was previously the standard approach,
phacoemulsification has been associated with improvements in the safety of cataract surgery.88
The RCTs83–85 all assessed effects of second-eye cataract surgery on measures of visual acuity, contrast
sensitivity and stereopsis, but did not measure other vision outcomes that are affected by cataracts,
such as glare disability. According to the Royal College of Ophthalmologists, glare, contrast sensitivity and
patient-reported visual disability are outcomes that are increasingly being considered when making
recommendations for cataract surgery.1 A range of patient-reported outcomes covering general health
and quality of life, symptoms, psychological distress and vision-related disability were reported in the
included RCTs. However, several of the instruments were self-developed ad hoc by the RCT investigators
without wider validation. As their clinical interpretation and reliability are unclear, we did not include these
study-specific instruments in data synthesis. Where validated patient-reported measures were employed in
the RCTs, there are a number of limitations and uncertainties about their interpretation (see Uncertainties).
Results of the RCTs83–85 should be interpreted with caution as they were judged to be at high risk of
performance bias (although it was not practicable to mask patients to their allocated study group, so this
source of potential bias was not avoidable). Assuming that the outcomes were reliable, improvements in
binocular visual acuity following second-eye compared with first-eye cataract surgery would be less than
1 Snellen line equivalent, which is smaller than would normally be regarded as clinically important. However,
on average, patients already had near-normal visual acuity after first-eye surgery (0.02–0.22 log-MAR, or
Snellen 6/6 to 6/9.5), limiting the degree to which the second-eye surgery could have further improved
their visual acuity. This ceiling effect was also evident for other outcomes reported in the RCTs,
with relatively high proportions of patients also having good contrast sensitivity as well as relatively high
scores for falls efficacy, handicap and vision-related disability before second-eye surgery (see Clinical
effectiveness outcomes).
Among the visual outcomes assessed in the RCTs, notable improvements in stereopsis occurred following
second-eye surgery, with the changes likely to be clinically meaningful to patients. Good stereopsis is
important for everyday tasks that involve judging distances,35 including driving.40 Deterioration of stereopsis
can adversely affect motor skills (e.g. threading a needle, climbing stairs)42 and increases the risk of
accidents such as falls,43 negatively affecting quality of life.40 Although the evidence base is limited,
stereopsis may be a more sensitive than binocular visual acuity as an indicator of patients’ vision before
and after second-eye cataract surgery. However, stereopsis is unlikely to be assessed routinely in clinical
practice as the stereotests required are more complex than tests of visual acuity.
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The severity and type of cataract were not explicitly reported in the RCTs, but patients would appear to
have had relatively mild cataracts, according to the vision parameters reported prior to second-eye surgery.
A study in Singapore has suggested that the benefits of second-eye cataract surgery are related to the
difference in vision between the pseudophakic and phakic eyes.107 People who have more severe bilateral
cataracts might show a greater incremental benefit from having second-eye surgery than the included
RCTs suggest, as treatment of the first cataract may create a vision imbalance (e.g. anisometropia or
binocular inhibition) (see Description of the underlying health problem).
Cost-effectiveness
There is a limited evidence base for the cost-effectiveness of second-eye cataract surgery. We identified
only three published full economic evaluations, which varied in their study methods, patient characteristics
and findings. Of these evaluations, one was a modelling study, one was a within-trial analysis and the
other was an analysis alongside a prospective HRQoL study. All three had limitations, for example only
one study included post-surgical complications. None was based on a systematic review of the evidence
(though one was conducted alongside a RCT) or were considered wholly relevant to the NHS. For this
reason it was considered necessary to develop a de novo economic model to assess cost-effectiveness.
The findings show that second-eye cataract surgery is cost-effective under conventional willingness-to-pay
thresholds. The ICER in the base case analysis was £1964 per QALY gained, which is comparable with a
number of other health-care interventions regarded to be cost-effective. Our results are comparable to
those from the Busbee and colleagues92 study, which reported an ICER of US$2495 per QALY, but differ
significantly from the other two cost-effectiveness studies.90,91 The reason for these differences is largely
driven by the utility gain for second-eye surgery assumed in the studies, and the assumptions used for
long-term utility for non-second-eye cataract surgery patients. The patient cohort modelled in this study
reflected the characteristics of the UK Cataract National Dataset,20 specifically the degree of visual
impairment, whereas patients in the Sach and colleagues91 study were selected for inclusion in a RCT and
had good vision prior to surgery.
Varying the input parameter values in the sensitivity analyses and considering alternative model scenarios
did not significantly change this finding, except for one scenario varying utility values using a study that
found a utility loss associated with second-eye surgery. Although there was some uncertainty around the
utility change associated with second-eye surgery, with some studies in our review finding a utility gain
while other a utility loss, our critical assessment of the studies found that the most appropriate HRQoL
studies reported a utility gain associated with second-eye surgery.
Strengths and limitations of the assessment
This HTA was conducted by an independent academic team with extensive experience in the methods
of systematic reviews and economic evaluations. We employed standard, rigorous and transparent
methods for evidence synthesis and economic decision modelling, based on criteria set out a priori in a
peer-reviewed research protocol. Sets of evidence for clinical effectiveness, cost-effectiveness and HRQoL
were sought, appraised, synthesised and checked systematically by a minimum of two reviewers.
The economic model was informed by previously published models and their limitations were taken into
account, where possible. The model structure and data inputs are clearly presented in this report,
to facilitate replication and testing of our model assumptions.
Experts in ophthalmology and patient care have been consulted for input throughout the project and the
current report was subjected to independent peer review by the National Institute for Health Research
HTA programme.
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Inevitably, this HTA has some potential limitations, although these appear unlikely to substantially alter our
conclusions. For pragmatic reasons, searches were limited to studies published in English; however, none
of the clinical experts we contacted identified any additional relevant RCTs to those obtained in
our searches.
Given the possibility of introducing recall bias owing to the age of the primary studies, we did not contact
authors of the primary studies for additional information. This is unlikely to have influenced our
conclusions, as the decision not to quantitatively pool outcomes in a meta-analysis was based on
heterogeneity of the study characteristics rather than on the availability of quantitative data.
We also took a pragmatic decision to limit the systematic review of clinical effectiveness to RCTs because
well-conducted RCTs are at lower risk of bias than non-randomised studies (especially selection bias, which
can only be controlled through randomisation), and initial scoping work indicated that RCT evidence for
clinical vision outcomes would be available. However, RCTs may not always capture long-term or rare
outcomes, such as adverse events. To ensure that adverse events parameters for the economic model
were as up to date and complete as possible, we conducted targeted searches for the specific parameters
(e.g. rates of retinal detachment) as well as asking clinical experts for their opinions and for sources of
data; these sources have been transparently reported (see Methods for economic analysis).
As is common in many economic evaluations, certain assumptions have been made regarding resources,
costs, surgical complications, patient characteristics and outcomes. These have all been explicitly reported
and tested in sensitivity and scenario analyses. For example, it would have been desirable to stratify our
base case analyses by age or baseline visual acuity, as these factors may predict outcome of surgery.
However, this was not possible because of limited availability of data that would have been required for
all of the model parameters. Instead we accounted for these variables in a scenario analysis.
Finally, our cost-effectiveness analysis focuses on the costs and benefits for patients attending hospital
ophthalmology departments and does not include the wider benefits to the NHS and to society that would
be made by the prevention of accidents and their sequelae that result from poor vision related to cataracts.
Uncertainties
There are a number of uncertainties around the use and interpretation of the patient-reported outcomes.
The VF-14 appears to be commonly used in research assessing vision-related functional ability after cataract
surgery, and was employed in two of our three included RCTs. However, there are uncertainties about the
validity and interpretation of VF-14 scores. The MCID for the VF-14 was originally considered to be 5.0
points116 (as quoted by Castells and colleagues85 in their RCT) but, more recently, has been proposed as
being higher, at 15.57 points.87 The differences in VF-14 scores between first- and second-eye surgery
groups in the RCTs by Foss and colleagues83 and by Castells and colleagues85 would be considered clinically
important at the lower MCID, but not if the more recently proposed higher MCID is applied. The relevance
of the VF-14 for cataract referral pathways in the NHS is also being called into question56 and ceiling effects
appear common,117 with more than half of NHS patients who were sampled presenting VF-14 scores of
90 or more points (out of 100 points) before second-eye surgery.56 As a result, the VF-14 is not supported
by the UK Department of Health for use as a standard tool in the assessment of eligibility for cataract
surgery referral.1,56 So, although patient-reported visual disability may be considered in cataract surgery
referral recommendations,1 it is unclear which assessment instrument(s) should be employed. The clinical
interpretation of some generic patient-reported outcomes assessing specific domains of HRQoL and
psychological distress would also benefit from clarification. We are not aware of a relevant MDC or MCID
for the Falls Efficacy Scale or the London Handicap Scale when these instruments are applied in surgical
ophthalmology. The authors of primary studies which employ these instruments did not provide justification
for their choice of outcome measures or explain their clinical interpretation.
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Our systematic review of HRQoL found that very small gains (and in some cases losses) were associated
with second-eye surgery compared with no second-eye surgery. A potential explanation is that generic
patient-reported outcome instruments may not be sensitive to effects of changes in vision, as they do not
include sensory domains, although the evidence for their responsiveness following cataract surgery appears
to be mixed.56,86,90,91 However, even where studies used the same preference-based utility assessment
(e.g. TTO), results varied, with indication of utility gains94 and losses101 after second-eye surgery.
The EQ-5D is important as a generic tool for enabling comparisons of utilities across health conditions,
but only one of the RCTs included in our systematic review of clinical effectiveness employed the EQ-5D,
finding no significant difference in scores between the first- and second-eye cataract surgery groups.
Utility estimates for our economic model were obtained instead from other published studies and tested
in sensitivity and scenario analyses (see Results of the economic analysis). The EQ-5D, like other generic
instruments, has been criticised for being insensitive to visual function (it does not contain questions
related specifically to vision);90,91 however, the evidence is mixed, with some studies reporting changes in
EQ-5D scores following cataract surgery.108,118 It is unclear, therefore, whether the absence of effects of
second-eye cataract surgery on EQ-5D scores in the included RCT can be attributed to limitations of the
EQ-5D instrument or an actual lack of effects of the surgery on patients’ HRQoL. These uncertainties
around the relevance of the EQ-5D suggest that a preference-based measure that includes a visual
sensation domain (such as, for example, the HUI-3) may be more appropriate for estimating utility changes
in relation to cataract surgery.94,108
The explanation for heterogeneity among the studies in utility changes is unclear. In particular, a study by
Dolders and colleagues appeared to indicate a consistent utility decline after second-eye surgery for several
preference-based measures. The study101 was somewhat unique among the studies we included in not
being designed specifically to test for differences between first- and second-eye surgery and confidence
in its ability to detect utility changes is uncertain since no statistical testing was reported. A possible
explanation for variation in utility changes among the included studies could be variation in the time that
patients had to wait for second-eye surgery,119 although this was not explicitly investigated by any of
the primary study authors and may be only one of various contributory factors (e.g. also differences
between the study designs and their population characteristics).
Other relevant factors
As mentioned above (see Current service provision), there is considerable regional variation in the
criteria employed by NHS CCGs in their cataract referral pathways. Ideally, referral pathways for both
first- and second-eye cataract surgery should be evidence based.60 A number of ways of assessing vision
and vision-related functional ability could be considered when making recommendations for cataract
surgery referral.1 Binocular visual acuity is commonly assessed, but visual acuity thresholds for first- and
second-eye surgery have fallen in recent years.55 Other measures, such as contrast sensitivity and
stereopsis, may be more important than visual acuity for functional tasks, especially in elderly people,40,106
although they may be less straightforward to assess than visual acuity and may therefore require
additional resources if routine tests are to be implemented in clinical practice. The RCTs suggested that
stereopsis was more sensitive than visual acuity for indicating changes in vision following second-eye
cataract surgery, although they did not indicate any major changes in contrast sensitivity. Another
measure of visual function which might be important to patients, especially drivers, is glare disability,
but this was not assessed in any of the RCTs. Future research to improve the cataract surgery referral
guidelines should consider which of the vision outcomes (binocular and monocular visual acuity,
contrast sensitivity, stereopsis, glare disability) should be routinely assessed, what the clinical thresholds
of these outcomes should be for decision-making, and how feasible any additional testing would be in
clinical practice.
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The published economic evaluations included in our systematic review of cost-effectiveness favoured visual
acuity as a measure of clinical vision rather than stereopsis. Consequently, there are no published methods
linking changes in stereopsis to health utilities. Current generic preference-based utility instruments are
unlikely to reflect changes in stereopsis. For example, the visual subscale of the HUI-3 (which has been
used to inform this economic evaluation) appears to refer predominantly to clearness of vision (e.g. ability
to read ordinary newsprint and recognise a friend on the other side of the street), rather than depth
perception. It would therefore be useful for future economic evaluations of cataract surgery to consider
methods to link health utilities to other measures of clinical vision, to provide a more comprehensive
assessment of HRQoL.
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Chapter 8 Conclusions
The evidence base for the clinical effectiveness of second-eye cataract surgery in patents with bilateralcataracts is relatively limited. Three RCTs were identified, all of which were conducted more than
9 years ago, and one of which was conducted before the current practice of phacoemulsification was
introduced in the UK. Each was judged to be at high risk of performance bias on patient-reported
outcomes, as it was not possible to mask patients to the study group. Populations in the RCTs were in
their 70s and had relatively good visual acuity, contrast sensitivity and HRQoL at baseline, limiting room for
improvement after surgery, with changes mostly small and not clinically important. However, stereopsis
was suboptimal in many patients at baseline and improved to a clinically meaningful degree when
second-eye surgery was compared with surgery in the first eye alone. The mental health component of
HRQoL (assessed with the SF-12 instrument in one RCT) appeared to show benefit from second-eye
surgery, but other measures of HRQoL and vision-related functional ability did not differ to a clinically
meaningful extent before and after second-eye surgery. Interpretation of several patient-reported
outcomes is uncertain because of a lack of clearly established MCIDs or other limitations. Although the
populations included in the RCTs were broadly reflective of cataract surgery patients in the NHS, it is
questionable whether the results of the RCTs can be extrapolated reliably to current practice, given
changes in surgical techniques. A more up-to-date RCT that stratifies patients according to the
range of baseline (pre-surgery) vision currently found in the UK and which is planned a priori to
include an economic evaluation would enable more precise estimation of the clinical effectiveness and
cost-effectiveness of second-eye cataract surgery in the NHS. There is a need for clarification as to which
clinical vision and vision-related patient-reported outcomes are most appropriate for assessing the
effectiveness of cataract surgery in the NHS, and for guidance on their clinical interpretation.
Based on economic modelling, second-eye surgery is generally considered cost-effective under
conventional willingness-to-pay thresholds used in the NHS, tested under a range of scenarios and
assumptions and using the best available evidence. In the base case analysis, second-eye cataract surgery
generated 0.68 incremental QALYs at an additional cost of £1341 compared with cataract surgery in one
eye only. The ICER was £1964. The base case results did not change significantly when input parameters
and assumptions were varied in deterministic sensitivity analyses and scenario analyses. Notable exceptions
were the utility changes associated with second-eye surgery where ICERs ranged between −£2908 and
£5734 per QALY in sensitivity analyses. In the probabilistic analysis, the mean ICER was £1970 and the
probability that second-eye cataract surgery was cost-effective at willingness-to-pay thresholds of £10,000
and £20,000, respectively, was 100%.
Implications for service provision
Our findings suggest that second-eye cataract surgery would likely be cost-effective if implemented
routinely in the NHS. Although the mean visual acuity gain would be higher in patients who have lower
pre-operative visual acuity, second-eye surgery appears to be cost-effective even in those with a relatively
small deficiency of pre-operative binocular visual acuity (the base case assumed 6/12 or better). However,
measuring visual acuity alone does not reflect patients’ functional disability resulting from a cataract.
Therefore, careful consideration should be given to ensure that appropriate evidence-based measures are
applied consistently for assessing patients’ eligibility for surgery (e.g. binocular and monocular visual acuity,
contrast sensitivity, stereopsis, glare disability, vision-related functional ability and/or other aspects of
HRQoL) and that clinically meaningful reference values for these measures are established.
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Suggested research priorities
To determine the clinical effectiveness of second-eye cataract surgery, a well-designed RCT would be
appropriate, to overcome the lack of recent RCTs in this area and to improve on the methodological
limitations of the previous RCTs. In order to design such a RCT it may be necessary first to clarify which
outcomes are most appropriate for NHS cataract surgery pathways. Currently, the outcomes which
are used in clinical practice to make referral decisions vary among the NHS CCGs and there is no
recommended patient-reported outcome for assessing effects of cataracts on vision-related functional
ability.56 Specific limitations of previous RCTs that should be addressed in any future RCTs in this area are
as follows:
l Patient-reported outcomes should employ validated instruments, with accepted MCID, and should be
scaled in such a way that they are not limited by ceiling effects when applied to people with bilateral
cataracts in the UK (this may be challenging56).
l To fully capture the effects of cataracts and cataract surgery on patients’ clinical vision, HRQoL and
visual disability, a ‘core’ set of outcome measures may be appropriate, including specified tests of vision
(e.g. including stereopsis, glare disability) as well as the aforementioned patient-reported outcome(s),
and these may benefit from being developed in consultation with patients to ensure that all functional
domains of importance to patients can be considered.
l The study population should capture the range of age groups and cataract severity classes relevant to
age-related cataract in the UK; it may be appropriate to stratify a RCT population according to cataract
severity (or pre-operative vision measures) so as to enable effects of cataract severity on second-eye
surgical outcomes to be explored.
l Cataract severity should ideally be reported for both eyes, using an agreed classification system;
monocular assessments of visual acuity and other vision measures such as stereopsis should be
reported for both eyes, as this may identify patients more likely to benefit from second-eye surgery.107
l An a priori planned economic evaluation should be included, so as to improve precision of the
estimates of cost-effectiveness in NHS settings.
l To inform the economic evaluation, utilities should be estimated using a preference-based measure
(e.g. TTO) to ensure direct relevance of utility estimates to the NHS cataract surgery population; it may
be appropriate to compare several preference-based measures (e.g. including the EQ-5D because it is
widely used for comparisons across health conditions) and a preference-based measure with a vision
subscale (e.g. the HUI-3) to ensure adequate sensitivity to the effects of cataract surgery).
Measures of vision that require a high-quality retinal image in each eye, notably stereopsis, would be
expected to be more sensitive than binocular visual acuity as an indicator of the effects of cataracts and
cataract surgery, and this was demonstrated by the improvements in stereopsis seen after second-eye
surgery in the included RCTs. However, stereopsis is not routinely monitored in cataract surgery patients
and, although stereopsis affects HRQoL, it is not clear how this would translate into utility estimates.
Research to clarify how changes in stereopsis influence utilities would be helpful to inform future economic
evaluations and to clarify whether or not assessment of stereopsis should be made routinely in cataract
surgery patients as part of the surgery referral decision process.
CONCLUSIONS
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Appendix 1 Protocol
1. Cost-effectiveness of second-eye cataract surgery
2. Name of TAR team and project ‘lead’
Southampton Health Technology Assessments Centre (SHTAC)
University of Southampton
First Floor, Epsilon House
Enterprise Road
Southampton Science Park
Southampton
SO16 7NS
www.southampton.ac.uk/shtac
Project lead:
Dr Geoff Frampton, Senior Research Fellow, SHTAC
Tel: +44 (0) 23 80 599299 Fax: +44 (0) 23 80 595662 Email: gkf1@soton.ac.uk
Other members of the team:
Ms Petra Harris, Research Fellow, SHTAC
Dr Keith Cooper, Senior Research Fellow (Health Economics), SHTAC
Professor Andrew Lotery, Professor of Ophthalmology and Honorary Consultant Ophthalmologist,
University Hospital Southampton NHS Foundation Trust
Dr Jonathan Shepherd, Principal Research Fellow, SHTAC
3. Plain English Summary
A cataract is a clouding that develops in the lens of the eye which results in symptoms such as blurred or
reduced vision. Cataracts are linked to ageing and are more common in people over 65. Other risk factors
include smoking, alcohol, diabetes, and use of medical drugs such as corticosteroids. The main treatment
for cataracts is surgical extraction. Surgery involves removal of the natural (crystalline) lens of the eye
that has developed an opacification (cataract) and replacement with an artificial lens to restore clarity of
vision. Cataract extraction is a common procedure and is beneficial to patients in improving their vision
and ability to perform daily activities. Cataract is generally a bilateral condition (i.e. affecting both eyes)
and surgery is generally performed on one eye at a time. It is currently standard practice for surgeons to
offer surgery where a second-eye cataract exists and the patient is symptomatic and wishes to proceed.
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Cataract extraction in the first eye is known to be cost-effective for health services, however, there is
uncertainty about how cost-effective second-eye cataract surgery is.
We propose to summarise the most up-to-date and highest quality evidence on the benefits, harms and
costs of second-eye cataract surgery in adults. We will search for, review and assess the quality of trials
that examine how effective second-eye cataract surgery is, compared with single eye cataract extraction.
The review will be undertaken following a recognised, systematic and transparent approach, allowing
people to understand and judge the process and methods we have used. We will summarise the findings
of the review through a discussion and, if appropriate, by combining results statistically.
We will develop an economic model either through adapting an existing model or developing a new
economic model to examine the costs and benefits of second-eye cataract surgery within the UK. The
model will use data from our review of trials, and data from recognised sources (e.g. national published
data, data from local hospitals’ finance departments), as well as advice from experts in the field. We will
also identify the areas where further research is needed. The results of this study will be used to inform
health policy and practice.
4. Decision problem
4.1 Research aim and objectives
The aim of this project is to assess the clinical effectiveness and cost-effectiveness of second-eye cataract
surgery. The objectives are:
l To conduct a systematic review of studies assessing the clinical effectiveness of second-eye surgery.
l To conduct an economic evaluation comprising: a systematic review of cost-effectiveness studies of
second-eye surgery; and to develop/adapt an economic model to estimate cost-effectiveness.
Cataract removal surgery is a common procedure in the UK and has been shown to be cost-effective in the
initial eye.1 Some patients with bilateral cataract may only have surgery on one eye, but it is suggested
that surgery on the second eye may have additional benefit for patients in terms of improving vision and
being able to perform everyday activities (e.g. being able to drive). However, there is debate about how
cost-effective second-eye surgery would be.
Scoping searches for this protocol have identified three published randomised controlled trials (RCTs) of
second-eye cataract surgery compared with first-eye surgery.2–4 All of these trials reported varying degrees
of benefit associated with second-eye surgery, in terms of improved visual acuity, visual symptoms, and
quality of life. No published systematic reviews of the clinical effectiveness and cost-effectiveness of
second-eye cataract surgery have been identified. Three published economic evaluations have been
identified5–7 (one of which was a trial-based evaluation conducted in the UK5) which have used divergent
methods and generated mixed results (see section 6). An evidence synthesis and economic evaluation
would therefore be useful to inform health service policy and practice in this area.
4.2 Background
A cataract is a clouding that develops in the crystalline lens of the eye which results in symptoms such as
blurred or reduced vision, and problems associated with glare or low-contrast conditions. Formation of
cataracts is linked to ageing, with the gradual accumulation of yellow-brown pigment within the lens
reducing light transmission. Cataracts can also be congenital or secondary to other causes (e.g. chronic
uveitis). Other, extrinsic, risk factors include smoking, alcohol diabetes, and use of systemic corticosteroids.
In developing countries malnutrition and acute dehydrating diseases are also associated with
cataract development.8
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Cataracts are a common cause of visual impairment worldwide, and are more common in older people.
The North London Eye Study randomly sampled people aged over 65 years from general practices in north
London (1547/1840 responding), and found a prevalence of cataract causing visual impairment (visual
acuity in one or both eyes poorer than 6/12, attributable to lens opacity) of 30%.9 The prevalence of
cataract increased steadily with age from 16% in the 65 to 69 age group, to 71% in people aged over
85 years. In the MRC Trial of Assessment and Management of Older People in the Community, nurses
tested visual acuity in 14,403 people aged 75 years and older from 49 general practices in Britain.10
Of 976 people with binocular visual impairment (binocular acuity <6/18) excluding refractive error,
36% were classified as having cataract.
4.3 Definition of the intervention
Cataract extraction surgery is considered to be the only curative intervention available. First-eye cataract
surgery refers to removal of the cataract in only one eye. Second-eye cataract surgery is performed in
patients with bilateral cataract at a point in time following first-eye surgery. Surgery involves removal of
the natural (crystalline) lens of the eye that has developed an opacification (cataract) and replacement with
a synthetic lens to restore clarity of vision.
Phacoemulsification is the standard method of cataract removal in the NHS and is associated with better
visual outcome than conventional extracapsular surgery.11 It involves making small incisions (e.g. 3mm in
width) where the clear front covering (cornea) meets the white of the eye (sclera). A circular opening is
created on the lens surface (capsule). A small surgical instrument (phaco probe) is inserted into the eye
and ultrasound waves are used to break the cataract into small pieces. The cataract and lens pieces
are removed from the eye using suction and an intraocular lens implant may then be placed inside the
lens capsule. The procedure is usually carried out under local anaesthetic as day surgery.
4.4 Place of the intervention in the treatment pathway(s)
People with cataracts may be referred to an ophthalmologist by a GP or optometrist. Referral criteria
include clinically significant visual symptoms related to the cataract (e.g. reduced visual acuity, functional
impairment), negative effects on the patient’s lifestyle by the cataract, and patient’s wish to
undergo surgery.
Cataract extraction is one of the most common elective surgical procedures in the UK. In 2009–10 there
were 334,142 cataract extractions performed in England.12 It is estimated that over a one-third of NHS
cataract operations are performed in the second eye.13 Patients are generally assessed for their second-eye
surgery at their first-eye surgery post-operation check (e.g. 4 weeks post-operation). They then may wait
up to a further 18 weeks for surgery unless there is an urgent reason to do it sooner. It is very uncommon
for cataract extraction to take place in both eyes simultaneously due to the risk of associated complications
including bilateral infective endophthalmitis (inflammation of the inside of the eye) which may lead to
blindness in both eyes. Expert clinical opinion suggests that 1% or fewer extractions are simultaneous.
The indication for second-eye surgery is based on whether the patient has a cataract in the second eye,
is symptomatic and wishes to undergo surgery. Patients would have a glasses check so that they can assess
the full benefit of the first-eye surgery, in order to correctly judge their level of symptoms and visual
rehabilitation with a change in glasses. The threshold for impairment to visual acuity would be the same
as for initial cataract extraction surgery, and expert clinical opinion suggests that thresholds may vary
between health trusts. A proportion of patients choose not to undergo second-eye surgery and some die
before they develop a second cataract.
The Royal College of Ophthalmologists cataract surgery guidelines (2010) state that it is clinically and
economically appropriate for second-eye surgery to be offered to those patients who want it. A 1b
recommendation is given (recommendation based on at least one randomised trial).13 Similarly, the Scottish
Health Technologies Group issued an advice statement in September 2012 advising that there is RCT
evidence to support second-eye surgery and evidence from cost–utility analysis to demonstrate lifetime
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cost-effectiveness.14 In England and Wales, the National Institute for Health and Care Excellence (NICE) has
not appraised second-eye cataract surgery.
4.5 Relevant comparators
Single eye cataract surgery can be considered a relevant comparator in patients with bilateral cataracts
not currently scheduled for second-eye surgery. They may receive additional supportive care such as
prescription glasses.
4.5 Outcomes
The clinical effectiveness of cataract surgery can be measured in a variety of ways. Commonly used clinical
visual measures include: visual acuity (clearness of vision measured via, for example, a Snellen chart);
stereopsis (depth perception); contrast sensitivity (the ability to see objects that may not be outlined clearly
or that do not stand out from their background) and stereoacuity (the smallest detectable depth difference
that can be seen in binocular vision).
Functional status is measured using assessment tools including the visual functioning index (VF-14),
a well-established patient questionnaire designed to measure functional impairment caused by cataracts.
In the VF-14 patients rate their ability to undertake activities such as reading a newspaper or a book,
driving and reading traffic signs or taking part in games, and a total score is computed representing the
degree of visual function.15 It is suggested, however, that the VF-14 is not sensitive to all cataract
symptoms and therefore a new instrument to assess the impact of cataract surgery in terms of visual
function and quality of life is needed.16
The health-related quality of life of people with cataracts has been assessed in clinical trials using generic
instruments such as the SF-362 and the EuroQoL EQ-5D.5 The EQ-5D has five dimensions (mobility,
self-care, usual activities, pain/discomfort, and anxiety/depression) with three possible levels of severity
for each.
Like all forms of surgery, cataract removal is associated with adverse events. These can include:
endophthalmitis; retinal detachment; bullous keratopathy (swelling of the cornea); and intraocular
lens dislocation.
4.6 Population and relevant subgroups
As discussed earlier, cataracts mainly affect older people, with increasing prevalence with age. Some
people may have eye comorbidities such as age-related macular degeneration or glaucoma.
5. Report methods for synthesis of evidence of
clinical effectiveness
A review of the evidence for clinical effectiveness will be undertaken systematically following the general
principles outlined in Centre for Reviews and Dissemination (CRD) report ‘Undertaking Systematic Reviews
of Research on Effectiveness’ (Third edition)17 and the PRISMA statement (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) (formally QUOROM statement).18
5.1 Search strategy
A comprehensive search strategy will be developed, tested and refined by an experienced information
scientist (see Appendix for draft MEDLINE search strategy). Separate searches will be conducted to identify
studies of clinical effectiveness, cost-effectiveness, Health Related Quality of Life (HRQoL), resource use and
costs, and epidemiology.
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The search strategy will comprise the following main elements:
l Searching of electronic databases
l Contact with experts in the field
l Scrutiny of bibliographies of retrieved papers
Electronic databases to be searched will include:
l General health and biomedical databases – MEDLINE (Ovid); PreMedline In-Process & Other
Non-Indexed Citations; EMBASE; the Cochrane Central Register of Controlled Trials; and the Science
Citation Index.
l Specialist databases – the Cochrane Database of Systematic Reviews; Database of Abstracts of Reviews
of Effectiveness (DARE); Health Technology Assessment database; EconLit; NHS Economic
Evaluation Database.
l Grey literature and research in progress – UK Clinical Research Network Portfolio Database; and
Conference Proceedings Citation Index –Science (Web of Science); Current Controlled Trials; Clinical
Trials.gov; BIOSIS; NIHR Clinical Research Network Portfolio; CenterWatch; Health Services Research
Projects in Progress and Computer Retrieval of Information on Scientific Projects (CRISP).
All databases will be searched from inception to the current date and searches will be limited to
English language.
5.2 Inclusion/exclusion criteria
l Population: adults (aged 18 or over) who have had one cataract operation already and still have or
develop significant cataract causing visual impairment in the other eye.
l Interventions: cataract surgery for the second eye. Studies reporting any surgical technique will
be included.
l Comparators: cataract extraction surgery in one eye only.
l Outcomes: clinical visual measures (visual acuity; stereoacuity; contrast sensitivity); patient-reported
visual disability and symptoms (e.g. VF-14); patient satisfaction with surgery and vision; health-related
quality of life (e.g. EQ-5D); adverse events.
l Types of studies: Randomised controlled trials (RCTs) will be included. If necessary non-RCT data will be
sought to inform the cost-effectiveness analysis (e.g. on safety). Any systematic reviews identified will
be used only as a source of references.
l Studies published as abstracts or conference presentations will only be included if sufficient details are
presented to allow an appraisal of the methodology and the assessment of results to be undertaken.
5.3 Inclusion, data extraction and quality assessment process
Studies will be selected for inclusion through a two-stage process using the predefined and explicit criteria
(as specified in section 5.2). The literature search results will be screened by two reviewers to identify all
citations that may meet the inclusion criteria. Full manuscripts of relevant studies will be retrieved and
assessed by two reviewers using a standardised eligibility form.
Data extraction and quality assessment will be undertaken by one reviewer and checked by a second
reviewer using a pre-designed and piloted data extraction form to avoid any errors. At each stage, any
disagreements between reviewers will be resolved by consensus or if necessary by arbitration by a
third reviewer.
5.4 Quality assessment
Included trials will be assessed in terms of their risk of bias (e.g. selection bias, detection bias, performance
bias, attrition bias, and selective reporting bias) using Cochrane Collaboration criteria.19,20 Aspects of study
quality including statistical procedures, outcome measurement and generalisability will also be assessed.
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5.5 Methods of analysis/synthesis
Studies will be synthesised through a structured narrative review with tabulation of results of included
studies. Where appropriate and where suitable data are available, meta-analysis will be employed to
estimate a summary measure of effect on relevant outcomes. The specific methods for meta-analysis and
for the detection and investigation of heterogeneity will depend upon the summary measure selected
and will used standard procedures recommended by the Cochrane Collaboration.19 Cochrane Review
Manager (RevMan) software will be used to perform any meta-analysis. Heterogeneity will be explored
through consideration of the study populations, methods and interventions, by visualisation of results and,
in statistical terms, by the χ2 test for homogeneity and the I2 statistic.
6. Report methods for synthesising evidence of
cost-effectiveness
The cost-effectiveness of second-eye cataract surgery will be assessed through two stages: a systematic
review of cost-effectiveness studies and the development of a decision analytic economic model.
6.1 Review of published cost-effectiveness studies
The sources detailed in section 5.1 will be used to identify studies of the cost-effectiveness of second-eye
cataract surgery. Studies will be included in the systematic review of cost-effectiveness if they are full
economic evaluations (cost-effectiveness, cost–utility or cost–benefit analyses) that report both measures
of costs and consequences. The methodological quality of included studies will be assessed using
accepted criteria for appraising economic evaluations.21 Where relevant this will be supplemented with
additional criteria for critical appraisal of model-based evaluations.22 Studies will be synthesised through a
narrative review that includes a clear explanation of the assessment process, detailed critical appraisal of
study methods, critical assessment of data used in any economic models and tabulation of the results
of included studies.
Published studies conducted in the UK and adopting an NHS and Personal Social Services (PSS) perspective
will be examined in more detail. Stand alone cost analyses based in the UK NHS will also be searched
for – these will not be included in the systematic review, but will be retained as sources of information on
resource use and cost associated with second-eye cataract surgery (including short-term and longer-term
adverse events).
Scoping searches have identified two published cost–utility studies of second-eye cataract surgery,5,7
in addition to the one study identified in the NIHR HTA programme commissioning brief, by Busbee and
colleagues.6 One of the additional studies was conducted in the UK and has an NHS and Personal Social
Services (PSS) perspective.5 Neither of the additional studies is a model-based evaluation – one was a study
of ‘routine’ cataract surgery (of 219 patients, 73 had both eyes operated on and 59 had a second-eye
operation, the first eye having been operated earlier)7, the other was conducted alongside a RCT.5
6.2 Evaluation of costs and cost-effectiveness
Existing economic models developed to estimate the cost-effectiveness of second-eye cataract surgery,
identified in the systematic review of economic evaluations, will be assessed for their quality, relevance and
suitability for adoption in the current review. If considered relevant and valid the models will be adapted
(if required) and populated with updated (and UK-practice-relevant) clinical and cost parameter values
using data identified in our clinical and cost-effectiveness reviews.
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The decision tree model presented by Busbee and colleagues,6 will be considered for adaptation in this
economic evaluation. Key assumptions of this study will be discussed with our clinical and methodological
advisors for their appropriateness. These include:
l the inclusion and timing of adverse events: endophthalmitis; cystoid macular oedema; lost lens
fragments (each occurring within 4 months of surgery); posterior capsular opacification (occurring
at rate of 28% over 5 years, with treatment occurring on average 2 years after surgery); retinal
detachment (in 0.81% of cases, with treatment on average 1 year after surgery); intraocular lens
dislocation (in 1.1% of cases); and pseudophakic bullous keratopathy (in 0.3% of cases, with
treatment on average 1 year after surgery). Retinal detachment following posterior capsular
opacification was assumed to occur in 3% of cases.
l the most appropriate measure of outcome. The model uses assumed levels of bilateral visual acuity
which are then mapped to utility values derived using the time-trade-off technique. However,
it is recognised that bilateral visual acuity may have limitations and other measures, including
patient-reported visual dysfunction, may be more informative.
Current guidelines for good practice in decision-analytic modelling and the general principles outlined in
the NICE ‘reference case’ will be followed.22–24 Development of the structure and parameters of the model
will be informed by several sources including previous models identified in the systematic review of
cost-effectiveness, evidence from our systematic review of clinical effectiveness, as well as guidance from
clinical and methodological advisors. The model will be validated through discussion with expert advisors.
Additional targeted literature searches will be required to populate other parameters in the model
as necessary.
The model will adopt a UK NHS and PSS perspective with cost and outcomes discounted at an annual
rate of 3.5%. The model will present estimates of the cost-effectiveness of second-eye cataract surgery,
in terms of incremental cost per quality adjusted life-year (QALY) gained, compared with first-eye
surgery only.
Resource use for second-eye cataract surgery, including management of adverse events, will be estimated
from studies included in the systematic review of clinical effectiveness, published costing studies identified
by our searches, any relevant clinical guidelines and from discussion with expert advisors.
As far as is possible, costings developed for the model will proceed by first identifying and quantifying
resource use and then applying appropriate unit costs. Where resource use data from published literature
is insufficient we would use estimates from relevant clinical experts and this will be clearly identified in
the final report. To develop unit cost estimates we will assess official, nationally representative sources
(NHS Reference Costs,25 Unit Costs of Health and Social Care,26 British National Formulary27) for
applicability and level of detail, as well as unit cost estimates applied in studies included in the systematic
review of cost-effectiveness and in costing studies identified by our searches. If these sources are
inadequate we would develop unit cost estimates in collaboration with the costing unit at Southampton
University Hospitals NHS Trust. Costs will be inflated to current prices using the Hospital and Community
Health Services Pay and Prices Index, where necessary.26
Health-related quality-of-life (HRQoL) data, where available, will be extracted from studies included in the
clinical- and cost-effectiveness systematic reviews. Where available, the impact of treatment adverse effects
on patients will also be incorporated. Where QoL data are insufficient to calculate utility estimates, data
will be derived from the broader literature or estimated from other sources. In accordance with the NICE
methodological guide for technology appraisals,24 the utility values used in the model will be elicited where
possible from the general population using a preference-based method. Where these are not available,
utility estimates will be derived from alternative sources and the assumptions made will be explicitly stated.
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The cost–utility studies identified in our preliminary searches vary in the approaches used to estimate the
utility gain associated with second-eye cataract surgery. Busbee and colleagues6 estimated levels of
bilateral visual acuity (they assumed the same utility values based on VA outcomes for patients having
first-eye surgery) and mapped these to previously estimated utility values associated with given levels of
bilateral visual acuity. This yielded comparatively large utility gains of 0.109. In contrast, the other studies
based their utility estimates on patient responses to generic HRQoL instruments (EQ-5D5 and 15D7) valued
using population-derived tariffs. These both estimated substantially lower utility gains following second-eye
surgery [a small QALY gain of 0.015 for a 12 month time horizon (difference in EQ-5D utility at
post-surgery follow-up not reported) in one study6 and a statistically non-significant decrease of −0.01 in
the other7]. Both studies using patient-reported QoL measures included patients with limited vision loss
(Sach and colleagues5 report that 86% of trial participants had baseline visual acuity of 6/12 or better,
while Rasanen and colleagues7 noted that 17% of patients reported having no pre-operative difficulty in
seeing and 47% only minor difficulties). It is not clear how far differences in patient populations studied
may have given rise to divergent results in these studies, although baseline visual dysfunction (in the eye to
be operated on) is likely to be an important factor in determining the potential gain from second-eye
surgery. Current Cataract Surgery Guidelines published by the Royal College of Ophthalmologists13 note
potential benefits from second-eye surgery, but do not indicate the degree of visual dysfunction in the
second eye at which it would be appropriate to undertake second-eye surgery.
Sensitivity analyses and scenario analyses will be conducted with respect to variables over which there is
greatest uncertainty. For the deterministic analyses this will be oriented towards variables with the greatest
uncertainty over their methods of derivation or where choices/judgments have had to be made between
alternative sources. The key variables to be explored in sensitivity/scenario analyses are likely to be the
clinical benefit (for example gain in bilateral visual acuity) from second-eye cataract surgery and the
utility associated with such benefits. However the robustness of model results to other clinical variables
(including incidence and timing of adverse events) and to resource use assumptions will also be
considered. The importance of the underlying model assumptions will be assessed through an analysis of
different scenarios, particularly where evidence to populate the model is inadequate or conflicting
(for example where the model uses data derived using expert opinion).
The results of the probabilistic sensitivity analysis will be presented using cost-effectiveness acceptability
curves (CEACs).
7. Expertise in this TAR team
SHTAC is one of nine academic research teams in the UK contracted to the National Institute for
Health Research (NIHR) Health Technology Assessment (HTA) programme to assess the clinical and
cost-effectiveness of health technologies. Our research supports several key decision-making bodies
within the UK, including the National Institute for Health and Clinical Excellence (NICE). With expertise
in evidence synthesis, health economics, statistical modelling and epidemiology, SHTAC is involved
in research addressing major policy questions on the use of drugs, devices, procedures, screening
programmes, health promotion and public health, and other interventions. SHTAC has previously
conducted research into eye diseases, including a systematic review and economic evaluation of
ranibizumab and pegaptanib for age-related macular degeneration.28,29
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Advisory group
An AG has been recruited comprising clinical experts in ophthalmology, experts in health technology
assessment methodology (including health economics) and representatives from patient organisations.
The group will has commented on the draft protocol and will comment on the draft final report. The
group will be consulted during the course of the project for advice as necessary. The current members of
the group are:
l Professor Janet Marsden, Professor of Ophthalmology and Emergency Care & Chair of the RCN
Ophthalmic Nursing Forum, Research Institute for Health and Social Change (Health Care Studies
Department), Manchester Metropolitan University.
l Professor John Sparrow, Consultant Ophthalmologist, University Hospitals Bristol NHS Foundation Trust,
& Honorary Professor of Ophthalmic Health Services Research and Applied Epidemiology, University
of Bristol.
l Mr Simon P Kelly, Chair of Quality & Safety subcommittee of the Royal College of Ophthalmologists,
& Consultant Ophthalmic Surgeon at Royal Bolton Hospitals NHS Foundation Trust.
l Dr Ewen Cummins, Health Economist, McMaster Development Consultants
Additional members may be recruited to the group during the course of the project, as required.
8. Competing interests of authors
None.
9. Timetable/milestones
To follow.
10. Appendices
10.1. Draft Medline (Ovid) search strategy
1. exp cataract extraction/ (26,455)
2. (cataract* adj5 (surg* or remov* or extract* or procedure* or operat* or excis* or aspirat* or
incis*)).tw. (19,067)
3. phacoemulsification.tw. (5253)
4. (PKE or PCIOL or ECCE or ICCE or MSICS or MISICS or SICS).tw. (931)
5. (pseudoaphakia or pseudoaphakic or phakectomy or phakectomies or “enzymatic zonulolysis” or
“zonulolyses enzymatic” or “enzymatic zonulolyses” or “zonulolysis enzymatic”).tw. (107)
6. lens implantation, intraocular/ or lenses intraocular/ (16,135)
7. “cataract patient*”.tw. (1092)
8. or/1-7 (36,944)
9. (“single eye*” or “right eye*” or “left eye*” or “one eye” or “dominant eye*” or “better seeing
eye*” or “either eye” or “unilateral cataract*” or “first eye*”).tw. (22,936)
10. (“fellow eye*” or “second eye*” or “both eyes” or “other eye*” or “two eyes” or “next
eye*”).tw. (16,331)
11. (eye* adj5 (sequential* or simultaneous* or serial*)).tw. (1275)
12. (bilateral* adj5 cataract*).tw. (1369)
13. 8 and (9 or 10 or 11 or 12) (3749)
14. Randomized Controlled Trials as Topic/ (83,981)
15. randomized controlled trial.pt. (339,605)
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16. controlled clinical trial.pt. (85,425)
17. Controlled Clinical Trial/ (85,425)
18. placebos/ (31,477)
19. random allocation/ (76,252)
20. Double-Blind Method/ (117,819)
21. Single-Blind Method/ (16,898)
22. (random* adj2 allocat*).tw. (18,020)
23. placebo*.tw. (140,190)
24. ((singl* or doubl* or trebl* or tripl*) adj (blind* or mask*)).tw. (115,464)
25. crossover studies/ (30,752)
26. (crossover* or (cross adj over*)).tw. (51,975)
27. Research Design/ (68,167)
28. ((random* or control*) adj5 (trial* or stud*)).tw. (452,653)
29. Clinical Trials as Topic/ (163,152)
30. random*.ab. (567,167)
31. or/14-30 (1,175,731)
32. 13 and 31 (612)
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Appendix 2 Search strategies
Ovid MEDLINE(R); Ovid MEDLINE (R) Daily Update; Ovid MEDLINE(R)
In-Process & Other Non-Indexed Citations
Search: 1946 to February week 4 2013; 12 March 2013; 12 March 2013.
Date of search: 13 March 2013.
Search strategy
1. exp cataract extraction/ (26,480)
2. exp cataract/ (21,988)
3. (surg* or remov* or extract* or procedure* or operat* or excis* or aspirat* or incis* or
implant*).tw. (2,884,239)
4. 2 and 3 (7602)
5. (cataract* adj5 (surg* or remov* or extract* or procedure* or operat* or excis* or aspirat* or incis*
or implant*)).tw. (19,222)
6. (pha?oemulsif* or capsulor?hexis).tw. (5916)
7. (PKE or PCIOL or ECCE or ICCE or MSICS or MISICS or SICS).tw. (941)
8. (pseudophaki* or pseudoaphaki* or phakectomy or phakectomies or “enzymatic zonulolysis” or
“zonulolyses enzymatic” or “enzymatic zonulolyses” or “zonulolysis enzymatic”).tw. (2658)
9. lens implantation, intraocular/ or lenses intraocular/ (16,139)
10. (cataract* and (IOL* or “intraocula* lens*” or “intra ocula* lens*”)).tw. (5879)
11. (cataract* adj5 patient*).tw. (7222)
12. (cataract* and (endocapsula* or “endo capsula”* or extracapsula* or “extra capsula*” or capsulor*
or capsulot*)).tw. (3664)
13. 1 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 (40,118)
14. (“single eye*” or “right eye*” or “left eye*” or “one eye” or “dominant eye*” or “better seeing
eye*” or “either eye” or “unilateral cataract*” or “first eye*” or “initial eye”).tw. (23,081)
15. (“fellow eye*” or “second eye*” or “both eyes” or “other eye*” or “two eyes” or “next
eye*”).tw. (16,323)
16. (eye* adj5 (sequential* or simultaneous* or serial*)).tw. (1280)
17. (bilateral* adj5 cataract*).tw. (1361)
18. 13 and (14 or 15 or 16 or 17) (4160)
19. Randomized Controlled Trials as Topic/ (83,796)
20. randomized controlled trial.pt. (342,617)
21. controlled clinical trial.pt. (85,357)
22. Controlled Clinical Trial/ (85,357)
23. placebos/ (31,395)
24. random allocation/ (76,571)
25. Double-Blind Method/ (118,451)
26. Single-Blind Method/ (17,153)
27. (random* adj2 allocat*).tw. (18,091)
28. placebo*.tw. (140,578)
29. ((singl* or doubl* or trebl* or tripl*) adj (blind* or mask*)).tw. (115,971)
30. crossover studies/ (31,186)
31. (crossover* or (cross adj over*)).tw. (52,412)
32. Research Design/ (72,908)
33. ((random* or control*) adj5 (trial* or stud*)).tw. (456,444)
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34. Clinical Trials as Topic/ (162,983)
35. random*.ab. (572,735)
36. or/19-35 (1,187,578)
37. 18 and 36 (665)
38. limit 37 to humans (612)
39. limit 38 to (“all infant (birth to 23 months)” or “newborn infant (birth to 1 month)” or “infant
(1 to 23 months)” or “preschool child (2 to 5 years)” or “child (6 to 12 years)”) (60)
40. 38 not 39 (552)
41. (child* or infant* or newborn* or paediatric* or pediatric* or toddler*).tw. (1,218,343)
42. 40 not 41 (550)
43. “second-eye cataract surgery”.tw. (41)
44. 42 or 43 (582)
45. limit 44 to english language (538)
EMBASE (Ovid)
Search: 1974 to 12 March 2014.
Date of search: 13 March 2013.
Search strategy
1. Randomized Controlled Trial/ (341,060)
2. Randomization/ (60,956)
3. Single Blind Procedure/ (17,104)
4. Double Blind Procedure/ (116,041)
5. ((single or doubl* or trebl* or tripl*) adj (mask* or blind*)).tw. (156,621)
6. (placebo* and control* and trial*).tw. (66,289)
7. randomi?ed control* trial*.tw. (87,684)
8. (random* adj2 allocat*).tw. (23,594)
9. (placebo* and random* and (trial* or study or studies)).tw. (106,340)
10. (randomized or randomised).tw. (440,771)
11. Controlled Clinical Trial/ (394,901)
12. Meta Analysis/ (69,502)
13. (meta-analys* or meta analys* or metaanalys*).tw. (64,286)
14. (systematic* adj3 review*).tw. (57,534)
15. health technology assessment*.ti,ab,in. (3383)
16. biomedical technology assessment/ (11,452)
17. or/1-16 (895,494)
18. exp cataract extraction/ (35,068)
19. lens implantation/ (5183)
20. exp cataract/ (43,214)
21. (surg* or remov* or extract* or procedure* or operat* or excis* or aspirat* or incis* or
implant*).tw. (3,900,922)
22. 20 and 21 (15,788)
23. (cataract* adj5 (surg* or remov* or extract* or procedure* or operat* or excis* or aspirat* or incis* or
implant*)).tw. (24,554)
24. (pha?oemulsif* or capsulor?hexis).tw. (7825)
25. (PKE or PCIOL or ECCE or ICCE or MSICS or MISICS or SICS).tw. (1259)
26. (pseudophaki* or pseudoaphaki* or phakectomy or phakectomies or “enzymatic zonulolysis” or
“zonulolyses enzymatic” or “enzymatic zonulolyses” or “zonulolysis enzymatic”).tw. (3166)
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
100
27. (cataract* and (IOL* or “intraocula* lens*” or “intra ocula* lens*”)).tw. (7704)
28. (cataract* adj5 patient*).tw. (9283)
29. (cataract* and (endocapsula* or “endo capsula*” or extracapsula* or “extra capsula*” or capsulor*
or capsulot*)).tw. (4513)
30. or/18-19,22-29 (48,985)
31. (“single eye*” or “right eye*” or “left eye*” or “one eye” or “dominant eye*” or “better seeing
eye*” or “either eye” or “unilateral cataract*” or “first eye*” or “initial eye”).tw. (31,441)
32. (“fellow eye*” or “second eye*” or “both eyes” or “other eye*” or “two eyes” or “next
eye*”).tw. (21,105)
33. (eye* adj5 (sequential* or simultaneous* or serial*)).tw. (1586)
34. (bilateral* adj5 cataract*).tw. (1792)
35. or/31-34 (47356)
36. 17 and 30 and 35 (571)
37. limit 36 to english language (507)
38. limit 37 to (infant <to one year> or child <unspecified age> or preschool child <1 to 6 years> or
school child <7 to 12 years> or adolescent <13 to 17 years>) (39)
39. 37 not 38 (468)
40. (infant* or newborn* or toddler* or child* or paediatric* or pediatric* or schoolchild* or preschool or
adolesc*).tw. (1,571,707)
41. 39 not 40 (457)
42. limit 41 to human (437)
43. 41 not 42 (20)
44. from 43 keep 3,18 (2)
45. 42 or 44 (439)
Web of Science Science Citation Index Expanded
(SCI-EXPANDED)
Conference Proceedings Citation Index- Science (CPCI-S) – 1990–present; Conference Proceedings Citation
Index – Social Science & Humanities (CPCI-SSH); BIOSIS Previews on Web of Science platform 1956–2013.
Search: 1970–present.
Date of search: 13 March 2013.
Search strategy
# 1 (TS=(cataract* NEAR (surg* or remov* or extract* or procedure* or operat* or excis* or aspirat* or
incis* or implant*))) (14,211)
# 2 (TS=(cataract* NEAR (pha?oemulsif* or capsulor?hexis))) (2150)
# 3 (TS=(cataract* NEAR (PKE or PCIOL or ECCE or ICCE or MSICS or MISICS or SICS))) (328)
# 4 (TS=(pseudophaki* or pseudoaphaki* or phakectomy or phakectomies or “enzymatic zonulolysis” or
“zonulolyses enzymatic” or “enzymatic zonulolyses” or “zonulolysis enzymatic”)) (2077)
# 5 (TS=(intraocula* NEAR ("lens* implant*”))) (3053)
# 6 (TS=(cataract* and (IOL* or “intraocula* lens*” or “intra ocula* lens*”))) (5509)
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# 7 (TS=(cataract* NEAR patient*)) (7086)
# 8 (TS=(cataract* NEAR (endocapsula* or “endo capsula”* or extracapsula* or “extra capsula*” or
capsulor* or capsulot*))) (2149)
# 9 #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1 (18,158)
# 10 (TS=(“single eye*” or “right eye*” or “left eye*” or “one eye” or “dominant eye*” or “better
seeing eye*” or “either eye” or “unilateral cataract*” or “first eye*” or “initial eye”)) (15,249)
# 11 (TS=(“fellow eye*” or “second eye*” or “both eyes” or “other eye*” or “two eyes” or “next eye*”)) (11,121)
# 12 (TS=(eye* NEAR (sequential* or simultaneous* or serial*))) (2525)
# 13 (TS=(bilateral* NEAR cataract*)) (1121)
# 14 (#13 OR #12 OR #11 OR #10) (25,184)
# 15 #14 AND #9 (2957)
# 16 151 (TS=(cataract and “second eye*”)) (151)
# 17 #16 OR #15 (2959)
# 18 (TS=(random* NEAR (trial* or study or studies or allocat*))) (355,822)
# 19 (TS=(randomized or randomised)) (352,591)
# 20 (TS=((single or doubl* or trebl* or tripl*) NEAR (mask* or blind*))) AND Language=(English) (137,950)
# 21 (TS=(placebo* and control* and trial*)) (59,613)
# 22 (TS=(placebo* and control* and stud*)) (65,141)
# 23 #22 OR #21 OR #20 OR #19 OR #18 (490,189)
# 24 #23 AND #17 (397)
# 25 (TS=(child* or infant* or newborn* or paediatric* or pediatric* or toddler)) (689,724)
# 26 (#24 NOT #25) (355)
# 27 (TS=(animal* or monkey* or rabbit* or rat* or mouse or mice or cat or cats or dog or dogs)) (5,387,399)
# 28 (#26 NOT #27) (231)
# 29 (TS=(randomi?ed and cataract* and second and eye*)) (119)
# 30 (#29 NOT #27) (80)
# 31 (#30 NOT #25) (78)
# 32 (#28 or #31) (279)
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The Cochrane Library Central; Health Technology Assessment;
Cochrane Database of Systematic Reviews; Database of
Abstracts of Reviews of Effects
Search: Issue 2 of 12; Issue 1 of 4; Issue 2 of 12; Issue 1 of 4.
Date of search: 20 March 2013.
Also searched Cochrane Eyes and Vision Group (lens disease and cataract topic).
Search strategy
#1 MeSH descriptor: [Cataract Extraction] explode all trees
#2 MeSH descriptor: [Cataract] explode all trees
#3 (surg* or remov* or extract* or procedure* or operat* or excis* or aspirat* or incis* or implant*)
#4 #2 and #3
#5 (cataract* near (surg* or remov* or extract* or procedure* or operat* or excis* or aspirat* or incis*
or implant*))
#6 (pha?oemulsif* or capsulor?hexis)
#7 (PKE or PCIOL or ECCE or ICCE or MSICS or MISICS or SICS)
#8 (pseudophaki* or pseudoaphaki* or phakectomy or phakectomies or “enzymatic zonulolysis” or
“zonulolyses enzymatic” or “enzymatic zonulolyses” or “zonulolysis enzymatic”)
#9 MeSH descriptor: [Lens Implantation, Intraocular] explode all trees
#10 MeSH descriptor: [Lenses, Intraocular] explode all trees
#11 (cataract* and (IOL* or “intraocula* lens*” or “intra ocula* lens*”))
#12 (cataract near patient*)
#13 (cataract* and (endocapsula* or “endo capsula*” or extracapsula* or “extra capsula*” or capsulor*
or capsulot*))
#14 #1 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13
#15 (“single eye*” or “right eye*” or “left eye*” or “one eye” or “dominant eye*” or “better seeing
eye*” or “either eye” or “unilateral cataract*” or “first eye*” or “initial eye”)
#16 (“fellow eye*” or “second eye*” or “both eyes” or “other eye*” or “two eyes” or “next eye*”)
#17 (eye* near (sequential* or simultaneous* or serial*))
#18 (bilateral* adj5 cataract*)
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#19 #15 or #16 or #17 or #18
#20 #14 and #19
#21 (child* or infant* or newborn* or paediatric* or pediatric* or toddler* or schoolchild* or
“school child*”)
#22 #20 not #21
Centre for Reviews and Dissemination Database of Abstracts of
Reviews of Effects Health Technology Assessment
Date of search: 20 March 2013.
Search strategy
1. (phacoemulsif* or phakoemulsif* or capsulorhexis) (30)
2. (cataract* near (surg* or remov* or extract* or procedure* or operat* or excis* or aspirat* or incis*
or implant*)) (165)
3. (pseudophaki* or pseudoaphaki* or phakectomy or phakectomies or “enzymatic zonulolysis” or
“zonulolyses enzymatic” or “enzymatic zonulolyses” or “zonulolysis enzymatic”) (10)
4. (cataract* and (IOL* or “intraocula* lens*” or “intra ocula* lens*”)) (52)
5. (cataract near patient*) (35)
6. (cataract* and (endocapsula* or “endo capsula*” or extracapsula* or “extra capsula*” or capsulor*
or capsulot*)) (20)
7. (PKE or PCIOL or ECCE or ICCE or MSICS or MISICS or SICS) (12)
8. MeSH DESCRIPTOR Cataract Extraction EXPLODE ALL TREES (80)
9. MeSH DESCRIPTOR Lens Implantation, Intraocular EXPLODE ALL TREES (32)
10. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9) (188)
11. (“second eye*”) (13)
12. (“fellow eye”) (8)
13. (#12 or #13) (18)
14. (#11 and #14) (9)
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Appendix 3 Clinical effectiveness study
selection worksheet
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Appendix 4 Data extraction forms for
clinical effectiveness studies
Reviewer 1: PH Reviewer 2: GF
Reference
and design Technology Participants Outcome measures
Author: Castells et al.85
Publication year:
2006
Study year(s):
7/1999 – 7/2000
Study design: RCT
Number of centres: 2
Country: Spain
Sponsor: Catalan
Agency for Health
Technology
Assessment and
Research (CAHTAR)
and the Fondo de
Investigación Sanitaria
(FIS)
Trial name:
none reported
Intervention group:
Both-eyes surgery (surgery
in the first eye 1 to
2 months after enrolment
and surgery in the second
eye 2 to 4 months after
first-eye surgery)
(n= 148)
Type of surgery:
ambulatory surgery using
a phacoemulsification
technique (3-mm corneal
incision without suture) –
same procedure in both
hospitals
Duration of surgery: not
reported
Type(s) of lens: foldable
lens
Type(s) of anaesthetic:
topical anaesthesia
Number of surgeons/
teams: not reported
Comparator group:
One-eye-only surgery
(control, surgery to first eye
only between 1 and
2 months after enrolling,
offered second-eye surgery
at end of study) (n= 148)
Length of experience/
training of surgeon(s):
not reported
Setting: ophthalmology
departments in public
teaching hospitals
Number of participants:
Eligible: not reported
Randomised: 296
Pre-, peri- and post-
operative therapy: not
reported
Inclusion criteria: scheduled
for first-eye cataract surgery
and presented bilateral
indication for cataract surgery
(visual acuity worse than 0.3
log-MAR in both eyes)
Exclusion criteria: severe
ocular comorbidity that would
contraindicate surgery in both
eyes (e.g. terminal glaucoma,
amblyopia or prior strabismus
surgery); undergoing surgery
combined with any other
ophthalmologic procedure
(e.g. glaucoma or
keratoplasty); experiencing
complications of first-eye
surgery that would
contraindicate surgery in
the fellow eye
Baseline measurements:
Gender male, n (%):
Intervention: 57 (39)
Comparator: 55 (37)
Age (years), mean (SD):
Intervention: 71.70 (9.07)
Comparator: 72.03 (8.87)
Ethnicity, n (%): not reported
Primary outcomes:
l Binocular visual acuity
l Binocular contrast sensitivity
l Stereopsis
l Patient-reported visual
disability
Secondary outcomes:
l Cataract symptoms score
l Two general questions about
overall amount of trouble
and satisfaction with vision
l General health status
Methods of assessing outcomes:
l Log-MAR best corrected visual
acuity: binocular with an
ETDRS chart calibrated for an
8-foot (≈2.5metres) distance,
by the letter-by-letter
scoring method
l Log-contrast sensitivity:
binocular with a Pelli–Robson
chart, by the letter-by-letter
scoring method, at 1m
l Stereopsis: Titmus circles test;
to widen the range of values,
it was combined with the Fly
and the TNO tests, giving
a range from 3000 to
15 seconds of arc. The
measures of stereopsis were
also transformed into a log
scale. Lower values of visual
acuity and stereopsis and
higher values of contrast
sensitivity indicate good vision
l VF-14: 14 everyday activities
that can be affected by
cataracts (e.g. reading a
newspaper, watching
television or taking part in
activities) (0–100/maximum
disability–no disability),
administered by trained
optometrists
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Reviewer 1: PH Reviewer 2: GF
Reference
and design Technology Participants Outcome measures
Weight (kg): not reported
Cataract classification status:
not reported
Ocular comorbidities
(not specified), n (%):
Intervention: 34 (23.0)
Comparator: 36 (24.3)
Other comorbidities:
not reported
Losses to follow-up:
Intervention: n= 9
(five withdrawals,
four post-randomisation
exclusions)
Control: n= 13
(eight withdrawals,
five post-randomisation
exclusions)
l Cataract symptoms score:
5-item symptoms
questionnaire on degree of
trouble caused by common
symptoms of cataracts (0–15;
0 = no symptoms, 5 = very
much trouble, due to all
five symptoms)
l Questions about overall
amount of trouble and
satisfaction with vision: no
details provided on scoring
l General health status:
SF-12 health survey
(0–100/worst–best)
l Other ophthalmologic clinical
information: comorbidity or
surgical complications,
obtained through
standardised clinical data
forms by ophthalmologists
l Sociodemographic
characteristics at baseline
visit obtained by optometrist
Timing of baseline and
follow-up assessments:
Baseline between 1 and 2 months
before first-eye surgery, follow-up
between 4 and 6 months after
the last surgery (first eye for the
control group, second eye for
the intervention group)
ETDRS, Early Treatment Diabetic Retiropathy Study; SD, standard deviation.
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Outcome, mean (SD)
Intervention (n= 139) Comparator (n= 135)
Difference (95% CI); p-value
p≥ 0.05 unless specifiedBaselinea Follow-up Baselinea Follow-up
Primary clinical visual outcomes
Binocular visual acuity,
log-MAR
0.54 (0.17) 0.11 (0.10) 0.56 (0.19) 0.18 (0.17) 0.07 (0.03 to 0.12);
p< 0.001
Decimal scale 0.31 0.80 0.30 0.71
> 0.3 (= 0.5 decimal),
n (%)
3 (2.2) 20 (14.8) p< 0.001
> 0.1 to ≤ 0.3, n (%) 72 (51.8) 79 (58.5)
≤ 0.1 (= 0.8 decimal),
n (%)
64 (46.0) 36 (26.7) p< 0.001
Change from baselinea
(log-MAR)
−0.43 (0.18) −0.38 (0.23) 0.05 (−0.002 to 0.11)
Binocular contrast
sensitivity, log-units
1.14 (0.29) 1.61 (0.1) 1.13 (0.35) 1.57 (0.18) 0.04 (−0.002 to 0.09)
< 1.30, n (%) 2 (1.4) 10 (7.4)
≥ 1.30 to < 1.70, n (%) 77 (55.4) 69 (51.1)
≥ 1.70, n (%) 60 (43.2) 56 (41.5)
Change from baselinea
(log-units)
0.46 (0.32) 0.44 (0.36) 0.02 (−0.09 to 0.14)
Stereopsis, log-units 2.86 (0.66) 1.75 (0.24) 2.89 (0.70) 2.37 (0.69) 0.62 (0.45 to 0.79);
p< 0.001
≥3.48 (=3000 seconds
of arc), n (%)
0 25 (18.5) p< 0.001
> 1.78 to < 3.48, n (%) 42 (30.4) 84 (62.2)
≤ 1.78 (= 60 seconds
of arc), n (%)
96 (69.6) 26 (19.3) p< 0.001
Change from baselinea
(log-units)
−1.11 (0.69) −0.51 (0.79) 0.60 (0.36 to 0.85);
p< 0.001
Health-related quality of life
Primary visual disability
(VF-14), units
58.08 (20.59) 97.7 (7.1) 61.01 (22.28) 89.5 (15.9) 8.24 (4.35 to 12.36);
p<0.001
≤ 80, n (%) 5 (3.6) 26 (19.3) p< 0.001
> 80 to < 100, n (%) 31 (22.3) 51 (37.8)
100, n (%) 103 (74.1) 58 (43.0) p< 0.001
Change from baselinea 39.9 (20.7) 28.3 (20.4) 11.57 (4.79 to 18.12);
p<0.001
Other self-reported
outcomes
Trouble with vision
score
3.11 (0.89) 1.17 (0.48) 3.11 (0.91) 1.58 (0.86) 0.41 (0.17 to 0.64);
p< 0.001
Change in score
from baselinea
−1.96 (1.03) –1.53 (1.3) 0.43 (0.06 to 0.81);
p< 0.05
No trouble with vision,
n (%)
120 (86.3) 83 (61.5) p< 0.001
Satisfaction with
vision score
3.72 (0.53) 1.13 (0.38) 3.64 (0.60) 1.53 (0.81) 0.40 (0.20 to 0.61);
p< 0.001
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Outcome, mean (SD)
Intervention (n= 139) Comparator (n= 135)
Difference (95% CI); p-value
p≥ 0.05 unless specifiedBaselinea Follow-up Baselinea Follow-up
Change in score
from baselinea
−2.61 (0.62) −2.10 (1.02) 0.51 (0.23 to 0.79);
p< 0.001
Very satisfied, n (%) 123 (88.5) 84 (62.2) p< 0.001
Cataract Symptoms
Score
3.85 (3.14) 0.12 (0.45) 3.84 (3.43) 0.78 (1.9) 0.66 (0.21 to 1.11);
p< 0.001
Change in score
from baselinea
−3.83 (3.13) −3.17 (3.81) 0.66 (−0.49 to 1.86)
General health status (SF-12)
Physical 45.57 (9.79) 47.5 (9.3) 44.82 (10.89) 46.2 (9.3) −1.30 (−4.40 to 1.85)
Change from baselinea 1.76 (10.6) 1.40 (9.2) −0.36 (−3.56 to 3.04)
Mental 48.51 (9.36) 53.1 (4.9) 48.23 (10.38) 51.2 (6.6) −1.90 (−3.79 to −0.03);
p< 0.05
Change from baselinea 4.27 (10.2) 2.96 (10.5) −1.31 (−4.71 to 2.16)
Complications, adverse events and comorbidities
Surgical complications Not reported Not reported Not reported Not reported
Adverse events Not reported Not reported Not reported Not reported
Ocular comorbidities,
n (%)
34 (23.0) Not reported 36 (24.3) Not reported
Other comorbidities Not reported Not reported Not reported Not reported
SD, standard deviation.
a Baseline measures were taken prior to any eye surgery.
Subgroups: within age groups (< 65 and ≥ 65 years), the two groups presented similar characteristics at baseline. Of the
younger patients, 65 completed the trial (n= 33 intervention and n= 32 control). Differences in primary outcomes between
treatment groups after surgery were similar in younger and older patients, except for VF-14: stronger effect of the
intervention in older patients (difference of 9.18 points between treatment groups, 95% CI from 5.73 to 12.63) than
younger patients (difference of 5.21 points, 95% CI from 0.53 to 10.96). For secondary outcomes, older patients presented
a higher benefit in satisfaction with vision in terms of the proportion of patients very satisfied with vision (older patients
58.3% control vs. 90.6% intervention; younger patients 75.0% control vs. 81.8% intervention).
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Methodological comments
Allocation to treatment groups: randomised after first-eye surgery using a computerised minimisation algorithm
with stratification by hospital, age (< 65 or ≥ 65 years) and pre-operative visual acuity (> 1 or ≤ 1 log-MAR).
Allocation concealment: patients were centrally randomised in a research unit (no further details).
Masking: masking for data analyst only.
Analysis by intention to treat: stated that final outcomes analysis performed on an ITT basis, however follow-up
results reported without post-randomisation exclusions or drop-outs.
Comparability of treatment groups at baseline: groups similar on age, gender,% living alone, education
achievement and % employed (no statistical comparison reported).
Method of data analysis: a subgroup analysis was planned according to age groups. Sociodemographic factors
and primary outcome variables were compared at baseline. The final outcomes analysis compared 4–6 months
post-operative visits between groups (after the second-eye surgery for the intervention group and after the
first-eye surgery for the control group) on means of the final measure and on the change from baseline, as well
as on three category groupings of the main outcome variables. Cut-off points were set at 0.3 and 0.1 log-MAR
for visual acuity; at 1.30 and 1.70 for log-contrast sensitivity; at 3000 and 60 seconds of arc for stereopsis;
and at 80 and 100 points for VF-14 scores. Non-parametric Mann–Whitney U-tests for quantitative variables and
chi-squared tests for qualitative variables were used for comparisons. Non-parametric CIs for the differences in
means between groups were calculated using the bootstrap method. A secondary analysis was performed upon
post-operative VF-14 and binocular visual acuity of patients in the control group (surgery in one eye only – not
data extracted).
Sample size/power analysis: sample size was calculated separately for patients aged < 65 and ≥ 65 years to
detect clinically relevant differences in VF-14 and binocular visual acuity. With 296 patients (148 per treatment
group; 36 younger and 112 older), the trial was able to detect a minimum relevant difference of 5 points
(SD= 8 for younger and SD= 14 for older patients) in mean post-operative VF-14 and a minimum clinically
relevant difference in post-operative visual acuity of one Snellen line (SD= 0.16 for younger and SD= 0.22 for
older patients). The sample sizes took into account a significance level of 5%, a power of 80%, and an
expected proportion of withdrawals of 15%.
Attrition/drop-out: intervention n= 5 (three lost to follow-up, two died), plus four post-randomisation exclusions
(two developed comorbidity, two complication in the first-eye surgery); control n= 8 (two lost to follow-up,
three expedited second-eye surgery, two switched to private sector and one died) plus five post-randomisation
exclusions (two developed comorbidity, two complications in first-eye surgery and one developed
senile dementia).
General comments
Generalisability: limited to those with bilateral cataracts and only moderate refractive errors, majority aged
> 65 years and of low education status.
Inter-centre variability: not reported.
Conflict of interests: not reported.
SD, standard deviation.
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Risk of bias assessment (for guidance, refer to chapter 8 of the
Cochrane Handbook)
Domain Judgement Support for judgement
Random sequence generation? (Is the
method used to generate the allocation
sequence described in sufficient detail to
allow an assessment of whether or not it
should produce comparable groups?)
Low Randomisation and allocation was performed by means
of a computerised minimisation algorithm with stratification
‘ . . . ‘ patients were centrally randomised in our research
unit after first-eye surgery
Allocation concealment? (Is the
method used to conceal the allocation
sequence described in sufficient detail
to determine whether intervention
allocations could have been foreseen in
advance of, or during, recruitment?)
Unclear Comment: no information provided
Detection bias: masking of outcome
assessors? (Which measures, if any,
were used to mask outcome assessors
from knowledge of which intervention
a participant received? Was any
information provided relating to whether
or not the intended masking was
effective?)
Unclear The random allocation was blinded to the data analyst
Comment: unclear if data analyst was outcome assessor.
Method of masking not stated (nor whether it was effective)
Performance bias: masking of
participants on self-reported
outcomes? (Which measures, if any,
were used to mask participants from
knowledge of which intervention they
received? Was any information provided
relating to whether or not the intended
masking was effective?)
High To avoid bias in patient expectations, patients assigned to
surgery in one eye only for study purposes were scheduled
to receive second-eye surgery immediately after the end of
study follow-up
Comment: authors acknowledge the risk of bias
due to not being able to mask patients to their
treatment allocation
Incomplete outcome data addressed?
(How complete was the reporting of
outcome data for each main outcome,
including the numbers and reasons
for attrition and exclusions from
the analysis?)
Unclear Comment: not all the reasons why patients were lost
to follow-up were reported. The number of patients
included in the review assessment excluded drop-out and
additional post-randomisation exclusions. No statistical
comparisons for results with and without drop-outs were
reported. Authors stated that the final outcomes analysis
was performed on an ITT basis, but the data do not
support this
Free of selective reporting? (Is there
any evidence that outcomes were
measured but not reported, or were
reported incompletely, or in an
inappropriate format?)
Unclear Comment: it is unclear if outcomes for the three category
groupings, proportion of change due to surgery in
one eye only and the second analysis of visual acuity by
patient-reported visual disability post operatively (first-eye
surgery) were planned a priori. Also, not stated whether the
control and intervention groups were equally distributed
between the two hospitals (i.e. whether different staff
assessed each group)
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Reference
and Design Technology Participants Outcome measures
Author: Foss et al.83
Publication year:
2006
Study year(s): 2000–4
Study design: RCT
Number of centres: 1
Country: UK
Sponsor: The Health
Foundation and
former Trent Regional
Health Authority
Trial name:
none reported
Intervention group:
Expedited surgery (target
within a month) (n= 120)
Type of surgery:
small-incision cataract
surgery (team A and C
temporal clear cornea,
team B superior clear
cornea)
Duration of surgery,
mean phacoemulsification
time: 56–87 seconds
(team A 56 seconds,
team B 87 seconds,
team C 66 seconds)
Type(s) of lens: folding
silicone intraocular lens
Type(s) of anaesthetic:
local anaesthetic
Number of surgeons/
teams: three teams
Comparator group:
routine surgery (n= 119)
(a ‘waiting list’ control
group, target surgery
within 13 months or the
routine waiting time
when this became less
than 13 months)
Length of experience/
training of surgeon(s):
not reported
Setting: hospital
ophthalmology
department
Number of participants:
Eligible: 302
Randomised: 239
Pre-, peri- and
post-operative therapy:
none reported
Inclusion criteria: women
age > 70 years, had one
successful cataract operation
and a second operable
cataract
Exclusion criteria: complex
cataracts (Fuchs corneal
dystrophy, active intraocular
inflammation, lens zonule
dehiscence or lens instability),
visual field defects, severe
comorbid eye disease
affecting visual acuity, those
with memory problems
preventing the completion of
the lengthy questionnaires or
reliable recall of falls
Baseline measurements:
Gender, n (%): 100% female
Age (years), median:
Intervention: surgery:
79.2 (range 70 to 90)
Comparator: 79.9
(range 70 to 92)
Ethnicity, n (%): not reported
Weight (kg): not reported
Cataract classification status:
not reported
Mini-mental state, mean
(range):
Intervention: 27
(range 10–30)
Control: 27
(range 10–30)
Primary outcome: number of
patients experiencing a falla
Secondary outcomes:
l Health status
l Cognitive function
l Activity
l Anxiety and depression
l Confidence
l Activities of daily living
l Visual disability
l Handicap
l Overall quality of life (QoL)
l Ophthalmic outcomes
l Visual acuity
l Contrast sensitivity
l Stereopsis
Length of follow-up: 3, 6, 9 and
12 months
Methods of assessing outcomes:
l Mini-Mental State Examination
score (0–30; severe (≤ 9 points),
moderate (10–20 points),
mild (21–24 points) or no
cognitive impairment (> 25)
l Anxiety and depression:
Hospital Anxiety and
Depression Scale
(0–28/best–worst)
l Confidence: Falls Efficacy Scale
(FES) (1–10/completely
confident – no confidence,
total point range 10–100;
high score indicates low falls
self-efficacy)
l Activities of daily living:
Barthel Index (0–20/fully
dependent–independent,
lower scores indicate
increased disability)
l Visual disability: VF-14
(0–100/worst–best, higher
scores indicate less
functional impairment)
l Handicap: London Handicap
Scale, interview version,
0–100/extreme disadvantage–no
disadvantage)
l Overall quality of life:
EuroQoL (EQ-5D)
(5 dimensions, each 0–1.0,
worst–best imaginable health
state)
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Reference
and Design Technology Participants Outcome measures
Ocular comorbidities:
not reported
Other comorbidities, n/N (%):
Heart problems
Intervention: 39/120 (33)
Control: 36/119 (30)
Chest problems
Intervention: 25/120 (21)
Control: 23/119 (19)
Arthritis
Intervention: 91/120 (76)
Control: 93/119 (78)
Stroke
Intervention: 10/120 (8)
Control: 7/119 (6)
Pervious fracture (any)
Intervention: 57/120 (48)
Control: 57/119 (48)
Postural dizziness
Intervention: 42/120 (35)
Control: 28/119 (24)
Postural hypotension
Intervention: 19/120 (16)
Control: 14/119 (12)
Losses to follow-up,
n/N (%):
Intervention:= 5/120
(4.2)
Comparator:= 16/119
(13.4)
Ophthalmic outcomes:
Visual acuity: unaided,
with current spectacles and with
pinhole, recorded
As the logarithm of the minimum
angle resolvable, log-MAR, using an
ETDRS-modified Bailey–Lovie chart
(Precision Vision, Villa Park, IL, USA)
Contrast sensitivity: Pelli–Robson
chart (Clement Clarke, Harlow, UK)
Depth perception (5-point scale)
Stereopsis: Frisby system and the
Wirt Fly (Clement Clarke), which
together measure down to
150 seconds of arc
Full ocular examination
Timing of baseline and follow-up
assessments: participants recorded
dates of falls and fractures in a daily
diary, assessed by interview at
6 and 12 months (also telephoned
at 3 and 9 months). Health status
assessed at 6 months after
randomisation. Ophthalmological
examination was repeated 1 month
after surgery, and 6 and 12 months
after randomisation
a Falls defined as unintentionally coming to rest on the ground or at a lower level, with or without loss of consciousness.
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Outcome Expedited surgery Routine surgerya
Mean differenceb between
groups at 6 months
(95% CI); p-value
Primary outcome: no. of
patients with falls, n/N (%):
Total no. of patients
experiencing falling
48/120 (40) 41/119 (34) Not reported
Number of patients
experiencing first fall
26/120 (22)c 19/119 (16)c Hazard ratio 1.06 (95% CI,
0.69 to 1.61), log rank test 0.06,
1 df; p= 0.80
Number of patients
experiencing > 1 fall
22/120 (18) 22/119 (18) Hazard ratio 0.85 (95% CI,
0.49 to 1.56), log rank test 0.26,
1 df; p= 0.61
Rate of falling per 1000
patient-days (range)
2.9 (0 to 31) 4.3 (0 to 120) Rate ratio 0.68 (95% CI,
0.39 to 1.19); p= 0.18d
Fractures 5/120 (4%) 3/119 (3%) Risk ratio 2.5 (95% CI, 0.5 to 12.5);
Fisher’s exact test; p=0.45
Outcome
Expedited surgery Routine surgerya Mean differenceb between
groups at 6 months
(95% CI); p-valueBaseline 6 months Baseline 6 months
Clinical visual outcomes (binocular), mean
Unaided visual acuity (log-MAR) 0.22 0.15 0.26 0.23 −0.04 (−0.01 to −0.08); p= 0.001
Spectacles visual acuity
(log-MAR)
0.09 0.04 0.11 0.09 −0.04 (−0.01 to −0.06); p= 0.003
Pinhole visual acuity (log-MAR) 0.10 0.04 0.09 0.09 −0.06 (−0.03 to −0.09); p<0.0005
Change in median visual
acuity in the operated eye
(i.e. monocular), log-MAR
0.44 −0.02 Not reported
Contrast sensitivity
(Pelli–Robson, dB)
1.45 1.60 1.42 1.50 0.09 (0.06 to 0.13); p< 0.0005
Depth perception/5-point scale 1.66 1.36 1.85 1.93 −0.45 (−0.22 to −0.69); p<0.0005
Stereopsis (seconds of arc), n/N (%)
150 76/120 (63) 100/115 (87) 65/119 (55) 67/113 (59)
300 22/120 (18) 9/115 (8) 27/119 (23) 23/113 (20)
600 11/120 (9) 4/115 (4) 11/119 (9) 10/113 (9)
> 600 Wirt able 9/120 (8) 2/115 (2) 12/119 (10) 8/113 (7)
> 600 Wirt unable 2/120 (2) 0/115 (0) 4/119 (3) 5/113 (4)
health-related quality of life, mean
Activity scale 7.4 7.6 8.1 7.8 0.4 (−0.8 to 1.5); p= 0.53
Confidence – Falls Efficacy
Scale/100
85.5 86.1 84.4 81.7 3.6 (0.9 to 6.2); p= 0.008
HADS – anxiety/28 6.4 6.6 6.8 7.1 −0.2 (−1.0 to 0.5); p= 0.54
HADS – depression/28 4.6 4.6 4.5 4.7 −0.5 (−0.7 to 0.3); p= 0.47
Barthel Index/20 18.7 18.7 18.9 18.8 −0.1 (−0.2 to 0.3); p= 0.61
VF-14 visual disability/100 87.5 94.7 87.5 87.2 7.5 (5.1 to 9.9); p< 0.0005
London Handicap Scale/100 82.3 85.2 82.2 80.8 4.4 (2.2 to 6.5); p< 0.0005
EuroQoL (EQ-5D)/1.0 0.74 0.73 0.72 0.69 0.02 (−0.03 to 0.08); p= 0.36
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Outcome Expedited surgery Routine surgerya
Mean differenceb between
groups at 6 months
(95% CI); p-value
Other self-reported outcomes
Surgical complications,
n/N (%) Expedited surgery Routine surgerya
Mean differenceb
(95% CI); p-value
Section stitched 4/115 (3) Not reported
Iris hooks 1/115 (0.9) Not reported
Iris damage 1/115 (0.9) Not reported
Endophthalmitis 0/115 (0) Not reported
Anterior vitrectomy
performed
4/115 (3) Not reported
Posterior capsular
opacification noted
at 6 months
12/115 (10) Not reported
YAG capsulotomy performed
during study period
10/115 (9) Not reported
Surgical complications by
surgical approach, n/N (%)
Team A: temporal
clear cornea
Team B: superior
clear cornea Team C: temporal clear cornea
Section stitched 1/63 (1.6) 3/38 (7.9) 0/19 (0)
Iris hooks 0/63 (0) 0/38 (0) 1/19 (5.3)
Iris damage 0/63 (0) 1/38 (2.6) 0/19 (0)
Anterior vitrectomy
performed
1/63 (1.6) 2/38 (5.3) 1/19 (5.3)
Posterior capsular
opacification at 6 months
2/63 (3.2) 8/38 (21.1) 2/19 (10.5)
YAG capsulotomy performed
during study period
4/63 (6.4) 4/38 (10.5) 2/19 (10.5)
Expedited surgery Routine surgerya
Mean differenceb
(95% CI); p-value
Adverse events Not reported Not reported
Ocular comorbidities Not reported Not reported
Other comorbidities Baseline data only
df, degrees of freedom.
Baseline values reported in table 2 and appendix 2 differ. Data extracted from table 2.
a Waiting-list control.
b Mean difference adjusted for baseline values.
c Calculated by reviewer.
d States that statistically adjusting the relative risk of falling for history of falls (1 and 12 months prior to randomisation),
history of stroke, poor visual acuity, reported postural dizziness, and baseline visual disability and confidence,
or separately for activity level at 6 months had no effect on the results. Restricting the analysis to the 111 participants
(reported as 109 in Appendix 3; intervention n= 57, control n= 52) who reported falling in the 12 months prior to
randomisation also had no effect on the results (HR 1.30, 95% CI, 0.8 to 2.2; p= 0.35).
Median time from randomisation to expedited surgery: 30 days (range 8 to 204, lower quartile 22 and upper quartile 45);
median time to routine surgery: 316 days (range 37 to 527, lower quartile 241 and upper quartile 344).
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Additional comments
Surgical teams had different workloads, team A completed 63 cases, team B 38 cases and team C 19 cases
(temporal clear cornea cases n= 82, superior clear cornea cases n= 38).
While no cataract classification was reported, authors suggest that the cataracts operated on were less severe
than those of a comparable study.84
Authors suggest that as a result of high baseline ratings for some measures (30% of scores on the London
Handicap Scale, 50% on the Falls Efficacy Scale and VF-14 visual disability scale were above 90% of the scale
maximum), there was limited scope for measuring further improvements. Similarly binocular visual acuity and
contrast sensitivity were already good at baseline: limited scope for improvement.
Methodological comments
Allocation to treatment groups: randomisation was from lists prepared by one of the authors from random
numbers, in variably sized, permuted blocks to maintain approximate equality in the size of the groups.
Allocation concealment: allocation was concealed in sequentially numbered, opaque, sealed envelopes that
were opened after consent was obtained and baseline assessment made.
Masking: assessment (after baseline) was not masked to allocation.
Analysis by intention to treat: stated that all analyses were ITT, but ITT not defined in terms of sample size.
Comparability of treatment groups at baseline: groups were reported to be well matched at baseline
(no statistical comparison reported), although poor vision (proportion with Snellen acuity worse than 6/12)
was higher in the expedited surgery group (8%) compared with the routine surgery group (3%).
However, frequency of postural dizziness was more than 10% higher in the expedited surgery group compared
with the routine surgery group (n= 42/120 vs. 28/119, respectively).
Method of data analysis: primary analysis was a comparison of the rate of falling (total number of falls/number
of days in the trial). Negative binomial regression was used for statistical testing and to generate CIs around the
rate ratio as falls in the same patient are not statistically independent events. Observation time for routine
surgery patients was up to a final assessment, scheduled about a week before surgery (including surgery
performed before 12 months of follow-up was complete). For both first and second falls, a Cox proportional
hazards regression analysis was used to compare the proportions of participants falling (regardless of the
number of falls they have) and to estimate relative risk. Participants reaching the end of observation without
experiencing a fall, and those withdrawing or having out-of-trial early surgery, were censored. The proportions
of participants experiencing fractures were also compared. Health gains were assessed by comparing changes
in visual functions, activity, anxiety, depression, confidence, disability, handicap and quality-of-life measures
between operated and control groups using linear regression to adjust for baseline imbalances. The relative size
of differences in health status measures was compared using the effect size (mean change/initial SD).
Sample size/power analysis: the expected prevalence of falls was 50%. A one-third reduction in participants
falling, giving a difference of 16% between the two groups, was taken to be clinically significant. To have an
80% chance of detecting this at 95% confidence required 160 patients in each arm, giving a trial size of 320.
Authors state that due to a reduction in waiting time to less than 6 months for routine surgery, it was
impractical and unethical for the trial to continue and leaving it under-powered (n= 239).
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Attrition/drop-out: expedited surgery n= 5. At: 3 months n= 2 (one ill health, one other), 6 months n= 1
(withdrew), 9 months n= 2 (one died, one withdrew) and 12 months n= 0.
Routine surgery: n= 16. At: 3 months n= 3 (1 withdrew, 2 non-trial surgery), 6 months n= 3 (1 died,
2 withdrew), 9 months n= 2 (1 died, 1 non-trial surgery) and 12 months n= 8 (4 withdrew, 4 non-trial surgery)
General comments
Generalisability: limited to women aged over 70 years with age-associated comorbidities and bilateral cataracts.
Inter-centre variability: not applicable.
Conflict of interests: reported as none.
SD, standard deviation.
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Risk of bias assessment (for guidance refer to chapter 8 of the
Cochrane Handbook)
Domain Judgement Support for judgement
Random sequence generation? (Is the
method used to generate the allocation
sequence described in sufficient detail to
allow an assessment of whether or not it
should produce comparable groups?)
Unclear Randomisation was from lists prepared (by RH) from random
numbers, in variably sized, permuted blocks to maintain
approximate equality in the size of the groups
Comment: unclear how the author prepared the lists used
for randomisation
Allocation concealment? (Is the
method used to conceal the allocation
sequence described in sufficient detail
to determine whether intervention
allocations could have been foreseen in
advance of, or during, recruitment?)
Low Allocation was concealed in sequentially numbered, opaque,
sealed envelopes that were opened after consent was
obtained and baseline assessment made
Comment: allocation concealment was not maintained after
baseline assessment
Detection bias: masking of outcome
assessors? (Which measures, if any,
were used to mask outcome assessors
from knowledge of which intervention
a participant received? Was any
information provided relating to whether
or not the intended masking was
effective?)
High Comment: stated ‘assessment (after baseline) was not
masked to allocation’
Performance bias: masking of
participants on self-reported
outcomes? (Which measures, if any,
were used to mask participants from
knowledge of which intervention they
received? Was any information provided
relating to whether or not the intended
masking was effective?)
High Comment: stated ‘assessment (after baseline) was not
masked to allocation’
Incomplete outcome data addressed?
(How complete was the reporting of
outcome data for each main outcome,
including the numbers and reasons
for attrition and exclusions from
the analysis?)
Unclear All analyses were by intention to treat
Comment: loses to follow-up not included in analysis
Attrition rates differed between groups (expedited surgery
n= 5, 4%; routine surgery n= 16, 13%); reasons
incompletely reported but stated that seven of the
16 drop-outs from routine surgery went on to receive
non-trial surgery (not defined but assumed by reviewers to
mean second-eye cataract surgery). Unclear whether this
would have led to a prognostic imbalance between the
study groups
Free of selective reporting? (Is there
any evidence that outcomes were
measured but not reported, or were
reported incompletely, or in an
inappropriate format?)
Unclear Comment: unable to establish without a protocol.
Unclear whether list of surgical complications complete
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Reviewer 1: PH Reviewer 2: GF
Reference and design Technology Participants Outcome measures
Author: Laidlaw et al.84
Publication year: 1998
Study year(s):
1994–1995
Study design: RCT
Number of centres: 1
Country: UK
Sponsor: Wellcome
Trust
Trial name:
none reported
Intervention group:
Expedited surgery
(target within 6 weeks)
(n= 105)
Type of surgery:
not reported
Duration of surgery:
not reported
Type(s) of lens:
not reported
Type(s) of anaesthetic:
not reported
Number of surgeons/
teams: not reported
Comparator group:
routine surgery (target
7–12 months)
(n= 103)
Length of experience/
training of surgeon(s):
not reported
Setting: eye hospital
Number of participants:
Eligible: 350
Randomised: 208
Pre-, peri- and
post-operative therapy:
post-operative
rehabilitation based on
a treatment schedule
(no further details)
Inclusion criteria:
awaiting second-eye
cataract surgery, unilateral
cataract and
uncomplicated
contralateral pseudophakia
with corrected Snellen
visual acuity of at least
20/40 in the pseudophakic
eye, absence of other
visually significant
ophthalmic pathology
affecting either eye,
ability to understand
questionnaires
Exclusion criteria:
patients with ocular
comorbidities were
excluded
Baseline measurements:
Gender male, n (%):
Intervention: 40 (38)
Comparator: 40 (39)
Age (years), mean (range):
Intervention: 76 (52–97)
Comparator: 76 (41–93)
Ethnicity, n (%):
not reported
Weight (kg): not reported
Cataract classification
status: not reported
Primary outcomes:
l 4/18 questions (Q2: Do you have
difficulty reading normal print in
books or newspapers because of
trouble with your eyesight;
Q5: How often does your
eyesight prevent you from doing
the things you would like to do;
Q11: How would you describe
your vision overall – with both
eyes open, wearing glasses or
contact lenses if you usually do;
Q30: Overall, how much do
problems with your eyesight
interfere with your life)
l Binocular log-MAR distance
visual acuity
l Binocular log-MAR near-reading
acuity
l Binocular Pelli–Robson
contrast sensitivity
l Stereoacuity
Secondary outcomes: stated that
there were 39 secondary outcomes,
but not explicitly listed
l Remaining 14 questions
l General health status
l Reading speeds (monocular,
binocular, and the difference
between them)
l Subjective vision (question:
during the past month, how
would you describe the vision in
your left (right) eye with your
right (left) eye closed)
Length of follow-up: surgery
patients had to have completed
their post-operative rehabilitation,
including any post-operative
treatment schedule, before the
review assessment could take place
(e.g. at least 1 month should have
elapsed after post-operative refractive
correction). Median time from
recruitment to review: expedited
surgery 6.4 (IQR 5.7–7.7) months,
median time from surgery to review
4.9 (IQR 4.4–6.2) months; routine
surgery median time from
recruitment to review 6.0
(IQR 5.5–6.3) months
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Reviewer 1: PH Reviewer 2: GF
Reference and design Technology Participants Outcome measures
Ocular comorbidities:
not reported
Other comorbidities:
not reported
Losses to follow-up:
Intervention: n= 7
Comparator: n= 9
Methods of assessing outcomes:
l Questionnaire (newly developed
questionnaire that was pilot
tested): 18 questions relating to
symptoms of visual dysfunction
(9 on QoL, 3 on visual function).
Primary question 2: 6-point scale
(1–6/best–worst); question 5:
4-point scale (1–4/best–worst);
question 11: 7-point scale
(1–7/best–worst); question 30:
4-point scale (1–4/best–worst).
Subjective vision question:
6-point scale (1–6/best–worst)
No details reported for the
remaining 13 questions
l General health status: SF-36
(8 dimensions: physical
functioning, role physical, bodily
pain, general health, vitality,
social functioning, role
emotional, and mental health)
l Visual-function tests:
stereoacuity was assessed
by a combination of the
TNO stereo test and the Wirt Fly
(range of measurements of
15–3000 seconds of arc).
TNO test was presented first.
If stereoacuity worse than 1980
seconds of arc, Wirt Fly was
presented (3000 seconds of arc).
If undetectable Wirt Fly,
stereoacuity for the purposes of
analyses were taken to have a
value which was worse than
3000 seconds of arc. Standard
test procedure distance:
log-MAR was measured at 4m
and test distance adjusted as
appropriate for off-the-scale
measurements. Distance
log-MAR values were corrected
for test distance, but no
correction was made for the
reading and stereoacuity tests,
with patients using their habitual
distance or near-optical
correction as appropriate for
each test
Timing of baseline and follow-up
assessments: baseline (immediately
before randomisation) and 6 months
IQR, interquartile range.
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Outcome
Expedited surgery Routine surgery
Difference (control –
expedited surgery;
95% CI); p-valuea
Baseline
(n= 105)
6 months
(n=98)
Baseline
(n=103)
6 months
(n=94)
Primary clinical visual outcomes, mean (SD)
Binocular mean distance log-MARb 0.022 (0.101) −0.027 0.063 (0.127) 0.052 0.063 (0.035 to 0.090)c;
p< 0.0001
Binocular mean near-reading
log-MARc
0.28 (0.13) 0.23 0.29 (0.13) 0.27 0.047 (0.017 to 0.077)b;
p< 0.0029
Binocular mean Pelli–Robson
contrast sensitivityc
1.56 (0.15) 176 1.53 (0.16) 1.54 −0.21 (−0.25 to −0.17)b;
p< 0.0001
Stereoacuity, 3000 seconds of arc or
worse,d n/N (%)
64/105 (61) 12/98 (12) 73/103 (71) 66/94 (70) 58% (47 to 69%);
p< 0.0001
Monocular log-MAR acuity, mean difference (control – expedited surgery). Analysis of covariance adjusting for baseline
differences (unspecified)
Initially pseudophakic eye Not reported Not reported 0.025 (−0.004 to 0.054)
Initially cataractous eye Not reported Not reported 0.756 (0.650 to 0.861)
health-related quality of life
HRQoL Not reported Not reported
Primary self-reported outcomes, n/N (%)
Q2 – at least some difficulty reading
normal print
36/105 (35) 6/98 (6) 34/103 (34) 33/94 (36) 30% (19 to 41%);
p< 0.0001
Q5 – eyesight preventing activities
most or all of the time
11/105 (10) 0 9/103 (9) 10/94 (11) 11% (4.4 to17%);
p< 0.0001
Q11 – below average overall
vision
15/105 (14) 0 17/103 (17) 17/94 (18) 18% (10 to 26%);
p< 0.0001
Q30 – eyesight interfering with
life quite a lot or a great deal
27/105 (26) 1/98 (1) 26/103 (25) 24/94 (26) 25% (15 to 34%);
p< 0.0001
Complications, adverse events and comorbidities
Surgical complications,
sight threatening or requiring
further surgery
n= 9/98 (9%),
11 complications
Not reported
Vitreous loss 2 Not reported
Retinal detachment 1 Not reported
Cystoid macular oedema 3 Not reported
Iris prolapse 3 Not reported
Corneal oedema 1 Not reported
Implant failure with subsequent
secondary lens implantation
1 Not reported
Adverse events Not reported Not reported
Ocular comorbidities Not reported Not reported
Other comorbidities Not reported Not reported
SD, standard deviation.
a Mann–Whitney U-tests for ordinal variables, analysis of covariance (adjustment for baseline values) for
quantitative variables.
b The clinical importance of the significant differences in binocular acuity measures is only slight.
c From analysis of covariance adjusting for baseline (hence apparent discrepancies with observed differences between the means).
d Includes those with undetectable stereoacuity and those able to see Wirt fly only. Data reported for subjective vision
question were not data extracted.
Monocular distance log-MAR acuities for the initially pseudophakic eye did not change between baseline assessment and
follow-up in either group. The change in acuity between baseline and follow-up was not significantly different between the
groups (p= 0.30). No data for secondary outcomes were reported, but authors stated that there were no significant
differences for either of the two questions on whether their visual function was bothersome, the three reading speed
assessments or for any of the eight SF-36 health-profile dimensions. After Bonferroni corrections, Mann–Whitney U-tests
found statistically significant differences in 14/17 symptom questions, 2/2 visual function questions and 5/7 quality of life
questions in favour of the expedited-surgery group.
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Methodological comments
Allocation to treatment groups: random allocation was on a 1/1 basis in blocks of 20. Method of generating
random sequence not stated.
Allocation concealment: used numbered sealed opaque envelopes produced by members of the research team
not in contact with patients.
Masking: none reported.
Analysis by ITT: authors state that groups were compared at review on an ITT basis. Results were reported
without drop-outs.
Comparability of treatment groups at baseline: sociodemographic (only age and gender reported) and primary
outcomes were broadly similar between groups apart from mean binocular distance log-MAR. Authors state
that the difference of mean binocular distance log-MAR is equivalent to less than half a Snellen line (no
statistical comparison reported). There were also some baseline differences in subjective vision between the
groups. Baseline data for other secondary outcomes were not reported.
Method of data analysis: the distributions of several variables (sociodemographic factors, monocular visual
acuity and primary outcome variables) were compared at randomisation. Simple comparisons of the variables at
the time of the review were done with chi-squared, Mann-Whitney U-, and t-tests as appropriate, together
with relevant 95% CI for differences between the groups. For the quantitative outcomes, analyses of
covariance were used to adjust for baseline differences. For the (ordinal) questionnaire items, simple differences
(review-baseline) between the two groups were compared by the Mann-Whitney U-test. No correction for
multiple testing was applied to the eight primary outcomes. For the 39 secondary outcomes a Bonferroni
correction, which maintains a 5% overall significance level, would indicate that test-wise p-values should only
be regarded as significant if they fell below 0.0013. Authors reported that many of the visual-acuity
assessments were positively skewed, but suggested that numbers in the two groups were large enough to
allow parametric analyses for outcome comparisons.
Sample size/power analysis: stated only that with sample sizes of about 100 in each group, the trial was able to
detect differences of 15–20% in the proportions reporting various symptoms between the two groups,
with 80% power and a two-sided 5% significance level.
Attrition/drop-out: expedited surgery – one did not receive as allocated (did not receive early eye surgery due to
an administrative error), seven lost to follow-up (reasons not reported); routine surgery – one did not receive as
allocated (underwent second-eye surgery), nine lost to follow-up (reasons not reported).
General comments
Generalisability: limited to those with bilateral cataracts who had undergone successful cataract surgery in
one eye and had no other visually significant ocular pathology in either eye.
Inter-centre variability: not applicable.
Conflict of interests: not reported.
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Risk of bias assessment (for guidance refer to chapter 8 of the
Cochrane Handbook)
Domain Judgement Support for judgement
Random sequence generation? (Is the
method used to generate the allocation
sequence described in sufficient detail to
allow an assessment of whether or not it
should produce comparable groups?)
Unclear Random allocation [. . .] on a 1/1 basis in blocks of 20
Comment: it is unclear how random numbers were obtained
Allocation concealment? (Is the
method used to conceal the allocation
sequence described in sufficient detail
to determine whether intervention
allocations could have been foreseen in
advance of, or during, recruitment?)
Low Numbered sealed opaque envelopes . . . the envelopes were
produced by members of the research team not in contact
with patients
Detection bias: masking of outcome
assessors? (Which measures, if any,
were used to mask outcome assessors
from knowledge of which intervention
a participant received? Was any
information provided relating to whether
or not the intended masking
was effective?)
Unclear Comment: none reported
Performance bias: masking of
participants on self-reported
outcomes? (Which measures, if any,
were used to mask participants from
knowledge of which intervention they
received? Was any information provided
relating to whether or not the intended
masking was effective?)
High It is clearly impossible to mask the participants in this trial
(p. 928)
Comment: authors acknowledged the risk of bias from
differing expectation between those scheduled for early
surgery compared with those assigned to routine
waiting times
Incomplete outcome data addressed?
(How complete was the reporting of
outcome data for each main outcome,
including the numbers and reasons
for attrition and exclusions from
the analysis?)
Unclear Comment: reasons why patients were lost to follow-up were
not reported. Authors state that the two patients that did
not receive the allocated treatment (one in each group) had
a review assessment, but do not explain how the data were
dealt with, as one patient in the control group received
surgery and one in the expedited group did not. The
number of patients included in the review assessment
excluded drop-out. No statistical comparisons for results
with and without drop-outs were reported. Authors stated
that results were compared at review on an ITT basis,
but ITT was not defined
Free of selective reporting? (Is there
any evidence that outcomes were
measured but not reported, or were
reported incompletely, or in an
inappropriate format?)
High Comment: subjective vision questionnaire not mentioned in
the method section, limited data for secondary outcomes
reported and responses to two questions related to vision in
the right and left eyes were recoded. Stated no difference
between groups in change in primary questions scores from
baseline but data were not reported
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Appendix 5 List of potentially relevant clinical
effectiveness abstracts
Castells X, Comas M, Espallargues M, Castilla M, Garcia-Arumi J, Alonso J. Benefits of cataract surgeryin both eyes compared to surgery only in the first eye. A randomized controlled trial. International
Society of Technology Assessment in Health Care, 17th Annual Meeting; Building Bridges Between Policy,
Providers, Patients and Industry, 3–6 June 2001, Philadelphia, PA, USA.
Laidlaw D, Whitaker A, Hopper C, Marsh G, Donovan J, Peters T, et al. Results of a multi disciplinary
randomised controlled trial of the benefits of second-eye cataract surgery: Changes in visual symptoms and
function. Invest Opthalmol Vis Sci 1996;37:ARVO.
Whitaker A, Laidlaw D, Hopper C, Donovan J, Sparrow J, Harrad R. Improvement in stereoacuity after
second-eye cataract extraction: Subjective and objective assessment in a randomised controlled trial.
Invest Opthalmol Vis Sci 1996;37:ARVO.
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Appendix 6 List of excluded full-text clinical
effectiveness papers
Reference
Reason(s)
for exclusiona
Anstey KJ, Lord SR, Hennessy M, Mitchell P, Mill K, von Sanden C. The effect of cataract surgery on
neuropsychological test performance: a randomized controlled trial. J Int Neuropsychol Soc
2006;12:632–9
P, I, C
Bardocci A, Ciucci F, Lofoco G, Perdicaro S, Lischetti A. Pain during second-eye cataract surgery under
topical anesthesia: an intraindividual study. Graefes Arch Clin Exp Ophthalmol 2011;249:1511–14
P, D
Bellucci R, Pucci V, Morselli S, Bonomi L. Secondary implantation of angle-supported anterior chamber
and scleral-fixated posterior chamber intraocular lenses. J Cataract Refract Surg 1996;22:247–52
P, I, C, D
Boezaart A, Berry R, Nell M. Topical anesthesia versus retrobulbar block for cataract surgery:
the patients’ perspective. J Clin Anesth 2000;12:58–60
P, I, C
Lane SS, Javitt JC, Nethery DA, Waycaster C. Improvements in patient-reported outcomes and visual
acuity after bilateral implantation of multifocal intraocular lenses with +3.0 diopter addition: multicenter
clinical trial. J Cataract Refract Surg 2010;36:1887–96
P, I, C, D
Mitsonis CI, Mitropoulos PA, Dimopoulos NP, Mitsonis MI, Andriotis NM, Gitsa OE, et al. Anxiety and
depression in cataract surgery: a pilot study in the elderly. Psychol Reports 2006;99:257–65
D
Sach TH, Foss AJ, Gregson RM, Zaman A, Osborn F, Masud T, et al. Second-eye cataract surgery in
elderly women: a cost-utility analysis conducted alongside a randomized controlled trial. Eye
2010;24:276–83
O
Talbot EM, Perkins A. The benefit of second-eye cataract surgery. Eye 1998;12:983–9 D
Wormald R. Second-eye cataract surgery was beneficial in otherwise healthy patients.
Evidence-Based Med 1999;4:86
D
a Failure to meet one or more inclusion criteria for P= population; I= intervention; C= comparator; D= design
and O= outcomes.
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Appendix 7 Data extraction forms for
cost-effectiveness studies
1 Reference (lead author, year, ref ID)
Busbee and colleagues (2003)92; Brown and Brown (2004)93 (linked study).
1.1 Health technology
Second-eye cataract surgery.
1.2 Interventions and comparators
What interventions/strategies were included?
Second-eye cataract surgery.
Was a no treatment/supportive care strategy included?
Yes. Unilateral pseudophakia.
Describe interventions/strategies.
As above.
1.3 Research question
What are the stated objectives of the evaluation?
To perform a reference case cost–utility analysis of second-eye cataract surgery.
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1.4 Study type
Cost-effectiveness/cost–utility/cost–benefit analysis?
Cost–utility.
1.5 Study population
What definition was used for [condition]? What are the characteristics of the baseline cohort for
the evaluation?
722 patients from the US National Cataract PORT study, who were undergoing a cataract extraction (median
age 73 years).
1.6 Institutional setting
Where is/are the intervention(s) being evaluated usually provided?
Not reported, but assumed to be secondary care.
1.7 Country/currency
Has a country setting been provided for the evaluation? What currency are costs expressed in and does the
publication give the base year to which those costs relate?
US$, base cost year 2001, Busbee and colleagues (2003);92 2003 US$, Brown and colleagues (2004).93
1.8 Funding source
Supported in part by the Retina Research and Development Fund, Philadelphia (PA), USA, the Principals
Initiative Research Award, Kingston, Canada, and the Premier’s Award for Research Excellence,
Kingston, Canada.
1.9 Analytical perspective
What is the perspective adopted for the evaluation (health service, health and Personal Social Services,
third-party payer, societal (i.e. including costs borne by individuals and lost productivity)?
The analysis was performed from the perspective of a third-party insurer.
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2 Effectiveness
Were the effectiveness data derived from: a single study, a review/synthesis of previous studies or expert
opinion? Give the definition of treatment effect used in the evaluation. Give the size of the treatment
effect used in the evaluation.
Visual acuity data for patients undergoing cataract extraction were taken from the report of the US National
Cataract PORT. The post-operative visual acuity of the second-eye surgery was assumed to be equal to that of
the first eye, i.e. 20/27.
Complication rates associated with cataract extraction were taken from a previous study for initial cataract
surgery.96 Complications included in the model were PCO, endophthalmitis, cystoid macular oedema, lost lens
fragments, intraocular lens dislocation, pseudophakic bullous keratopathy, and PCO with subsequent
retinal detachment.
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3 Intervention costs
Were the cost data derived from: a single (observational) study, a review/synthesis of previous studies or
expert opinion? Were the methods for deriving these data adequately described (give sources if using
data from other published studies)? List the direct intervention costs and other direct costs used in the
evaluation – include resource estimates (and sources for these estimates, if appropriate) as well as sources
for unit costs used.
The health-care costs associated with each of the primary costs of cataract surgery and the costs of defined
cataract complications were derived from multiple sources.
The costs of ambulatory procedures and surgical procedures were obtained from US Medicare statistics for
2001 (reference no longer available). Drug expenditure costs associated with cataract surgery, including the
medical and post-operative managements, were obtained from the 2001 Drug Topics Red Book.120 When
multiple evidence-based treatment options were available for management of complications associated with
cataract surgery, an estimate of the costs for a certain complication was derived from the weighted average of
the costs relating to each treatment option.
Cost item Total costs
Busbee et al. (2003)92 Brown and
Brown (2004)93
Cataract surgery $2314 $2318
Posterior capsular opacification $231 $244
Endophthalmitis – tap and inject $844 $903
Endophthalmitis – pars plana vitrectomy $4735 $2536
Intraocular lens dislocation $2035 $1730
Intraocular lens dislocation with pars plana vitrectomy $4757 $2666
Cystoid macular oedema $201 $118
Pseudophakic bullous keratopathy – surgical $2763 $2750
Pseudophakic bullous keratopathy –medical $1319 $3076
Lost lens fragments $4573 $2295
Retinal detachment – scleral buckle $4700 $2551
Retinal detachment – vitrectomy $5118 $3223
3.1 Indirect costs (costs due to lost productivity, unpaid inputs to patient care)
Were indirect costs included?
No.
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4 Health state valuations/utilities (if study uses quality-of-life
adjustments to outcomes)
Were the utility data derived from: a single (observational) study, a review/synthesis of previous studies or
expert opinion. Were the methods for deriving these data adequately described (give sources if using data
from other published studies)?
Utility values were based on data from a large study of patients with ophthalmic disease.98 Utility values were
derived from patient preferences by using a TTO model. Utility values associated with subsequent good
visual acuity in both eyes after uneventful cataract extraction were based on a study that compared the utility
change from unilateral good vision (i.e. 20/25 or better in one eye) vs. bilateral good vision (i.e. 20/25 or better
vision in both eyes).99
4.1 List the utility values used in the evaluation
For the Busbee study,92 the utility value corresponding to unilateral pseudophakia was 0.858. The reference
case utility value for an ocular health state after second-eye cataract surgery was 0.967. These visual outcomes
for each complication after treatment, with the exception of PCO, were assigned a utility value of 0.858.
For PCO without retinal detachment, it was assumed that visual acuity returned to 20/27 in the operated eye,
and had a utility value of 0.97.
The Brown study93 uses slightly different utility values to those in Busbee and colleagues.92 The mean utility
associated with cataract surgery and 20/27 vision in one eye (with vision ≤ 20/40 in the second eye) is 0.86.
The mean utility when the visual acuity is 20/27 in both eyes is 0.97.
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5 Modelling
If a model was used, describe the type of model used (e.g. Markov state transition model, discrete event
simulation). Was this a newly developed model or was it adapted from a previously reported model?
If an adaptation, give the source of the original. What was the purpose of the model (i.e. why was a
model required in this evaluation)? What are the main components of the model (e.g. health states within
a Markov model)? Are sources for assumptions over model structure (e.g. allowable transitions)
reported – list them if reported.
A decision tree model was developed in TreeAge (TreeAge Software, Inc., Williamstown, MA, USA). The model
incorporated costs and consequences associated with second-eye cataract surgery compared with unilateral
pseudophakia (20/27), including complications associated with cataract surgery (over 4 months).
It was assumed that the theoretical patient presented with visual acuity in the pseudophakia eye equal to the
mean post-operative visual acuity reported by the PORT study, and that the post-operative visual acuity for
the second-eye surgery was equal to that of the first-eye surgery (20/27).
5.1 Extract transition probabilities for [natural history/disease progression]
model and show sources (or refer to table in text)
Posterior capsule opacification occurs at a rate of 28% over a five year post-operative period. The mean time of
treatment after surgery was assumed to be 2 years. Retinal detachment was assumed to occur at a rate of
0.81% after cataract surgery, at a mean time of 1 year after surgery. Retinal detachment repair after treatment
of PCO occurred three years after cataract surgery. Intraocular lens dislocation was assumed to occur at a rate
of 1.1% after cataract extraction.
Pseudophakic bullous keratopathy was assumed to occur at a rate of 0.3%, with a mean time to post-operative
treatment of 1 year after cataract extraction. PCO with subsequent retinal detachment was assumed to occur
at a 3.9-fold increase from the cumulative retinal detachment rate of 0.81%.
5.2 What is the model time horizon?
Lifetime.
5.3 What, if any, discount rates have been applied in the model? Same rate
for costs and outcomes?
An annual discount rate of 3% was used for costs and benefits.
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6 Results/analysis
What measure(s) of benefit were reported in the evaluation?
QALYs.
6.1 Provide a summary of the clinical outcome/benefits estimated for each
intervention/strategy assessed in the evaluation
In the Busbee study,92 second-eye cataract surgery resulted in 1.308 QALYs gained. Discounting the QALYs
gained by an annual 3% rate resulted in 0.92 QALYs gained over 12 years.
In the Brown study,93 second-eye cataract surgery resulted in 1.2 QALYs gained. Discounting the QALYs gained
by an annual 3% rate resulted in 0.9954 QALYs gained over 12 years.
6.2 Provide a summary of the costs estimated for each intervention/strategy
assessed in the evaluation
For the Busbee study,92 second-eye cataract surgery resulted in a total discounted health-care cost $2509.
There were no costs presented for unilateral pseudophakia.
For the Brown study,93 second-eye cataract surgery resulted in a total discounted health-care cost $2484.
6.3 Synthesis of costs and benefits – are the costs and outcomes reported together
(e.g. as cost-effectiveness ratios)? If so, provide a summary of the results
The cost–utility of second-eye cataract surgery in Busbee and colleagues was $2727 per QALY gained.92
The cost–utility of second-eye cataract surgery in Brown and Brown was $2,495 per QALY gained.93
6.4 Give results of any statistical analysis of the results of the evaluation
Not applicable.
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6.5 Was any sensitivity analysis performed – if yes, what type(s)
[i.e. deterministic (one-way, two-way, etc.) or probabilistic]
One-way sensitivity analysis.92
6.6 What scenarios were tested in the sensitivity analysis? How do these
relate to structural uncertainty (testing assumptions over model structure
such as relationships between health states), methodological uncertainty
(such as choices of discount rate or inclusion of indirect costs) or parameter
uncertainty (assumptions over values of parameters in the model, such as
costs, quality of life or disease progression rates)?
One-way sensitivity analysis was performed by varying utility values, costs, and discounting rates.92
6.7 Give a summary of the results of the sensitivity analysis – did they differ
substantially from the base case analysis. If so, what were the suggested causes?
Increasing discounted costs by 25% resulted in $3408 per QALY gained (Busbee and colleagues, 2003),92
whereas decreasing the costs by 25% resulted in $2045 per QALY gained. When all utility values were
increased by 25%, the cost-effectiveness was $2182 per QALY gained. By decreasing all utility values by 25%,
the cost-effectiveness was $3646 per QALY gained. Varying the annual discount rate resulted in $1918 per QALY
gained for a 0% rate, $3445 per QALY gained for a 5% rate, and $5964 per QALY gained for a 10% rate.
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7 Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
The authors concluded that second-eye cataract surgery is an extremely cost-effective procedure.
7.1 What are the implications of the evaluation for practice?
Not reported.
8 SHTAC commentary
Selection of comparators:
Appropriate, based upon a US cataract study.
Validity of estimate of measure of benefit:
Appropriate, although not based upon systematic review. Utility values taken from a study of patients with
ophthalmic disease not specifically just cataracts. They also assume the same visual acuity benefit from the
second-eye surgery as for the first eye, and it is unclear how valid this assumption is.
Validity of estimate of costs:
Appropriate, all costs appear to have been included (US health care).
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1 Reference (lead author, year, ref ID)
Räsänen and colleagues (2006).90
1.1 Health technology
Second-eye cataract surgery.
1.2 Interventions and comparators
What interventions/strategies were included?
Cataract surgery.
Was a no treatment/supportive care strategy included?
Yes – described as a ‘hypothetical situation of no treatment’ using age and sex matched controls from the
general population based on data from a nation-wide survey.
Describe interventions/strategies.
Group A – only one eye was operated (n= 87).
Group B – both eyes were operated during the follow-up (n= 73).
Group C – first eye had been operated earlier, now the second eye was operated (n= 59).
Group C is of most relevance to this HTA as it allows a comparison between first and second-eye surgery. Data
for all groups are extracted here for completeness.
1.3 Research question
What are the stated objectives of the evaluation?
To evaluate the cost-utility of cataract surgery compared with a hypothetical situation of no treatment by
studying unselected patients referred by practicing ophthalmologists for a routine cataract operation to a large
university clinic because of objective signs of poor visual acuity.
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1.4 Study type cost-effectiveness/cost–utility/cost–benefit analysis?
Cost–utility.
1.5 Study population
What definition was used for [condition]? What are the characteristics of the baseline cohort for
the evaluation?
386 patients scheduled for routine cataract operation (219 available for final analysis). Mean age varied from
69 to 75 years across the three subgroups. Percentage female varied from 56 to 71 years across the groups.
Patients with no or only minor subjective pre-operative seeing problems at baseline (levels 1 and 2 of the
seeing dimension of the 15D): n= 140 (64%).
Patients with significant subjective pre-operative seeing problems at baseline (levels 3 to 5 of the seeing
dimension of the 15D): n= 79 (36%).
Compared with age- and gender-matched general population based on data from a nationwide survey,
cataract patients were pre-operatively statistically significantly worse off on the dimensions seeing, moving,
sleeping, usual activities, depression and distress, but better off on the dimension of mental function.
Best corrected visual acuity in the surgical eye and the non-surgical eye prior to cataract surgery in groups A–C:
group A, group B, group C, respectively.
Mean (SD) best corrected visual acuity in the surgical eye:
Snellen 0.19 (0.14); 0.17 (0.12); 0.24 (0.14)
Log-MAR 0.98 (0.66); 0.94 (0.49); 0.76 (0.48)
Differences between the groups (A, B, C) not statistically significant.
Mean (SD) best corrected visual acuity in the non-surgical eye:
Snellen 0.58 (0.23); 0.28 (0.16); 0.63 (0.25)
Log-MAR 0.29 (0.22); 0.65 (0.37); 0.25 (0.21)
A versus B p< 0.001
B versus C p< 0.001.
SD, standard deviation.
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1.6 Institutional setting where is/are the intervention(s) being evaluated
usually provided?
Helsinki University Eye Hospital.
1.7 Country/currency
Has a country setting been provided for the evaluation? What currency are costs expressed in and does the
publication give the base year to which those costs relate?
Finland is the country where the study was set. The currency is euros and the cost data were from 2002–3
(to coincide with when effectiveness data were collected).
1.8 Funding source
Funded by research grants from the Helsinki and Uusimaa Hospital Group.
1.9 Analytical perspective
What is the perspective adopted for the evaluation (health service, health and personal social services,
third-party payer, societal (i.e. including costs borne by individuals and lost productivity)?
Perspective of the secondary health-care provider.
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2 Effectiveness
Were effectiveness data derived from: a single study, a review/synthesis of previous studies or expert
opinion? Give the definition of treatment effect used in the evaluation. Give the size of the treatment
effect used in the evaluation.
Effectiveness was estimated from the 15D generic 15-dimensional, standardised HRQoL instrument.
Patients completed the 15D at baseline and then again approximately 6 months after the cataract operation.
Best corrected visual acuity was measured before the operation in both eyes by Snellen notation at
6metres. Best corrected visual acuity was not measured after surgery but the authors suggest that they
have no reason to doubt it would have improved in most of the patients.
The only statistically significant increase in the individual dimensions of the 15D was for ‘seeing’,
observed across all three subgroups.
Changes in utility scores for the individual domains are presented according to severity of HRQoL (levels 1 and
2 vs. levels 3 to 5 of the scoring dimension). They are given for the whole study rather than the three
subgroups and, therefore, data have not been extracted.
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3 Intervention costs
Were the cost data derived from: a single (observational) study, a review/synthesis of previous studies or
expert opinion? Were the methods for deriving these data adequately described (give sources if using
data from other published studies)? List the direct intervention costs and other direct costs used in the
evaluation – include resource estimates (and sources for these estimates, if appropriate) as well as sources
for unit costs used.
Direct health-care costs were obtained from the Ecomed® clinical patient administration system (Datawell Ltd,
Espoo, Finland), where all costs of treatment of individual patients in the hospital are routinely stored. Costing
covered all relevant specialty-related costs including pre- and post-operative outpatient visits to the eye hospital.
However, the costs of the visits to the referring ophthalmologists who were usually also responsible for the
post-operative re-examination of the patients and prescription of eyeglasses, was not included in the analysis.
Indirect costs, like period of disability, were not included.
Mean (SD) hospital costs at 6 months:
Group A= €1318 (184)
Group B= €2289 (266)
Group C= €1323 (361)
Whole sample= €1261 (246).
No other cost or resource estimates reported.
SD, standard deviation.
Indicate the source for individual cost values (if appropriate).
3.1 Indirect costs (costs due to lost productivity, unpaid inputs to
patient care)
Were indirect costs included:
Not included.
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4 Health state valuations/utilities (if study uses quality-of-life
adjustments to outcomes)
Were the utility data derived from: a single (observational) study, a review/synthesis of previous studies or
expert opinion. Were the methods for deriving these data adequately described (give sources if using data
from other published studies)?
As above under ‘2 Effectiveness’, HRQoL was estimated directly through patients completing the 15D
questionnaire before and after surgery.
The generic, 15-dimensional, standardised, self-administered HRQoL instrument can be used both as a profile
and a single index utility score measure. The 15D questionnaire consists of 15 dimensions: moving, seeing,
hearing, breathing, sleeping, eating, speech, eliminating, usual activities, mental function, discomfort and
symptoms, depression, distress, vitality and sexual activity. For each dimension, the respondent must choose
one of the five levels that best describes his/her state of health at the moment (the best level= 1;
the worst level= 5). The valuation system of the 15D is based on an application of the multiattribute utility
theory. A set of utility or preference weights, elicited from the general public through a three-stage valuation
procedure, is used in an additive aggregation formula to generate the utility score, i.e. the 15D score
(single index number) over all the dimensions. The maximum score is 1 (no problems on any dimension),
and minimum score 0 (equal to being dead). In most of the important properties the 15D compares favourably
with other instruments of that kind (references given).
The HRQoL gain was assumed to last till the end of the remaining statistical life expectancy of each patient
based on life tables from 2002 from Statistics Finland.
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4.1 List the utility values used in the evaluation
Whole sample, mean (SD)
HRQoL baseline= 0.82 (0.13)
HRQoL 6 months= 0.83 (0.14)
HRQoL difference= 0.01
p-value not stated, but reported to be statistically insignificant.
Group A, mean (SD)
HRQoL baseline= 0.85 (0.13)
HRQoL 6 months= 0.85 (0.14)
HRQoL difference= 0.00 (0.14); p= 0.852.
Group B, mean (SD)
HRQoL baseline= 0.80 (0.13)
HRQoL 6 months= 0.83 (0.14)
HRQoL difference= 0.03 (0.14); p=< 0.001.
Group C, mean (SD)
HRQoL baseline= 0.82 (0.11)
HRQoL 6 months= 0.81 (0.13)
HRQoL difference= –0.01 (0.07); p= 0.279.
SD, standard deviation.
Indicate the source for individual cost values (if appropriate).
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5 Modelling
If a model was used, describe the type of model used (e.g. Markov state transition model, discrete event
simulation). Was this a newly developed model or was it adapted from a previously reported model? If an
adaptation, give the source of the original. What was the purpose of the model (i.e. why was a model
required in this evaluation)? What are the main components of the model (e.g. health states within a
Markov model)? Are sources for assumptions over model structure (e.g. allowable transitions) reported –
list them if reported.
Analysis of a prospective HRQoL study, rather than a model.
5.1 Extract transition probabilities for [natural history/disease progression]
model and show sources (or refer to table in text)
Not applicable.
5.2 What is the model time horizon?
Lifetime.
5.3 What, if any, discount rates have been applied in the model? Same rate
for costs and outcomes?
5% for outcomes.
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6 Results/analysis
What measure(s) of benefit were reported in the evaluation?
QALYs.
6.1 Provide a summary of the clinical outcome/benefits estimated for each
intervention/strategy assessed in the evaluation
Mean (SD) QALYs gained
Group A= 0.1605 (0.9421)
Group B= 0.4464 (1.1966)
Group C= –0.0219 (0.7424).
SD, standard deviation.
6.2 Provide a summary of the costs estimated for each intervention/strategy
assessed in the evaluation
See ‘3 Intervention costs’ above.
6.3 Synthesis of costs and benefits – are the costs and outcomes reported
together (e.g. as cost-effectiveness ratios)? If so, provide a summary of
the results
Mean cost per QALY gained
Group A= €8212
Group B= €5128
Group C= not estimated (negative utility change)
Whole cohort= €7947.
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6.4 Give results of any statistical analysis of the results of the evaluation
10,000 re-samples from the original stochastic cost–utility data set were simulated using a
bootstrapping technique.
6.5 Was any sensitivity analysis performed – if yes, what type(s) (i.e. deterministic
(one-way, two-way, etc.) or probabilistic)
Deterministic one-way sensitivity analyses.
6.6 What scenarios were tested in the sensitivity analysis? How do these
relate to structural uncertainty (testing assumptions over model structure
such as relationships between health states), methodological uncertainty
(such as choices of discount rate or inclusion of indirect costs) or parameter
uncertainty (assumptions over values of parameters in the model, such as
costs, quality of life or disease progression rates)?
Base case analysis using median values:
Discount rate variation (5%, 3%, 1%)
Upper and lower 95% CI of the QALY gain
Upper and lower 95% CI of the treatment costs.
6.7 Give a summary of the results of the sensitivity analysis – did they
differ substantially from the base case analysis. If so, what were the
suggested causes?
Authors state that the results of the one-way sensitivity analysis were relatively robust when varying costs and
treatment effectiveness, but use of median values substantially increased the cost/QALY in the group of
patients whose first eye had been operated on earlier (presume this is a mistake as the group mentioned –
group C – did not have a cost per QALY estimated due to negative change in HRQoL. Presume they mean
group A where cost per QALY increased from €8212 to €39,188).
Bootstrap simulation suggested that compared with no treatment, surgery was more costly and less effective in
46.4% of simulated cases, and more costly and more effective in 53.6% of simulated cases in subgroup A
(quadrant I vs. quadrant II in figure 7). The corresponding percentages were 37.9% and 62.1% in subgroup B
(figure 8), and 51.1% and 48.9% in subgroup C (figure 9), respectively. Bootstrap sensitivity analysis also
suggested that at a willingness to pay threshold of €20,000 per QALY gained, the probability of cataract surgery
being acceptable was 51.7% in subgroup A, 59. 0% in subgroup B and 46. 4% in subgroup C (figure 10).
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7 Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
The utility gain from cataract surgery was small and confined to an improvement in seeing only.
Possible explanations: two-thirds of patients reported only minimal pre-operative subjective seeing problems
despite objective evidence of poor visual acuity in the surgical eye; the ‘real-world’ setting of a university clinic
and its ‘mixed sample’; one-third of patients had a secondary ophthalmic diagnosis (which might reduce the
benefit of surgery); potential insensitivity of the 15D to measure changes in HRQoL (it includes only one
question relating to sight).
7.1 What are the implications of the evaluation for practice?
The authors do not explicitly state practice implications. From the results it would seem that single eye or
bilateral eye cataract surgery is cost-effective (according to current willingness to pay thresholds). Second-eye
surgery does not appear to be cost-effective due to an apparent reduction in quality of life following
second-eye surgery.
8 Southampton Health Technology Assessments
Centre commentary
Selection of comparators:
Comparison of first- and second-eye surgery in this study comes from a single group of patients (group C),
rather than comparing one group who only had first-eye surgery with a separate group who had second-eye
surgery. It could be that their subjective assessment of HRQoL following second-eye surgery was confounded
by the benefit they derived from the first operation, such that the independent effect of second-eye surgery
cannot be estimated.
Validity of estimate of measure of benefit:
The authors acknowledge the limitations of translating measured visual acuity into utility values, and justify why
measuring HRQoL from patients directly might better reflect utility gain from cataract surgery. The 15D generic
HRQoL instrument is described by the authors, but they do not state whether or not it has been validated.
It’s potential insensitivity to changes in HRQoL related to eye conditions are acknowledged by the authors
(discussed above).
Validity of estimate of costs:
Relatively little detail is given on cost estimation.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
148
1 Reference (lead author, year, ref ID)
Sach and colleagues (2010).91
1.1 Health technology
Second-eye cataract surgery.
1.2 Interventions and comparators
What interventions/strategies were included?
Second-eye cataract surgery.
Was a no treatment/supportive care strategy included?
Yes, waiting list controls.
Describe interventions/strategies.
Patients were randomised to immediate second-eye cataract surgery (median time to surgery 30 days) or no
surgery (‘waiting list controls’ median time to surgery 216 days; range 37–527 days).
1.3 Research question
What are the stated objectives of the evaluation?
To evaluate the cost-effectiveness of second-eye cataract surgery for older women with minimal dysfunction in
the eye to be operated on, compared with waiting list controls who had already undergone first-eye
cataract surgery.
1.4 Study type cost-effectiveness/cost–utility/cost–benefit analysis?
Cost–utility.
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1.5 Study population
What definition was used for [condition]? What are the characteristics of the baseline cohort for
the evaluation?
Women over 70 years of age who had previously had successful first-eye cataract surgery and who had a
second operable cataract. Women were excluded if they had complex cataracts or other visual comorbidities.
Most participants (86%) had good vision in the eye to be operated upon (baseline Snellen acuity of 6/12
or better).
1.6 Institutional setting where is/are the intervention(s) being evaluated
usually provided?
Secondary care (ophthalmology clinic).
1.7 Country/currency
Has a country setting been provided for the evaluation? What currency are costs expressed in and does the
publication give the base year to which those costs relate?
UK, all costs were UK pounds and the price year was 2004 (inflated using the Hospital and Community Health
Services Inflation Index, where necessary).
1.8 Funding source
Trent Regional NHS Research and Development Scheme and the Public – Private Partnerships Foundation
(now the Health Foundation).
1.9 Analytical perspective
What is the perspective adopted for the evaluation (health service, health and PSS, third-party payer,
societal (i.e. including costs borne by individuals and lost productivity)?
UK NHS and PSS. (Carer costs were included in a separate analysis).
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2 Effectiveness
Were the effectiveness data derived from: a single study, a review/synthesis of previous studies or expert
opinion? Give the definition of treatment effect used in the evaluation. Give the size of the treatment
effect used in the evaluation.
The clinical evidence was from a published RCT.83 The trial consisted of 229 women, with 116 in the
intervention group and 113 in the control group. Patients were followed up for 1 year. The trial provided data
for quality of life for the economic evaluation. Other trial outcomes such as improvements in visual function
were not included in the model.
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3 Intervention costs
Were the cost data derived from: a single (observational) study, a review/synthesis of previous studies or expert
opinion? Were the methods for deriving these data adequately described (give sources if using data from other
published studies)? List the direct intervention costs and other direct costs used in the evaluation – include
resource estimates (and sources for these estimates, if appropriate) as well as sources for unit costs used.
Costs were derived from the Foss and colleagues RCT.83 Patient diaries were used to collect individual patient
level data on all contacts with health and social services, including care home admission, informal care,
equipment and home modifications. Data were collected at 3 and 9 months through telephone interviews and
at 6 and 12 months through face-to-face interviews.
Lifetime costs were estimated by using a life expectancy from UK government life tables. Annual costs for the
control group were assumed to remain constant in subsequent years as that observed in the trial period. Costs
in the final three-quarters of the year were rescaled to better reflect costs over a full year without a cataract
operation for the intervention group. As with the control group, these costs were assumed to remain constant
over the remaining lifespan.
TABLE A Base case unit costs
Resource item Unit cost (£) Source
Primary health care
GP (per surgery consultation lasting 9.36 minutes) 21 PSSRU
Practice nurse/district nurse (per consultation) 9 PSSRU
Secondary health care
A&E (per visit) 83 PSSRU
Outpatients first visit (geriatric medicine) 222 DH
Outpatients follow-up visit (geriatric medicine) 125 DH
Cost per bed day for elderly patients 166 PSSRU
Cataract operation 672 DH
Lower limb fractures (day case) 777 DH
Upper limb fractures (day case) 858 DH
PSS
Local authority home care worker (per visit) 12 PSSRU
Day centre visits (per visit) 29 PSSRU
Short-term residential care (per day) 56 PSSRU
Long-term residential care (per day) 53 PSSRU
Short-term nursing home (per day) 73 PSSRU
Long-term nursing home (per day) 75 PSSRU
Meals on wheels (per meal) 2.60 Wiltshire foods
Special equipment (per item) 4.10–499 Varied
Patient and carer
Home care (per visit) 10 PSSRU
Average net weekly earnings 320.95 NES
A&E, accident and emergency; DH, Department of Health; NES, New Earnings Survey 2003 (inflated to 2004
wage rates).
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TABLE B Mean cost (£) per patient over 12 months for second-eye cataract surgery and no second-eye
cataract surgery
Resource use item Surgery No surgery Difference
Secondary health care 1590 632 958
Cataract operation 672 30 643
Non-cataract-related outpatients 544 291 252
Bed-days 329 297 32
A&E 24 7 17
Lower limb fracture 13 7 7
Upper limb fracture 7 0 −7
Primary health care 138 110 28
GP 93 84 9
Practice/district nurse 45 26 18
PSS 411 750 −340
LA home care worker 241 235 5
Day centre visits 62 117 55
Residential care 45 321 −275
Nursing home 7 0 −7
Meals on wheels 31 53 22
Special equipment 25 24 −1
Patient and carer 575 364 210
Home care 539 313 226
Carer time 36 52 −16
A&E, accident and emergency; LA, local authority.
3.1 Indirect costs (costs due to lost productivity, unpaid inputs to patient care)
Were indirect costs included:
Carer costs were excluded from the base case.
Table shows mean cost (£) per patient over 12 months for second-eye cataract surgery and no second-eye
cataract surgery.
Resource use item Surgery No surgery Difference
Patient and carer 575 364 210
Home care 539 313 226
Carer time 36 52 −16
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4 Health state valuations/utilities (if study uses quality-of-life
adjustments to outcomes)
Were the utility data derived from: a single (observational) study, a review/synthesis of previous studies or
expert opinion. Were the methods for deriving these data adequately described (give sources if using data
from other published studies)?
Patients’ quality of life was estimated using the EuroQoL EQ-5D administered at baseline and at 6 months from
the Foss and colleagues’ trial.83 Area under the curve analysis was performed to take account of the baseline in
estimating the number of QALYs for a single year period. It was assumed that utility remained constant over
the remaining lifetime for both groups.
4.1 List the utility values used in the evaluation
EuroQoL EQ-5D, Foss et al. (2006)83 Baseline 6 months
Expedited second eye 0.74 0.73
Unoperated second eye (control) 0.72 0.69
Difference + 0.02 + 0.04
The time course of the gain in HRQoL was assumed to occur at 1 month after surgery in the base case.
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5 Modelling
If a model was used, describe the type of model used (e.g. Markov state transition model, discrete event
simulation). Was this a newly developed model or was it adapted from a previously reported model?
If an adaptation, give the source of the original. What was the purpose of the model (i.e. why was a
model required in this evaluation)? What are the main components of the model (e.g. health states
within a Markov model)? Are sources for assumptions over model structure (e.g. allowable transitions)
reported – list them if reported.
Trial-based economic analysis rather than a model.
5.1 Extract transition probabilities for [natural history/disease progression]
model and show sources (or refer to table in text)
Not applicable.
5.2 What is the model time horizon?
One year and lifetime.
5.3 What, if any, discount rates have been applied in the model? Same rate
for costs and outcomes?
3.5% for benefits and costs in the lifetime analysis only.
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6 Results/Analysis
What measure(s) of benefit were reported in the evaluation?
QALYs.
6.1 Provide a summary of the clinical outcome/benefits estimated for each
intervention/strategy assessed in the evaluation
Over 1 year, the mean difference in QALYs per patient in the base case was 0.015. For the lifetime analysis, the
mean difference in QALYs was 0.074.
6.2 Provide a summary of the costs estimated for each intervention/strategy
assessed in the evaluation
The mean total cost per patient (excluding carer time cost) in the operated group was £2139 compared with
£1492 in the control group. The mean total cost per patient for the lifetime analysis was £12,171 and £10,887
for the operated and control group, respectively.
6.3 Synthesis of costs and benefits – are the costs and outcomes reported
together (e.g. as cost-effectiveness ratios)? If so, provide a summary of
the results
The ICER for surgery in the base case was £44,263 per QALY gained. The long-term ICER was £17,299 per
QALY gained.
6.4 Give results of any statistical analysis of the results of the evaluation
Non-parametric bootstrap analysis was undertaken to produce CEACs.
6.5 Was any sensitivity analysis performed – if yes, what type(s)
(i.e. deterministic (one-way, two-way, etc.) or probabilistic)
Deterministic and probabilistic sensitivity analyses. Threshold analyses also conducted.
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6.6 What scenarios were tested in the sensitivity analysis? How do these
relate to structural uncertainty (testing assumptions over model structure
such as relationships between health states), methodological uncertainty
(such as choices of discount rate or inclusion of indirect costs) or parameter
uncertainty (assumptions over values of parameters in the model, such as
costs, quality of life or disease progression rates)?
Assumptions were tested regarding the time to quality of life improvement after surgery (immediately after
surgery to gradually over 6 months), discount rates (0 and 5%) and whether carer costs were included.
6.7 Give a summary of the results of the sensitivity analysis – did they differ
substantially from the base case analysis. If so, what were the
suggested causes?
Changing the assumptions about the time course of quality of life improvement after surgery, or the discount
rate, had little effect on conclusions. The unit cost threshold for the cataract operation itself, at which the ICER
fell beneath £30,000 was £454 (68% of the actual cost) for the trial period analysis.
7 Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
Although second-eye cataract surgery improves visual disability and general status, it is not likely to be
cost-effective in the short-term for those with mild visual dysfunction pre-operation. In the long term,
second-eye cataract surgery appears to be cost-effective unless carer costs are included.
7.1 What are the implications of the evaluation for practice?
Second-eye surgery appears to be a cost-effective treatment on the basis of the lifetime analysis.
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8 SHTAC commentary
Selection of comparators:
Appropriate.
Validity of estimate of measure of benefit:
Appropriate, based upon EQ-5D elicited from cataract patients directly in a RCT. The authors discuss the
potential limitations of using EQ-5D to assess cataract surgery, including possible lack of precision and
responsiveness making it hard to detect small changes. EQ-5D does not incorporate sensory function in its
descriptive system.
The authors also suggest their results are conservative due to the assumption that the difference in quality of
life between intervention and control being constant over the lifetime whereas one would expect some
deterioration in the control group in utility over time (mean utility declined from 0.72 to 0.69 in the 6-month
period used to measure utility in the study).
Validity of estimate of costs:
Appropriate and based upon UK patients. The costs of treating adverse events are not included.
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Appendix 8 List of excluded full-text
cost-effectiveness papers
Excluded study
Hiratsuka Y, Yamada M, Murakami A, et al. Cost-effectiveness of cataract surgery in Japan.
Jpn J Ophthalmol 2011;55:333–42.
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Appendix 9 Data extraction forms for
HRQoL studies
Reference (lead author, year, ref ID)
Clark and colleagues (2008).105
Study characteristics
Research question
What are the stated objectives of the study?
To determine if post-operative endophthalmitis adversely affects quality of life after cataract surgery.
Describe the type of study and study design.
Case–control study (prospective).
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease, and (iv) other?
Cataract patients who developed post-operative endophthalmitis.
What are the characteristics of the baseline cohort for the evaluation?
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Age Years, mean (SD)a:
Cases= 81.2 (8.5)
Controls= 76.60 (11.5)
Sex Male, N (%)a:
Cases= 6 (32)
Controls= 8 (27)
Race (if appropriate) Not stated
Indication/disease (e.g. presence or
absence of comorbidities)
Cataract patients who developed post-operative endophthalmitis within
1 month following cataract surgery (cases). The controls were patients with
uncomplicated cataract surgery, randomly selected
Baseline clinical vision Not reported
Other characteristics (sample size) Cases= 19
Controls= 30
QoL instrument (state when
administered)
EQ-5D
TTO
VFQ-25
Instruments administered 12 months post surgery. Cases were interviewed,
controls received questionnaires
Utility values Baseline values not collected
Treatment effect, if reported
(e.g. clinical vision measures)
The proportion of cases with post-operative VA < 6/12 in their operated
eye was significantly more than the comparison group (p= 0.01)
(authors consider VA < 6/12 to indicate vision impairment)
Degree of vision loss, n (%):
No visual impairment:
Cases= 9 (47)
Controls= 25 (83)
Unilateral visual impairment:
Cases= 9 (47)
Controls= 3 (10)
Bilateral visual impairment:
Cases= 1 (6)
Controls= 2 (7)
p= 0.009 (Fisher’s exact test)
SD, standard deviation; VA, visual acuity.
a 12-month post-operative data [baseline (pre-operative) data not collected].
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Country/setting
What is the country and setting for the evaluation?
Australia.
Data sources
Effectiveness
Were the quality of life data derived from: a single (observational) study, a review/synthesis or combination
of previous studies, expert opinion?
Case–control study, as above.
Results
Summarise the results
EQ-5D summary score, mean (SD):
Cases= 0.66 (0.32)
Controls= 0.81 (0.25).
Mean difference= 0.15.
p= 0.08.
Of the five EQ-5D subscales, the only statistically significant difference between cases and controls was for the
mobility subscale (p= 0.03) (further detail on EQ-5D sub-scales reported but not extracted here).
TTO, mean (SD):
Cases= 0.90
Controls= 0.96.
Mean difference= 0.06.
p= 0.12.
VFQ-25: cases generally had a statistically significant lower composite score than controls (p= 0.01), and a
statistically significant lower score for 5 of the 11 subscales after adjusting for age, sex and visual acuity in the
better eye (full data not extracted here).
SD, standard deviation.
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Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
Post-operative endophthalmitis following cataract surgery results in poorer patient perceived vision-related
quality of life compared with uncomplicated cataract surgery, irrespective of visual acuity. However,
no statistically significant effect upon general HRQoL was found. The authors suggest this is due to a
combination of a small sample size and the relative insensitivity of the EQ-5D and TTO for detecting more
subtle vision-related impacts on quality of life as detected by the VFQ-25.
What are the implications of the study for the model?
The difference in utility between patients with post-operative endophthalmitis and patients with uncomplicated
surgery (ranging from 0.06 to 0.15 TTO and EQ-5D, respectively) can be potentially used in the model to take
account of adverse events on HRQoL following treatment. However, it should be noted that the EQ-5D and the
TTO may be insensitive to changes in QoL following cataract surgery.
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Reference (lead author, year, ref ID)
Datta and colleagues (2008).40
Study characteristics
Research question
What are the stated objectives of the study?
To determine which factors contribute most to quality of life among elderly women patients with pre-operative
bilateral cataracts, and which visual factors best explain change in quality of life over time.
Describe the type of study and study design.
RCT.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease, (iv) other?
Patients with bilateral cataracts.
What are the characteristics of the baseline cohort for the evaluation?
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Age Years
Median= 78
Minimum= 70
Maximum= 94
Sex 100% female
Race (if appropriate) Not stated
Indication/disease (e.g. presence or
absence of comorbidities)
Comorbid diagnoses, n
Median= 8
Minimum= 4
Maximum= 11
Baseline clinical vision Entire sample (n= 306 randomised)
Spectacle-corrected
visual acuity (log-MAR)
Contrast sensitivity
(Pelli–Robson)/
log-contrast
Stereopsis
(1–5)a
Median 0.28 1.35 1
Minimum −0.08 0.05 1
Maximum 0.96 1.95 5
Randomised study groupsb (subset of patients completing baseline and
6-month assessments)
Expedited first-eye
surgery (n= 148)
Unoperated first
eye (n= 140)
Mean
Unaided VA 0.51 0.56
Spectacles VA 0.30 0.29
Pinhole VA 0.21 0.22
Contrast sensitivity (dB) 1.37 1.39
Depth perception
(5-point scale)
1.71 2.03
VA, visual acuity.
VA reported in log-MAR units.
Other characteristics (sample size) 306 women randomised – 154 allocated to expedited (within a month of
randomisation) first-eye surgery, 152 allocated to routine (12-month wait)
surgery (control)
Authors describe the study population as moderately frail, and half had
fallen in the year before randomisation. Heart problems were reported by
31%, chest problems by 20%, arthritis by 76% and history of stroke by 7%
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QoL instrument (state when
administered)
EQ-5D
London Handicap Scale (data not extracted here)
VF-14 (data not extracted here)
Activities of daily living (Barthel Index) (data not extracted here)
Administered at baseline and 6 months after randomisation
Utility values EQ-5D
Entire sample
Median (0–1.0) (transformed)= 0.73 (0.26)
Minimum= –0.08 (0.0)
Maximum= 1.0 (0.32)
(The EuroQoL scores varied from –0.08 to 1.0, and they were transformed by
the equation: transformed EuroQoL= log10 (Baseline EuroQoL+ 1.08),
1.08 being a constant added to give positive scores for logarithmic function.
This substantially improved kurtosis and skew)
Expedited first-eye surgeryb
Mean= 0.70
Unoperated first eyeb
Mean= 0.70
Treatment effect, if reported
(e.g. clinical vision measures)
Expedited
first-eye
surgery
(n= 148)
Unoperated
first eye
(n= 140)
Mean
difference 95% CI p-valueMean
Unaided VA 0.22 0.56 −0.32 −0.27 to
–0.36
< 0.0005
Spectacles VA 0.10 0.35 −0.25 −0.22 to
–0.29
< 0.0005
Pinhole VA 0.09 0.26 −0.17 −0.14 to
–0.19
< 0.0005
Contrast
sensitivity (dB)
1.55 1.33 0.23 0.18 to
0.27
< 0.0005
Depth
perception
(5-point scale)
1.47 2.24 0.62 0.41 to
0.83
< 0.0005
VA, visual acuity.
Mean difference adjusted for baseline values.
a Ordinal category from 150 (seconds of arc), 300, 600, Wirt able, Wirt unable.
b Data are from Harwood et al. (2005)4 (not included in the HRQoL review, but sourced separately to provide additional
information lacking from the Datta et al. (2008)40 publication).
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Country/setting
What is the country and setting for the evaluation?
UK.
Data sources
Effectiveness
Were quality of life data derived from: a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
RCT, as above.
Results
Summarise the results.
EQ-5D at 6 months.
Entire sample:
Median (0–1.0) (transformed)= 0.73 (0.26)
Minimum=−0.24 (0.08)
Maximum= 1.0 (0.32).
(NB: The above figures appear to be based on the whole trial population, half of which were patients who had not
yet received their cataract surgery. They are also near identical to baseline values. For this reason they are not very
useful for estimating change in quality of life following surgery, but have been reported here for completeness).
Authors report that no visual variables were significantly associated with EuroQoL, based on univariate and
multivariate linear regression.
Expedited first-eye surgery Unoperated first eye
Mean difference 95% CI p-valueMean
EQ-5D 0.73 0.67 0.06 0.01 to 0.11 0.02
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
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Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
Authors describe a ‘weak and inconsistent effect of visual factors on EuroQoL’. They suggest that the lack of
responsiveness of the EuroQoL to clinically significant changes in vision make it an inadequate instrument
for measurement of vision-related quality of life.
From the main results of the RCT4 the authors suggest that first-eye surgery is associated with ‘large’ gains in
visual function and these changes are accompanied by improvements in quality of life. Referring specifically to
the EQ-5D they go on to say that ‘although we did demonstrate changes on this scale, they were small in
magnitude, and suggest that this scale is insufficiently sensitive to change for this intervention (by virtue of its
content)’ [p. 58 of Hartwell et al. (2005)].4
What are the implications of the study for the model?
The statistically significant mean EQ-5D difference between operated and unoperated patients (0.06) (which
is accompanied by an improvement in visual acuity) could be used in the economic evaluation. The authors
consider the changes in vision to be large, but note that the changes in utility were small. Therefore, this is
likely to be an underestimate. The estimate is not necessarily representative of the difference in utility that
might be observed between first- and second-eye patients either. Furthermore, the study comprised only
women, who were fairly elderly and with comorbidities, and therefore is not likely to be generalisable to the
general cataract surgical population.
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Reference (lead author, year, ref ID)
Dolders and colleagues (2004).101
Study characteristics
Research question
What are the stated objectives of the study?
To conduct a cost–utility analysis of monofocal and multifocal IOLs in cataract surgery, following a
societal perspective.
Describe the type of study and study design.
A cost-effectiveness analysis conducted alongside a RCT.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease, (iv) other?
Patients awaiting cataract surgery.
What are the characteristics of the baseline cohort for the evaluation?
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Age Years, mean (SD)
Monofocal IOL= 72.2 (7.9)
Multifocal IOL= 72.9 (7.0)
Sex Female-to-male ratio
Monofocal IOL= 56.0 : 44.0
Multifocal IOL= 64.7 : 35.3
Race (if appropriate) Not stated
Indication/disease (e.g. presence or
absence of comorbidities)
Patients with bilateral senile cataract. Ocular comorbidity was an
exclusion criterion
General comorbidity (%)
Monofocal IOL
No= 41.3
Yes= 58.7
Multifocal Iol
No= 42.6
Yes= 57.4
Baseline clinical vision T1 (1–2 weeks before first-eye surgery), mean (SD)
Monofocal IOL Multifocal IOL
VA (first eye) 0.46 (0.27) 0.49 (0.27)
VA (second eye) 0.31 (0.22) 0.28 (0.19)
VA, visual acuity.
(log-MAR).
Refraction error in spherical equivalent reported but not extracted.
Other characteristics (sample size) Monofocal IOL n= 75
Multifocal IOL n= 68
General health status
EQ-5D (%) Monofocal IOL Multifocal IOL
Healthy 36.0 26.5
(Very) mild 60.0 47.0
(Very) severe 4.0 26.5
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QoL instrument (state when administered) Patients were interviewed to assess quality of life and all other
outcomes at three time points:
T1: 1 to 2 weeks before first-eye surgery
T2: 3 months after first-eye surgery
T3: 3 months post operatively after second-eye surgery
EQ-5D
VAS*
TTO
SG
*It is not specified if this was the EQ-VAS or another instrument
Utility values See below under ‘Results’
Treatment effect, if reported (e.g. clinical
vision measures)
Monofocal IOL (0) (n= 75)
T1 T2 T3
VA (first eye) 0.46 (0.27) 0.12 (0.22) NA
VA (second eye) 0.31 (0.22) NA 0.07 (0.14)
Multifocal IOL (1) (n= 68)
T1 T2 T3
VA (first eye) 0.49 (0.27) 0.13 (0.17) NA
VA (second eye) 0.28 (0.19) NA 0.09 (0.16)
Differences between monofocal and multifocal IOL at T2 or T3
reported as not statistically significant.
Refraction error in spherical equivalent reported but not extracted.
SD, standard deviation.
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Country/setting
What is the country and setting for the evaluation?
The Netherlands.
Data sources
Effectiveness
Were quality of life data derived from: a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
Derived from patients in a RCT, as described above.
Results
Summarise the results
Utility values, mean (SD).
Monofocal IOL (0) (n= 75)
T3–T2*
Multifocal IOL (1) (n= 68)
T3–T2*T1 T2 T3 T1 T2 T3
VAS 0.78 (0.19) 0.80 (0.19) 0.79 (0.17) −0.01 0.66 (0.22) 0.76 (0.22) 0.70 (0.24) −0.06
TTO 0.68 (0.28) 0.74 (0.28) 0.67 (0.29) −0.07 0.70 (0.26) 0.70 (0.30) 0.62 (0.28) −0.08
SG 0.94 (0.06) 0.95 (0.06) 0.94 (0.05) −0.01 0.95 (0.06) 0.94 (0.06) 0.93 (0.07) −0.01
SD, standard deviation.
Odds ratio (95% CI).
*Calculated by reviewers.
VAS.
0.08** (0.01 to 0.56) between T2 and T1 (first eye).
0.10** (0.02 to 0.64) between T3 and T1 (both eyes).
**p< 0.05 (authors suggest that the significant difference between trial arms for the VAS was due to baseline
significant differences between arms).
TTO and SG stated as not significant.
VAS, TTO and SG correlated significantly (p< 0.01). Correlations varied from 0.40 to 0.43, indicating that the
underlying construct is similar.
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Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
Cataract surgery implanting a monofocal or a multifocal IOL is equally cost-effective.
What are the implications of the study for the model?
Although the aim of this study was to compare monofocal or a multifocal IOL in cataract surgery patients,
it appears that patients underwent first-eye surgery and then 3 months later had second-eye surgery
(as opposed to just single-eye surgery, or both eyes simultaneously). Patients were assessed before first-eye
surgery, after first- and second-eye surgery, therefore, permitting comparison of changes in quality of life
between first- and second-eye surgery in both trial arms. However, whilst there was an increase in utility from
baseline (T1) to post-first-eye surgery (T2), between first-eye surgery (T2) and second-eye surgery (T3) utility
values declined (in both trial arms). It may have been that patients perceived to have benefited most from
first-eye surgery, and pre-surgical visual impairment in the second eye may have been mild [in both trial arms
the eye with the highest visual impairment (in terms of log-MAR visual acuity) was prioritised for first-eye
surgery]. Also, the TTO and SG instruments may not have been sensitive enough to capture changes in quality
of life following second-eye surgery.
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Reference (lead author, year, ref ID)
De Juan-Marcos and colleagues (2012).106
Study characteristics
Research question
What are the stated objectives of the study?
To assess the correlation between visual acuity, visual function, and health-related quality of life
before-and-after Nd:YAG laser posterior capsulotomy in patients with posterior capsule opacification (PCO).
Describe the type of study and study design.
Single cohort before-and-after study.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease, (iv) other?
Patients with PCO following cataract surgery.
What are the characteristics of the baseline cohort for the evaluation?
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Age Mean= 72 years
Range= 40–87 years
Sex n (%)
Male 51 (34)
Race (if appropriate) Not stated
Indication/disease (e.g. presence or absence
of comorbidities)
Patients with posterior capsule opacification (PCO)
Comorbidities n (%)
Systemic 120 (80)
Ocular 107 (71.3)
Baseline clinical vision Mean VA in PCO eye, decimal
Before capsulotomy 0.4 (0.39 log-MAR)
After capsulotomy 0.7 (0.15 log-MAR)
Mean VA in fellow eye, decimal 0.68 (0.16 log-MAR)
Mean (SD) binocular visual acuity (BVA), log-MAR
0.28 (0.16)
Other characteristics (sample size) 150 patients, with a total of 175 PCO eyes included
QoL instrument (state when administered) EuroQoL EQ-5D and EQ-VAS
VF-14 (data not extracted here)
Before surgery and 3 weeks after capsulotomy
Utility values EQ-VAS
58.8 (SD 14.5)
The authors note a celling effect for EQ-5D and EQ-VAS in
11 (8.5%) and 2 (1.5%) of the patients, respectively, at baseline
Treatment effect, if reported (e.g. clinical
vision measures)
Post-capsulotomy
Mean (SD) BVA log-MAR
0.08 (0.1)
Mean difference= 0.2
p< 0.01
BVA, binocular visual acuity; SD, standard deviation; VA, visual acuity.
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Country/setting
What is the country and setting for the evaluation?
Spain.
Data sources
Effectiveness
Were qualiy of life data derived from: a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
Single cohort before-and-after study, as above.
Results
Summarise the results
BVA, log-MAR Number of patients
Post-capsulotomy,
mean (SD) EQ-VAS
Mean change
from baseline p-value
All patients 150 72.4 (17.3) 13.5 < 0.01
≤ 0.52 44 67.5 (19.2) 15.5 < 0.01
0.51–0.16 58 70.5 (17.2) 10.8 < 0.01
≥ 0.15 48 79.2 (11.5) 14.2 < 0.01
BVA, binocular visual acuity; SD, standard deviation.
Authors report that the EQ-VAS improvement did not demonstrate relationship to binocular visual acuity at
baseline. They found significant mean changes in the VAS scores when patients were categorised in BVA groups
at baseline; however, the analysis of variance did not reflect a significant (p= 0.084) linear trend in the mean
EQ-VAS across the three binocular visual acuity groups (table).
The authors measured the MCID (the smallest difference in a score that is considered to be worthwhile or clinically
important and which would lead the clinician to consider a change in the patient’s management). The MCID after
capsulotomy was 0.28 for binocular visual acuity, and 11.8 for EQ-VAS.
The EQ-VAS score improvement had a weak relationship to the binocular visual acuity improvement (r= 0.21,
p< 0.01). The correlation coefficients between EQ-VAS score improvement and changes in satisfaction with vision
and changes in VF-14 scores were 0.41 (p< 0.01) and 0.61 (p< 0.01), respectively.
The percentage of patients reporting problems on the 5 dimensions of the EQ-5D before-and-after capsulotomy is
reported (data not extracted here).
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Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
There was a substantial improvement in visual acuity after Nd:YAG laser capsulotomy. The study also shows
that treatment of PCO leads to noticeable changes for the patient in everyday life; there is a reduction in
patients’ perceived difficulties performing activities of daily living.
Measuring the outcomes of capsulotomy by clinical indicators alone may underestimate the overall benefits of
treatment. Visual acuity in conjunction with visual function and HRQoL questionnaires will likely prove to be
better indicators of the need for and outcome of capsulotomy.
What are the implications of the study for the model
The pre-capsulotomy EQ-VAS utility value [58.8 (SD 14.5)] could be used to estimate the disutility associated
with PCO in the modelled cohort. The post-capsulotomy utility value could be used for patients successfully
treated for PCO (NB PCO treatment led to adverse events in 11 eyes).
SD, standard deviation.
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Reference (lead author, year, ref ID)
Feeny and colleagues (2012).86
Linked to: Kaplan and colleagues (2011).102
Study characteristics
Research question
What are the stated objectives of the study?
To examine agreement among generic preference-based measures of HRQoL and vision-specific measures in
classifying patients into the same categories of change – better, stable or worse.
Describe the type of study and study design.
Prospective single cohort study. (NB The study included a cohort of cataract patients, and a cohort of heart
disease patients, but only the cataract cohort is reported here).
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease, (iv) other?
A cohort of patients undergoing cataract extraction surgery with lens replacement. No detail given on whether
first, second or bilateral eye surgery.
What are the characteristics of the baseline cohort for the evaluation? [NB These data have been extracted
from the subset of patients with complete baseline and 1 month follow-up data for all measures (n= 210)
reported in the Feeny paper. The Kaplan paper reports baseline data for all enrolled patients (n= 376).]
Age N (%)
35–44 years, n= 3 (1)
45–64 years, n= 71 (34)
65–91 years, n= 136 (65)
Sex Female
n= 124 (59%)
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Race (if appropriate) n (%)
White= 184 (88)
Black= 7 (3)
Asian= 13 (6)
Other= 2 (1)
Missing= 4 (2)
Indication/disease Cataract patients undergoing cataract extraction surgery with lens replacement.
Patients were excluded if undergoing simultaneous glaucoma, corneal or
vitreoretinal procedures
Baseline clinical visual
(e.g. visual acuity)
Not reported
Other characteristics
(sample size)
Enrolled n= 376
Complete data n= 210
QoL instrument Generic instruments:
EQ-5D
HUI-2
HUI-2 sensation
HUI-3
HUI-3 vision
QWB–SA
SF-6D
Disease-specific instruments:
VFt
VFQui
SRH
Mostly self-completed (93% reported that no one helped them to complete
the questionnaires)
Administered at baseline, 1 and 6 months post-operation. In the Feeny et al. (2012)86
publication data are reported only for the 1 month follow-up as the authors note that
changes are most common during the first month following surgery and then
stabilise thereafter. The Kaplan et al. (2011)102 paper does report 6-month data,
but these are not extracted here
The authors suggest that a change of 0.03 or more in the overall preference score for
each of the preference-based measures is interpreted as a clinically important change.
Empirical estimates of clinically important change for the 5 preference-based measures
vary from 0.01 to 0.08. For the single-attribute utility scores for HUI-2 sensation (which
includes vision) and HUI vision the guideline for a clinically important difference is 0.05
Utility values Yes
Treatment effect, if reported Not reported
SRH, self-rated health (questionnaire); VFQui, Visual Function Questionnaire preference-based score based on total score of
the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25); VFt, total score of the NEI-VFQ-25.
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Country/setting
What is the country and setting for the evaluation?
USA.
Data sources
Effectiveness
Were quality of life data derived from: a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
Prospective single cohort study.
Results
Summarise the results
Generic instrument Mean SD
EQ-5D
Baseline 0.83 0.17
1 month post-operation 0.84 0.16
Change from baseline 0.02 0.13
HUI-2
Baseline 0.79 0.17
1 month post-operation 0.81 0.19
Change from baseline 0.02 0.14
HUI-2 sensation
Baseline 0.76 0.14
1 month post-operation 0.84 0.17
Change from baseline 0.08 0.19
HUI-3
Baseline 0.66 0.27
1 month post-operation 0.72 0.28
Change from baseline 0.05 0.21
HUI-3 vision
Baseline 0.80 0.22
1 month post-operation 0.91 0.15
Change from baseline 0.12 0.22
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Generic instrument Mean SD
QWB–SA
Baseline 0.59 0.14
1 month post-operation 0.60 0.14
Change from baseline 0.01 0.13
SF-6D
Baseline 0.74 0.12
1 month post-operation 0.73 0.12
Change from baseline −0.01 0.09
SD, standard deviation.
NB The values provided by Kaplan and colleagues102 differ slightly from those in the above table.
This appears to be due to Kaplan and colleagues102 reporting data for all patients who completed each
instrument at both baseline and at the 1-month follow-up. In contrast, Feeny and collaegues86 report only
the subset of 210 patients who completed baseline and the 1-month follow-up and all instruments.
Values do not differ markedly and should not affect interpretation.
NB Kaplan and colleagues102 report that at 1 month, differences were statistically significant for all the
indices except the SF-6D (for their dataset). Feeny and collaegues86 do not mention statistical significance.
NB Data in agreement between the different instruments were reported by Feeny and collaegues86 but
have not been extracted here.
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
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Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
The mean change in HUI-3 vision score and HUI-2 sensation score exceed the 0.03 clinically important
difference guideline. The mean changes in scores for EQ-5D, QWB-SA, SF-6D and self-rated health
(questionnaire) (SRH) are less than the guidelines for a clinically important difference (0.03).
There was very little pair-wise agreement between the disease-targeted measures and the five preference-based
measures about which patients improved, were stable or deteriorated. The instruments must be regarded as
not interchangeable.
What are the implications of the study for the model?
It is not clear whether patients received first-eye, second-eye or bilateral cataract surgery. It is therefore difficult
to extrapolate the utility values to patients undergoing second-eye surgery. The severity of patients’ baseline
clinical vision impairment is also not stated, making it difficult to generalise to the modelled patient cohort.
The EQ-5D and SF-6D are not responsive to changes in quality of life following cataract surgery. The HUI-2 and
HUI-3 would appear to be more sensitive to changes in quality of life following cataract surgery.
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Reference (lead author, year, ref ID)
Hiratsuka and colleagues (2011).94
Study characteristics
Research question
What are the stated objectives of the study?
To evaluate the cost-effectiveness of cataract surgery through measurement of the cost per QALY in Japan.
To confirm the generalisability of the cost–utility of cataract surgery in the real-world setting in Japan.
Describe the type of study and study design.
Authors define it as a prospective multicentre observational study (conducted by the ECCERT). The study can
also be classed as a full economic evaluation as cost per QALYs are reported (though not extracted here).
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease, (iv) other?
Patients scheduled for first-eye, second-eye or bilateral cataract surgery.
What are the characteristics of the baseline cohort for the evaluation?
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Age Years, mean (SD) 71.0 (7.9)
Sex Women n= 335 (61%); men= 214 (39%)
Race (if appropriate) Not stated, presume Japanese
Indication/disease Scheduled for first-eye, second-eye or bilateral cataract surgery. Patients were
excluded if surgery was combined with glaucoma, corneal, or vitreoretinal surgery,
or if significant ocular comorbidity
Baseline clinical vision VA (log-MAR), mean (SD):
Better eye= 0.16 (0.28)
Worse eye= 0.51 (0.52)
Other characteristics
(sample size)
549 patients enrolled. Numbers of patients available for analysis vary according to
different measures
Baseline Post surgery
VA 549 529
TTO 440 381
EQ-5D 541 482
HUI-3 496 434
QoL instrument TTO
EQ-5D (Japanese version)
HUI-3 (Japanese version)
Administered at baseline and 3 months post surgery
Utility values Baseline utility values, mean (SD)
TTO (n= 440 patients)= 0.60 (0.28)
EQ-5D (n= 541 patients)= 0.84 (0.15)
HUI-3 (n= 496 patients)= 0.65 (0.24)
Treatment effect, if reported The mean better VA (log-MAR) and worse VA (log-MAR) improved to –0.05± 10 and
0.03± 0.25, respectively (no further information given). (presume ‘better’ and ‘worse’
means better eye/worse eye VA, respectively)
SD, standard deviation; VA, visual acuity.
Country/setting
What is the country and setting for the evaluation?
Twelve clinical sites in Japan. Seven ophthalmologic departments in university hospitals, three ophthalmologic
departments in public hospitals, and two private surgical clinics.
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Data sources
Effectiveness
Were quality of life data derived from a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
A single (observational) study, as described above.
Results
Summarise the results.
Post-operative utility values, mean (± SD).
First-eye surgery
(N= 157)
Second-eye surgery
(N= 60)
Bilateral surgery
(N= 312)
TTO n= 109 n= 38 n= 234
Utility (before surgery) 0.66± 0.25 0.64± 0.29 0.58± 0.29
Utility (after surgery) 0.84± 0.28 0.88± 0.23 0.85± 0.25
Utility gain 0.18± 0.27 0.24± 0.30 0.27± 0.33
p-value < 0.001 < 0.001 < 0.001
EQ-5D n= 138 n= 52 n= 292
Utility (before surgery) 0.85± 0.16 0.83± 0.16 0.84± 0.15
Utility (after surgery) 0.89± 0.15 0.92± 0.13 0.90± 0.15
Utility gain 0.05± 0.15 0.09± 0.17 0.06± 0.16
p-value < 0.001 < 0.001 < 0.001
HUI-3 n= 131 n= 47 n= 256
Utility (before surgery) 0.71± 0.25 0.70± 0.20 0.62± 0.24
Utility (after surgery) 0.79± 0.18 0.79± 0.22 0.76± 0.25
Utility gain 0.08± 0.21 0.08± 0.25 0.14± 0.25
p-value < 0.001 < 0.05 < 0.001
In the entire group of 381 patients (i.e. all three subgroups together) the overall TTO utility showed a statistically
significant improvement from 0.60 to 0.85 3 months after cataract surgery.
Pre-surgery TTO utilities were stratified according to the corrected distance VA (decimal) in the better seeing
eye. The utilities were correlated with six different visual stratifications. As the VA in the better seeing eye
decreased, the corresponding TTO utilities decreased at every stratification level (data not extracted, see table 2
in the publication).
In a multiple linear regression model the better VA (log-MAR) showed a significant correlation with TTO utilities.
Utility changed by 0.21 for each change in VA of one (log-MAR) (p< 0.001).
SD, standard deviation; VA, visual acuity.
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
186
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
The TTO method is more sensitive to small changes in utility than generic survey questionnaires such as
the EQ-5D and HUI-3. However, even the relatively smaller utility gains for EQ-5D and HUI-3 were
statistically significant.
What are the implications of the study for the model?
The difference between the post-surgery utility gains from the first- and second-eye surgery subgroups can be
estimated from this study for the three instruments used, as follows:
TTO= 0.06
EQ-5D= 0.04
HUI-3= 0.
[NB This study was screened for inclusion in our cost-effectiveness systematic review. However, it did not meet
the criteria as cost-effectiveness outcomes were not reported for second-eye surgery (the first- and second-eye
cataract surgery groups were merged into one overall group ‘one eye’ and compared with bilateral
cataract surgery).]
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Reference (lead author, year, ref ID)
Kishimoto and colleagues (2012).103
Study characteristics
Research question
What are the stated objectives of the study?
To calculate and evaluate the utility value of surgical treatment in patients with cataract, glaucoma,
and comitant strabismus, and to compare their changes using TTO analysis. The validity of TTO analysis was
assessed by correlating the TTO value with the VF-14.
Describe the type of study and study design.
Single cohort retrospective analysis.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease, (iv) other?
Patients with cataract, glaucoma, and comitant strabismus. The cataract patients were stratified by unilateral or
bilateral cataract surgery (only the cataract subgroup are extracted here).
What are the characteristics of the baseline cohort for the evaluation?
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Age Mean (SD) 70.9 (10.9)/74.5 (5.8) (unilateral/bilateral)
Sex Male, n (%) 14 (67)/17 (59)
Race (if appropriate) Not stated but presume Japanese
Indication/disease Unilateral and bilateral cataracts
Baseline clinical vision VA in better eye, mean (SD), decimal:
Unilateral n= 0.9 (0.5)
Bilateral n= 0.7 (0.3)
VA in worse eye, Mean (SD), decimal:
Unilateral n= 0.3 (0.3)
Bilateral n= 0.4 (0.3)
Other characteristics
(sample size)
Number of cataract patients responding to the questionnaire:
Unilateral n= 21
Bilateral n= 29
(NB On p. 196, it is stated that only 44 cataract patients completed the TTO questionnaire)
QoL instrument TTO measurement sheet (self-completed). Patients were told to assume there was a surgical
treatment that would offer them perfect vision if successful, and asked whether they would
be willing to trade-off some of their expected remaining years for perfect vision. The
expected remaining years were based on data from the Japanese Ministry of Health,
Labour and Welfare of 2008. The utility value was calculated using the following equation:
utility value= 1 – time traded/expected remaining years
VF-14
Utility values Baseline, mean (SD):
Unilateral= 0.727 (0.279)
Bilateral= 0.663 (0.196)
Treatment effect,
if reported
VA, mean (SD), decimal:
Better eye Worse eye
Baseline Post surgery Baseline Post surgery
Unilateral 0.9 (0.5) 0.9 (0.4) 0.3 (0.3) 0.6 (0.4)
Bilateral 0.7 (0.3) 1.1 (0.4) 0.4 (0.3) 0.7 (0.4)
SD, standard deviation; VA, visual acuity.
Note
Data in the above table are for the unilateral cataract and bilateral cataract patients only.
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Country/setting
What is the country and setting for the evaluation?
Japan.
Data sources
Effectiveness
Were quality of life data derived from a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
Single observational study. The publication says utility was assessed retrospectively via questionnaires completed
2–3 months post operatively. However, pre- and post-operative values are given, so it is therefore assumed
that patients assessed their pre-operative quality of life retrospectively.
Results
Summarise the results
Post-operative utility values, mean (SD):
Unilateral= 0.894 (0.228)
Bilateral= 0.909 (0.155).
Post-operative utility gain, mean (SD):
Unilateral= 0.167 (0.237)
Bilateral= 0.245 (0.167).
Difference in gain between unilateral and bilateral= 0.078.
The TTO utility value improved significantly post operatively in all four patient groups.
SD, standard deviation.
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes, though it is not clear how baseline utility values were assessed if patients only completed the
questionnaire post operatively.
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Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
None.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
The TTO utility value improved significantly compared with that before surgery in all four treatment groups.
The gain was larger for bilateral than unilateral surgery.
Statistically significant correlation was observed between post-operative bilateral cataracts TTO utility and the
VF-14, but not for unilateral cataracts.
Significant negative correlations were noted between the utility value and corrected visual acuity of the better
eye of the post-operative unilateral cataract.
What are the implications of the study for the model?
The difference in post-operative utility gain between unilateral and bilateral surgery (0.078) cannot be assumed
to be analogous to the difference between first- and second-eye surgery. However, it could be indicative of this
if the VA of the worst eye (0.6) post surgery in unilateral cataract patients is considered to be similar to the VA
of an unoperated bilateral cataract.
VA, visual acuity.
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Reference (lead author, year, ref ID)
Naeim and colleagues (2006).104
Study characteristics
Research question
What are the stated objectives of the study?
To evaluate the cost-effectiveness of first-eye surgery in persons with cataracts who had < 30% predicted
probability of benefiting from the procedure, and to determine whether any subgroup based on the Cataract
Surgery Index could be identified for whom the costs of surgery would outweigh the health benefits.
Describe the type of study and study design.
Randomised trial (first-eye surgery vs. watchful waiting) accompanied by an economic evaluation.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease, (iv) other?
People with bilateral cataracts.
What are the characteristics of the baseline cohort for the evaluation?
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Age Mean age 78 years
Sex 62% women
Race (if appropriate) 87% white
Indication/disease (e.g. presence or
absence of comorbidities)
Patients (older than 64) with bilateral age-related cataracts, with or
without other chronic eye diseases, with a CSI score equal to or greater
than 10 (representing < 30% predicted probability of reporting improvement
in visual function after surgery) (NB A higher CSI score= lower predicted
probability of improvement). The severity of cataracts was not graded
Patients were classified into CSI categories= 10,= 11, > 11. The scoring
system is based on ADVS score, amongst other factors (see p. 983
of publication)
Baseline clinical vision Best corrected Snellen acuity and pinhole acuity for vision worse than
20/100 was assessed, but results not reported in the publication
Other characteristics (sample size) 250 patients randomised, 133 assigned to surgery, 117 assigned to watchful
waiting. After withdrawals the sample sizes at 6 months were 117 and 100,
respectively
QoL instrument (state when
administered)
HUI-3, administered at baseline (pre surgery) and at 6 months post surgery
ADVS (data not extracted here)
SF-12 (data not extracted here)
Charlson Comorbidity Index (data not extracted here)
Utility values HUI-3 (n= 209)
All patients= 0.74 (SD 0.26)
See below for baseline utility values for HUI-3 (CSI> 11) and for visual
utility subscale
Treatment effect, if reported
(e.g. clinical vision measures)
Clinical vision measures not reported. ADVS scores are given, showing a
statistically significant benefit for surgery compared with watchful waiting
(data not extracted here)
ADVS, Activities of Daily Vision Scale; CSI, Cataract Surgery Index; SD, standard deviation.
Country/setting
What is the country and setting for the evaluation?
USA.
Data sources
Effectiveness
Were quality of life data derived from a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
RCT.
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Results
Summarise the results.
6-month follow-up.
Surgery Watchful waiting
HUI-3
Baseline 0.744 0.754
6-month follow-up 0.760 0.723
Change from baseline 0.016 −0.031
Adjusted impact of surgerya – mean (SD)= 0.041 (0.029), p= 0.156.
HUI-3 (CSI > 11)
Baseline 0.783 0.788
6-month follow-up 0.733 0.710
Change from baseline −0.05 −0.078
Adjusted impact of surgerya – mean (SD)= 0.024 (0.053), p= 0.657.
Visual utilityb
Baseline 0.927 0.92
6-month follow-up 0.954 0.92
Change from baseline 0.027 0
Adjusted impact of surgerya – mean (SD)= 0.031 (0.014), p= 0.035.
SD, standard deviation.
a Mean difference between the control arm and the cataract surgery arm. General linear multivariate regression
model analysis controlling for baseline HUI, age, diabetes, Physical Component Summary Score (PCS 12)
age-related macular degeneration (AMD), gender, baseline PCS 12, baseline Mental Composite Score (MCS 12),
and medical comorbidities.
b Not explicitly stated but presume this refers to the vision subscale of the HUI-3.
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Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
It is cost-effective for 75% of patients who were previously estimated to have a small probability (< 30%) of
benefiting from the procedure. There is a subgroup (those with CSI> 11) for whom the costs would exceed
$50,000 per QALY.
CSI, Cataract Surgery Index.
What are the implications of the study for the model?
The HUI-3 utility gains for the surgery group could potentially inform the economic evaluation, though as these
were patients undergoing first-eye surgery they cannot necessarily be assumed to apply to second-eye surgery.
Furthermore, the patients enrolled in this study cannot be considered representative of the general surgical
population as they were chosen to reflect a subgroup less likely to benefit, on the basis of comorbidities,
symptoms and age. Clinical benefit was measured in terms of favourable changes in ADVS scores for surgery
patients, though changes in post-surgical VA were not reported.
ADVS, Activities of Daily Vision Scale; VA, visual acuity.
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Reference (lead author, year, ref ID)
Räsänen and colleagues (2006).90
Study characteristics
Research question
What are the stated objectives of the study?
The aim was to evaluate the cost–utility of cataract surgery, compared with a hypothetical situation of no
treatment by studying unselected patients referred by practising ophthalmologists for a routine cataract
operation to a large university clinic because of objective signs of poor visual acuity due to cataract.
Describe the type of study and study design.
Single cohort (with three subgroups) pre- and post-study. The authors state that these data were collected in
the framework of a large trial.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease, (iv) other?
Patients with cataracts:
Group A – only one eye was operated (n= 87)
Group B – both eyes were operated during the follow-up (n= 73)
Group C – first eye had been operated earlier, now the second eye was operated (n= 59).
What are the characteristics of the baseline cohort for the evaluation?
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Age Mean (SD):
Group A= 69 (12)
Group B= 70 (12)
Group C= 75 (10)
Sex Female, n (%):
Group A= 49 (56%)
Group B= 52 (71%)
Group C= 53 (71%)
Race (if appropriate) Not stated
Indication/disease
(e.g. presence or absence of
comorbidities)
Patients scheduled for cataract surgery. Presence of comorbidities not reported other
than around a one-third of patients had secondary ophthalmic diagnosis
Baseline clinical vision Mean (SD) best corrected visual acuity in the surgical eye prior to cataract surgery
(all patients)
Group A Group B Group C Significance
Surgical eye
Snellen 0.19 (0.14) 0.17 (0.12) 0.24 (0.14) Not statistically
significant
Log-MAR 0.98 (0.66) 0.94 (0.49) 0.76 (0.48) Not statistically
significant
Non-surgical eye
Snellen 0.58 (0.23) 0.28 (0.16) 0.63 (0.25) Not statistically
significant
Log-MAR 0.29 (0.22) 0.65 (0.37) 0.25 (0.21) A vs. B
p< 0.001
B vs. C
p< 0.001
A vs. C
not statistically
significant
Mean (SD) best corrected visual acuity in the surgical eye prior to cataract surgery in
patients reporting minor or significant pre-operative seeing problems
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Patients with no or
only minor subjective
pre-operative seeing
problems at baseline
(levels 1 and 2 of the
seeing dimension
of the 15D).
N= 140 (64%)
Patients with
significant subjective
pre-operative seeing
problems at baseline
(levels 3 to 5 of the
seeing dimension
of the 15D).
N= 79 (36%) Significance
Surgical eye
Snellen 0.21 (0.14) 0.17 (0.12) Not
statistically
significant
Log-MAR 0.88 (0.59) 0.94 (0.52) Not
statistically
significant
Non-surgical eye
Snellen 0.57 (0.24) 0.35 (0.24) Not
statistically
significant
Log-MAR 0.30 (0.23) 0.58 (0.39) p< 0.001
Other characteristics
(sample size)
386 patients scheduled for routine cataract operation (219 available for final analysis)
QoL instrument (state
when administered)
15D generic 15-dimensional, standardised HRQoL instrument. Patients completed the
15D at baseline and then again approximately 6 months after the cataract operation
Utility values See below
The correlation between the best corrected visual acuity (expressed in log-MAR units)
in the surgical eye and the subjective level of seeing (the seeing dimension of the
HRQoL-instrument) was poor (r= 0.17, p= 0.013). However, the visual acuity of the
non-surgical eye correlated fairly well with the seeing dimension of the 15D
instrument (r= 0.503, p< 0.001)
Treatment effect, if reported
(e.g. clinical vision measures)
Not reported
SD, standard deviation.
Country/setting
What is the country and setting for the evaluation?
Finland.
Data sources
Effectiveness
Were quality of life data derived from: a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
Single cohort of patients, as above.
Baseline clinical vision
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Results
Summarise the results.
Mean (SD) utility values.
All patients Group A Group B Group C
Baseline 0.82 (0.13) 0.85 (0.13) 0.80 (0.13) 0.82 (0.11)
6-month follow-up 0.83 (0.14) 0.85 (0.14) 0.83 (0.14) 0.81 (0.13)
Change from baseline 0.01 0.00 (0.14) 0.03 (0.14) −0.01 (0.07)
p-value NR p= 0.852 p=< 0.001 p= 0.279
NR, not reported, but stated to be statistically insignificant.
The only statistically significant increase in the individual dimensions of the 15D was for ‘seeing’, observed across all
three subgroups.
Changes in utility scores for the individual domains are presented according to severity of HRQoL (levels 1 and 2 vs.
levels 3 to 5 of the scoring dimension). They are given for the whole study rather than the three subgroups and
therefore data have not been extracted.
SD, standard deviation.
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
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Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
Mean utility gain after routine cataract surgery in a real-world setting was relatively small and confined mostly
to patients whose both eyes were operated. Possible explanations: two-thirds of patients reported only minimal
pre-operative subjective seeing problems despite objective evidence of poor visual acuity in the surgical eye;
the ‘real-world’ setting of a university clinic and its ‘mixed sample’; one-third of patients had a secondary
ophthalmic diagnosis (which might reduce the benefit of surgery); potential insensitivity of the 15D to measure
changes in HRQoL (it includes only one question relating to sight).
What are the implications of the study for the model.
Group C is most relevant to this study as it evaluates the change in quality of life for second-eye cataract
surgery. However, there is a statistically significant decrease in quality of life after second-eye surgery which
is counterintuitive. The study sample could be seen to reflect a typical patient population, though around
two-thirds of patients were classified (by the 15D) as having no or only minor subjective seeing problems
(NB Baseline Snellen visual acuity and 15D correlated poorly in the surgical eye).
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Reference (Lead author, year, ref ID)
Sach and colleagues (2010).91
Study characteristics
Research question
What are the stated objectives of the study?
To evaluate the cost-effectiveness of second-eye cataract surgery for older women with minimal visual
dysfunction in the eye to be operated on from a health and PSS perspective, compared with waiting list
controls who had already undergone first-eye cataract surgery.
Describe the type of study and study design.
Cost–utility analysis conducted alongside a RCT.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease, (iv) other?
Patients with a second operable cataract.
What are the characteristics of the baseline cohort for the evaluation?
Age Aged over 70 years old
Sex 100% female
Race (if appropriate) Not reported
Indication/disease (e.g. presence
or absence of comorbidities)
Previous successful first-eye cataract surgery with a second operable cataract.
Exclusion criteria included complex cataracts, visual field defects, severe comorbid
eye disease
Baseline clinical vision Described as having minimal visual dysfunction in the eye to be operated on
(86% had VA 6/12 or better)
Other characteristics (sample size) 239 women randomised. 229 women were included in the economic analysis
(116 intervention; 113 control)
QoL instrument (state when
administered)
EuroQoL EQ-5D, administered at baseline and 6 months
Utility values See below
Treatment effect, if reported
(e.g. clinical vision measures)
Visual function, especially stereopsis, improved slightly after second-eye cataract
surgery, compared with unoperated controls (see Foss and colleagues83)
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Country/setting
What is the country and setting for the evaluation?
UK, secondary care ophthalmology clinics.
Data sources
Effectiveness
Were quality of life data derived from: a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
Quality of life data were collected as part of a RCT.
Results
Summarise the results.
From Foss and colleagues (2006).83
EuroQoL EQ-5D Baseline 6 months Difference
Expedited second eye 0.74 0.73 −0.01
Unoperated second eye (control) 0.72 0.69 −0.03
Difference between expedited and control (adjusted for baseline values)= 0.02 95% CI −0.03 to 0.08); p= 0.36.
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
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Conclusions/implications
Give a brief summary of the author’s conclusions from their analysis.
Second-eye cataract surgery is not likely to be cost-effective in the short-term for those with mild visual
dysfunction pre-operation. In the long term, second-eye cataract surgery appears to be cost-effective unless
carer costs are included.
What are the implications of the study for the model?
The utility data comes from a generic preference-based instrument (EQ-5D) and can therefore be used to
estimate QALYs. However, the difference between treatments at 6 months is slight and unlikely to be clinically
significant. The authors discuss the potential limitations of using EQ-5D to assess cataract surgery, including
possible lack of precision and responsiveness making it hard to detect small changes. EQ-5D does not
incorporate sensory function in its descriptive system. The fact that the study population was all female, and
had only mild visual impairment needs to be taken into account if using the utility data from this study for a
typical patient cohort in the model.
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Appendix 10 Parameters included in probabilistic
sensitivity analyses
Name Deterministic Higher CI Lower CI Standard error Distribution
Discount rate costs 3.5% 6.0% 1.5%
Discount rate benefits 3.5% 6.0% 1.5%
Visual acuity
Pre surgery 0.50
Post surgery 0.8 1.20 0.67 0.068 Beta
Costs
Cataract operation 862.66 £1121 £604 132.04 Gamma
Cataract OP 85.12 £111 £60 13.03 Gamma
GP visits 43 £56 £30 6.58 Gamma
PCO £506.42 £658.35 £354.49 77.51 Gamma
Retinal detachment £1615.65 £2100.35 £1130.96 247.29 Gamma
Endophthalmitis £760.11 £988.14 £532.08 116.34 Gamma
CMO £313.30 £407.29 £219.31 47.95 Gamma
Lost lens fragments £451.69 £587.20 £316.18 69.14 Gamma
Resources
OP surgery 6.94 7.98 5.9 0.53 Log normal
OP no surgery 2.81 Fixed
GP visits surgery 4.40 5.21 3.6 0.41 Log normal
GP visits no surgery 4.00 Fixed
Complications
PCO year 1 3.49% 5.24% 1.75% 0.009 Beta
PCO year 2 9.49% 14.24% 4.75% 0.024 Beta
PCO year 3 5.06% 7.59% 2.53% 0.013 Beta
Retinal detachment year 1 0.26% 0.39% 0.13% 0.001 Beta
Retinal detachment year 2+ 0.14% 0.21% 0.07% 0.000 Beta
Endophthalmitis 0.10% 0.15% 0.05% 0.000 Beta
CMO 1.62% 2.43% 0.81% 0.004 Beta
Lost lens fragments 0.45% 0.68% 0.23% 0.001 Beta
Utilities
No surgery 0.70 Fixed
Utility gain 0.08 0.14 0.02 0.031 Beta
Age (years) 75 Fixed
CMO, cystoid macular oedema; OP, outpatient.
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